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ABSTRACT 
UTILIZING CONSUMER HEALTH POSTS FOR PHARMACOVIGILANCE: 
IDENTIFYING UNDERLYING FACTORS ASSOCIATED WITH PATIENTS’ 
ATTITUDES TOWARDS ANTIDEPRESSANTS 
by 
Maryam Zolnoori 
The University of Wisconsin-Milwaukee, 2017 
Under the Supervision of Professor Timothy Patrick 
 
Non-adherence to antidepressants is a major obstacle to antidepressants therapeutic 
benefits, resulting in increased risk of relapse, emergency visits, and significant burden on 
individuals and the healthcare system. Several studies showed that non-adherence is weakly 
associated with personal and clinical variables, but strongly associated with patients’ beliefs and 
attitudes towards medications. The traditional methods for identifying the key dimensions of 
patients’ attitudes towards antidepressants are associated with some methodological limitations, 
such as concern about confidentiality of personal information. In this study, attempts have been 
made to address the limitations by utilizing patients’ self report experiences in online healthcare 
forums to identify underlying factors affecting patients attitudes towards antidepressants. The 
data source of the study was a healthcare forum called “askapatients.com”. 892 patients’ reviews 
were randomly collected from the forum for the four most commonly prescribed antidepressants 
including Sertraline (Zoloft) and Escitalopram (Lexapro) from SSRI class, and Venlafaxine 
(Effexor) and duloxetine (Cymbalta) from SNRI class. Methodology of this study is composed of 
two main phases: I) generating structured data from unstructured patients’ drug reviews and 
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testing hypotheses concerning attitude, II) identification and normalization of Adverse Drug 
Reactions (ADRs), Withdrawal Symptoms (WDs) and Drug Indications (DIs) from the posts, 
and mapping them to both The UMLS and SNOMED CT concepts. Phase II also includes testing 
the association between ADRs and attitude. The result of the first phase of this study showed that  
“experience of adverse drug reactions”, “perceived distress received from ADRs”, “lack of 
knowledge about medication’s mechanism”, “withdrawal experience”, “duration of usage”, and 
“drug effectiveness” are strongly associated with patients attitudes. However, demographic 
variables including “age” and “gender” are not associated with attitude. Analysis of the data in 
second phase of the study showed that from 6,534 identified entities, 73% are ADRs, 12% are 
WDs, and 15 % are drug indications. In addition, psychological and cognitive expressions have 
higher variability than physiological expressions. All three types of entities were mapped to 811 
UMLS and SNOMED CT concepts. Testing the association between ADRs and attitude showed 
that from twenty-one physiological ADRs specified in the ASEC questionnaire, “dry mouth”, 
“increased appetite”, “disorientation”, “yawning”, “weight gain”, and “problem with sexual 
dysfunction” are associated with attitude. A set of psychological and cognitive ADRs, such as 
“emotional indifference” and “memory problem" were also tested that showed significance 
association between these types of ADRs and attitude. The findings of this study have important 
implications for designing clinical interventions aiming to improve patients' adherence towards 
antidepressants. In addition, the dataset generated in this study has significant implications for 
improving performance of text-mining algorithms aiming to identify health related information from 
consumer health posts. Moreover, the dataset can be used for generating and testing hypotheses 
related to ADRs associated with psychiatric mediations, and identifying factors associated with 
discontinuation of antidepressants. The dataset and guidelines of this study are available at 
https://sites.google.com/view/pharmacovigilanceinpsychiatry/home 
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1.1 Statement of the Problem 
Depression is a major public health concern due to the high prevalence and it is a 
substantial burden on families, society, and healthcare system (De las Cuevas, Peñate, & Sanz, 
2014). It is estimated that 150 million people suffer from depression at a certain point in their life 
(World Health Organization, 2003) and by 2020, depression will be the most common cause of 
disability in the world (Murray & Lopez, 1997), mainly because of cognitive and emotional 
impairment, such as memory recall and low motivation.  
In the United States, according to The Centers for Disease Control and Prevention 
(CDC), about 9 percent of Americans show symptoms of desperation, regret, and sadness that 
result in depression (CDC 2014) and approximately six percent of adults annually are affected by 
depression, which is the major cause of suicide (NCCMH, 2010). The financial burden of 
depression in the United States increased from $173.2 billion to $210.5 billion (21.5 percent) 
from 2005 to 2010 (Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015). Forty-five percent of 
this cost was related to depression treatment, fifty percent of the cost was indirect cost related to 
patients’ dysfunction and low productivity in the workplace, and five percent of this cost was 
related to suicide-related behavior.  
Antidepressants from SSRI (Selective Serotonin Reuptake Inhibitor) and SNRI 
(Serotonin and Norepinephrine Reuptake Inhibitors) classes have proliferated pharmacological 
interventions for depression in both psychiatric and primary care settings. This level of 
popularity may be related to efficacy of these drugs and their relatively mild adverse effects 
(Sansone & Sansone, 2010). Therapeutic benefits of antidepressant treatment depend on 
maintaining an appropriate drug regimen for a certain period of time and a proper method of 
discontinuation. Many patients recognize the necessity of the treatment (Murata, Kanbayashi, 
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Shimizu, & Miura, 2012), but non-adherence to the treatment is a major obstacle to its clinical 
effectiveness (López-Torres, Párraga, Del Campo, & Villena, 2013). Non-adherence to 
antidepressants is associated with the increased rate of emergency visits, longer hospital 
admission, low quality of life, and significant cost at individual, family, and health care system 
levels (Vives et al., 2014). 
Research showed that across chronic medical illness in general, non-adherence is loosely 
associated with demographic information and clinical variables, such as severity of the 
symptoms or types of drug adverse effects. However, it is more strongly associated with patients’ 
beliefs and attitudes toward medication, low perceived necessity, and high perceived medication 
risks (Aikens & Klinkman, 2012), (Acosta, Rodríguez, & Cabrera, 2013; Aikens, Nease, & 
Klinkman, 2008; Brown et al., 2005; Chakraborty, Avasthi, Kumar, & Grover, 2009; De las 
Cuevas et al., 2014; López-Torres et al., 2013; Richardson, McCabe, & Priebe, 2013; Verdoux et 
al., 2000) . It is more likely that patients with positive attitudes show better adherence behavior 
than patients with negative or indifferent attitudes(Aikens, Nease, Nau, Klinkman, & Schwenk, 
2005; De las Cuevas et al., 2014; Richardson et al., 2013). Ultimately, It is patient perception of 
beneficial aspects of the medication versus the harmful aspects that will determine the 
acceptance or rejection of the medication (Acosta et al., 2013; Christensen, 2004). 
Identifying the key dimensions of patients’ attitudes towards antidepressants is   
challenging work that is often neglected (Demyttenaere et al., 2004). This partly due to the lack 
of reliable and comprehensive methods to capture underlying factors affecting patients’ attitudes. 
It has been evident that identifying potential predictive factors for attitude may have significant 
implications for understanding the complexity of this phenomenon and for designing effective 
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interventions to improve drug therapy adherence (Kessing, Hansen, Demyttenaere, & Bech, 
2005).   
Some studies have attempted to develop structured self-report measures to operationalize 
the concept of attitude towards psychiatric drugs in various scales. The Drug Attitude Inventory 
(DAI) (Hogan, Awad, & Eastwood, 1983) and the Antidepressants Compliance Questionnaire 
(ADCQ) (Demyttenaere, Adelin, Patrick, Walthère, & Michèle, 2008) are examples of self-
report scales employed by studies focused on measuring patient attitudes toward antidepressants. 
Although, the self-report scales are well validated, they are associated with some limitations. 
Firstly, the ADCQ is the only self-report scale that is primarily designed for measuring attitude 
to antidepressants. However, other scales, such as the DAI, which are primary designed for 
patients with psychotic disorders, have been widely used in the studies addressing attitudes to 
antidepressants. Secondly, the scales do not include a comprehensive set of potential factors 
influencing attitudes, such as antidepressants’ adverse effects or patients’ knowledge. Therefore, 
studies interested in determining association of the factors with attitude need to employ relevant 
self-report scales such as the Self-report Antidepressant Side-Effect (ASEC), which may increase 
complexity and cost of a study. Third, to reduce complexity of data analysis, most of the studies 
represented outputs of the self-report scales as dichotomous variables (positive vs. negative 
attitude) that may not capture meaningful variance in data. Finally, stigma associated with 
mental disorders (Griffiths, Calear, & Banfield, 2009), sample bias and inherent limitations with 
such data collection, concern about confidentiality of personal information, and patients’ 
reluctance to reveal personal information may reduce the reliability of the studies’ findings.  
Detecting Adverse Drug Reactions (ADRs) for antidepressants is also associated with 
several challenges. First of all, clinical trial studies, as the pre-marketing phase of 
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pharmacovigilance systems, suffer from limitations, such as specific inclusion and exclusion 
criteria for recruiting patients and limited duration and size of the trials. These limitations may 
hinder the discovery of long-term effects of antidepressants’ usage, such as antidepressants-
induced weight gain or rare adverse effects, such as “eye pain”, which may occur in less than 
5000 patients (Ferguson, 2001). In addition, the post-marketing phase of pharmacovigilance 
systems, such as Food and Drug Administration (FDA)’s Adverse Event Reporting System 
(FAERS), are voluntary in nature for clinicians and the general public, leading to detection that 
may not be timely and is incomplete (Sarker et al., 2015). To facilitate the process of assessing 
adverse effects of medications, some studies designed instruments to measure the adverse effects 
in clinicians’ offices, including Systematic Assessment for Treatment Emergent Side Effects 
(SAFTEE) (Levine & Schooler, 1986) and the UKU Side Effect Rating (Lingjaerde, Ahlfors, 
Bech, Dencker, & Elgen, 1987). However, these instruments are not widely in use because of 
their length, complexity, and demand on clinicians’ time. 
1.2 Significance of the Study  
A fundamental assumption of this project is that social media technologies may be used as a 
much needed and important source of data for determining attitudes leading to non-adherence 
with antidepressant medications. Social media sites show promise as a much needed and 
important source of data for determining attitudes leading to non-adherence with antidepressant 
medications. Novel social media technologies have provided patients with a unique platform to 
freely report their experiences and express their attitudes about healthcare services and 
treatments. Social media applications with a focus on healthcare topics have been constantly 
growing in recent years (Metke-Jimenez & Karimi, 2015).The findings of a public opinion 
survey conducted in 2009 by Pew Research Center’s Global Attitudes Project showed that 61 
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percent of Americans looked online for general health information, 41 percent read others 
experience and 30 percent were actively participating in creating new knowledge (Fox & Jones, 
2012).   
Facebook, Twitter, YouTube, and patient forums such as “patientslikeme.com”, and 
“Online Messaging Boards” (OMB) such as “webmd.com” are popular online platforms used by 
patients or caregivers for creating online healthcare communities. Patients and caregivers discuss 
various health concerns and treatment experiences in the communities (Metke-Jimenez & 
Karimi, 2015). Such communication can happen in various forms, such as sharing videos or 
images, questions/answers, posts/comments, and expressing emotional reactions using emoticons 
and “like” buttons (Mao et al., 2013).  
Currently, patients’ self-reports about their experience with pharmacological therapy in 
online communities has received growing attention in the area of psychiatric disorders, 
indicating that individual’s cognitive representations may be associated with therapeutic 
outcomes in this group of patients (Richardson et al., 2013). The International Society of Drug 
Bulletins emphasized in 2005 that “patient reporting systems should periodically sample the 
scattered drug experiences that patients reported on the internet” (Leaman et al., 2010).The self-
reports captured in OMB may provide practical information useful for identifying patient 
concerns and the root determinants of patients’ specific attitudes or behaviors that might not be 
traditional self-report tools, such as questionnaire or interview, and in a physician’s office 
(Benton, Ungar, et al., 2011; Harpaz et al., 2014; Sarker et al., 2015). This is particularly the case 
with antidepressants. 
Regarding the growing emphasis on individuals’ cognitive representations about 
treatment in the format of self-report evaluation, the ability to measure individuals’ attitudes 
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toward medications directly from their reviews in social media may increase early detection of 
factors that contribute to negative outcomes by highlighting aspects of treatment that prompt 
negative attitudes towards pharmacological treatment (Kane, Kishimoto, & Correll, 2013). In 
general, signals detected from social media, and in particular from OBMs could be used by 
pharmaceutical companies and the healthcare system to supplement existing pharmacovigilance 
systems. Patients in drugs’ review may disclose adverse effects associated with a particular drug, 
such as antidepressants that may not be captured by pharmacovigilance systems (Benton, Ungar, 
et al., 2011; Harpaz et al., 2014; Sarker et al., 2015). 
The premise of this study is that patients’ self-reports on OMBs of their experiences with 
antidepressants therapy may constitute a reliable source to uncover various dimensions of 
attitude towards these medications. To date, there are no reports in the medical or social sciences 
literature that focused on identifying underlying factors influencing attitude towards 
antidepressant treatment as reported by patients in social media, particularly in OMBs. 
1.3 Statement of Aims 
This study is composed of two main phases. The aim of the first phase is to determine 
usability of drug reviews in social media in providing insight into medication tolerability, 
adherence, and perception (attitude) towards antidepressants treatment. We aim to 
Aim (1): Explore reliability of drug reviews in social media to identify underlying factors 
for patients’ attitudes and adherence towards antidepressants. 
Aim (2): Evaluate usability of drug reviews in social media compare to self-report scales 
in measuring patients’ attitudes towards antidepressants.  
 The aim of the second phase of this study is to determine usability of drug reviews in 
social media in detecting ADRs associated antidepressants. We aimed to: 
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Aim (3): Evaluate reliability of drug review posts in social media for detecting 
pharmacological aspects of antidepressants, including adverse drug reactions (ADRs), 
withdrawal symptoms (WD), and drug effectiveness (EF).  
Aim (4): Explore the usability of Drug reviews in social media in addressing limitations 
of self-repot scales, such as the Antidepressants Side-Effect Checklist (ASEC)  
1.4 Data Source and Methodology of the Study 
 “Askapatient.com”, a particular OMB, constitutes the source of data for this study. It 
enables respondents to post reviews about prescribed medications and rate the medications on a 
scale from 1 to 5 where 1 represents the least satisfaction with the medication and 5 represents 
the highest satisfaction. In addition, for each review, respondents may disclose clinical and 
demographic attributes including age, gender, duration of use, and dosages of medication usage. 
We considered the rating number associated with each review as the respondent’s overall attitude 
towards the medication. Although, the rating originally indicates respondents’ satisfaction with 
the medications in “Askapatient.com”, patient’s satisfaction with a medical therapy in several 
studies was characterized by the patient’s attitude and belief (Taylor & Cronin Jr, 1994; 
Williams, 1994). Satisfied patients have positive attitude to the therapy, while dissatisfied 
patients have negative attitude. Therefore, we considered the respondents’ rate for a medication 
as their overall attitudes, which is equivalent to the ordinal discrete values (Likert scale) that 
used to represent output of structured self-report scales, such as the the Antidepressant 
Compliance Questionnaire (ADCQ) and the the Drug Attitude Inventory (DAI).  
892 patients’ reviews collected randomly from “askapatient.com” for the four most 
commonly prescribed antidepressants including Sertraline (Zoloft) and Escitalopram (Lexapro) 
from SSRI class, and Venlafaxine (Effexor) and duloxetine (Cymbalta) from SNRI class.  
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A mixed-method approach was used to provide structured data from the unstructured 
drug reviews and to test the hypotheses. In qualitative analysis, the framework method with 
hybrid approach of inductive and deductive analysis was used to provide the analytical 
framework for data analysis. The drug reviews at level of sentences were coded against the 
analytical framework. In quantitative analysis, the identified adverse drug reactions (ADRs), 
withdrawal symptoms (WD), and Drug Indications (DIs) were identified and normalized by 
mapping to both UMLS and SNOMED CT concepts. In addition, statistical methods have been 
used for developing a predictive model and testing the association between ADRs and patients 
attitude toward antidepressants.  
1.5 Contributions 
Major contributions of this study are as follows:  
① Developing an analytical framework for analyzing patients’ self-report experiences of 
pharmacological treatment in the social media. 
② Generating structured data from unstructured patients’ self-report experiences of 
psychiatric medications using the Framework Method.  
③ Using a systematic approach to develop a corpus consisted of three main components: (1) 
Sentence classification, (2) Entity identification (ADRs, WD, and DIs), and  (3) entities 
normalization: mapping the entities to equivalent medical concepts in both UMLS and 
SNOMED CT.  
④ Filling the gap between layperson and professional terminologies of psychiatric 
medications by identifying semantic links among the expressions of medical terms.  
⑤ Identifying ADRs and WDs associated with two classes of antidepressants (SSRI and 
SNRI) using real-world patients. 
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⑥ Identifying underlying factors associated with patients’ attitudes towards antidepressants 
using consumer health posts. 
⑦ Developing a predictive model of factors affecting patients’ attitudes toward 
antidepressants using data provided by real-world patients. 
⑧ Measuring association between physiological, psychological, and cognitive ADRs and 
levels of attitude. 
The dataset and guidelines of this study are available at:  
https://sites.google.com/view/pharmacovigilanceinpsychiatry/home 
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2.1 Treatment of Depression  
Treatment of depression disorder in patients with depression may include psychotherapy 
treatment or psychopharmacology treatment. Psychological treatment is characterized by three 
essential factors: (1) it is designed with the purpose of reducing anxiety and depression 
symptoms, 2) it is based on psychological theory, such as learning theory, and 3) it involves a 
structured interaction between a facilitator and a patient (Orgeta, Qazi, Spector, & Orrell, 2015). 
Eligible interventions for psychological treatment include cognitive behavioral therapies, 
relaxation training therapies, psychodynamic therapies, interpersonal therapies, and supportive or 
counseling therapies. McHugh, Whitton, Peckham, Welge, and Otto (2013) using a meta-analytic 
review showed that patient preferences across diverse settings yielded a significant three-fold 
preference for psychological treatment relative to pharmacology treatment. Therefore, improving 
access to psychotherapy treatment is needed to connect more patients to their preferred 
treatment. However, the focus of this study is on pharmacological treatment. 
Over the years, antidepressants as psychopharmacology treatment of depression have 
become the major source for treatment of depression, particularly for moderate to severe 
depression. Chisholm (2015) has introduced antidepressants as a cost-effective choice for 
depression treatment that is quite affordable and feasible to be prescribed in primary care 
settings. From 1999 to 2012, the percentage of Americans used antidepressants increased from 
6.8 percent to 13 percent (Karter, 2015). In 2010, antidepressants were the second most 
commonly prescribed medication after cholesterol medications, and about 254 million 
prescriptions were written, resulting in nearly $ ten billion (B. L. Smith, 2012).  
   
13 
2.2 Psychopharmacology Treatment VS. Psychological Treatment 
There is a wide range of pharmacological and psychological treatment that healthcare 
professionals use to treat patients with depression. The lay public’s preference is psychotherapy, 
and psychopharmacology treatment is rejected by most participants in studies conducted in the 
United States (US), United Kingdom (UK), Germany, and Australia. Although the preference of 
patients with depression is psychological treatment, financial factors such as low reimbursement 
by insurance companies and high out of pocket costs have led to increasing rate of 
pharmacological treatment for depression (Olfson & Marcus, 2009).  
Because this study aimed to identify the underlying factors affecting attitudes towards 
antidepressants, the focus of the rest of this study is on psychopharmacology treatment of 
depression.   
2.3 Types of Antidepressants  
Antidepressants for forty years were the core pharmacological treatment for depression. 
Tricyclic antidepressants (TCAs) were the first antidepressants introduced to market in the 1950s 
(Ferguson, 2001). The efficacy of this drug was linked to mood-elevating properties. Although 
TCAs were in practice for several years, anticholinergic and cardiac side-effects, the risk of 
morbidity and mortality in overdose cases, and the lack of specific treatments led to development 
of new classes of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs) and 
Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs).  
2.3.1 Selective serotonin reuptake inhibitors (SSRIs) 
SSRI class is currently the most common antidepressants recommended to be prescribed 
for patients suffering from different phases of depression (Sayyah, Eslami, AlaiShehni, & Kouti, 
2016). This class encompasses five agents: sertraline (brand name: Zoloft), Escitalopram (brand 
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name: Lexapro), paroxetine (brand name: Paxil), citalopram (brand name: Celexa), and 
fluoxetine (brand name: Prozac). SSRIs in comparison with TCAs use the same property 
(serotonin reuptake inhibitors) for mood elevation. However, the mechanism in SSRIs is 
selective, which causes fewer adverse reactions and therefore enhances the safety of the drugs. 
Since SSRIs treatment has reduced the risk of pharmacotherapy, antidepressants now can be 
prescribed for patients with mild or moderate phases of depression, possibly even subsyndromal 
symptomatic depression (SSD) (Santarsieri & Schwartz, 2015). Some SSRI agents, in addition to 
approval for treating major depression, received approval for treating other mental disorders such 
as obsessive-compulsive disorder and social anxiety disorder. Sertraline and paroxetine have the 
highest approval by the FDA to treat a wide range of mental disorders.  
SSRI agents have subtle yet notable differences in adverse effects and effectiveness. For 
example, Fluoxetine’s efficacious aspect takes longer to emerge in comparison with other SSRIs, 
and Escitalopram has better effectiveness in comparison with Citalopram (Gorman, Korotzer, & 
Su, 2002). All SSRIs may cause physiological and psychiatric adverse effects, such as 
gastrointestinal side effects, insomnia, weight gain, and fatigue. Sertraline may lead to more 
gastrointestinal disturbance than others, while Citalopram and Paroxetine are accompanied with 
more sedative side effects. In terms of withdrawal symptoms, Sertraline and Paroxetine, in the 
case of sudden discontinuation, can cause more severe effects. SSRIs plus the use of other 
medications may also lead to different drug-drug interactions. Lower adverse effects and the 
effectiveness of SSRIs, as well as diagnostic factors such as phase of depression and patient 
conditions, cause healthcare providers to prescribe a SSRI.  
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2.3.2 Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) 
The mechanism of Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs) is by 
inhibiting reuptake of serotonin and norepinephrine, which is similar to the mechanism of TCA 
class, but like the SSRI class, SNRIs have less adverse effects. Therefore, SNRIs are prescribed 
for a wide range of psychotic disorders. SNRIs include mainly Venlafaxine (brand name: 
Effexor), Desvenlafaxine (brand name: Pristiq), Duloxetine (brand name: Cymbalta) and 
Levomilnacipran (brand name: Fetzima). Like the SSRI class, SNRIs may cause physiological 
and psychiatric adverse effects, but they tend to induce more nausea, insomnia, dry mouth, and, 
in rare cases, elevated blood pressure(Santarsieri & Schwartz, 2015).  
 In terms of efficacy, SNRI agents may show higher effectiveness than SSRI agents. For 
example, results of three studies have shown that a greater number of patients treated with 
Venlafaxine showed depression symptom remission compared with patients on SSRIs and on 
placebos (Nemeroff et al., 2003; D. Smith, Dempster, Glanville, Freemantle, & Anderson, 2002; 
Thase, Entsuah, & Rudolph, 2001). On the other hand, one study did not find any significant 
statistical difference between the efficacy of Duloxetine and SSRI agents (Goldstein et al., 2004).  
According to the dataset from Symphony Health Solutions with one year of prescription-
filling data (from July 1, 2011 to June 30, 2012) for patients from Washington DC, Maryland, 
Virginia and West Virginia, Sertraline (Zoloft), Escitalopram (Lexapro), Venlafaxine (Effexor), 
and duloxetine (Cymbalta) are the four most common antidepressants prescribed for depression. 
2.4 Experience of Patients With Antidepressants  
The experiences of people using antidepressants vary considerably. It has been accepted 
that 10%-30% of people with mental disorders do not respond to medications (Al-Harbi, 2012). 
Some patients found the medications very helpful in treating symptoms of the disorders and they 
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could tolerate troublesome adverse effects. Others found the drugs ineffective and believed the 
risks associated with adverse effects outweighed the beneficial aspects of antidepressants and 
therefore had a low level of acceptance of the drugs (De las Cuevas & Sanz, 2007).  
2.5 Duration of Antidepressants Usage  
According to NCCMH (2010), antidepressant treatment should be continued at least for 
six months to reduce risk of relapse, even if the therapy goal was achieved and the full remission 
of depression symptoms was observed. More importantly, the relapse rate would be lower if the 
acute treatment dosage was maintained rather than reducing the dosage over the six months 
(NCCMH, 2010).  
2.6 Adherence to Antidepressant Treatment  
Despite the clinical trials’ proof of antidepressants efficacy, non-adherence to treatment is 
a major barrier to their effectiveness in clinical practice (López-Torres et al., 2013). Overall, 
therapeutic benefits of antidepressant treatment depend on maintaining an appropriate drug 
regimen for a certain period time and a proper method of discontinuation. Many patients 
recognize the necessity of treatment due to warnings by their healthcare providers about the 
importance of adherence (Murata et al., 2012). Unfortunately, a significant number of individuals 
diagnosed with depression do not follow the prescription and they may discontinue 
antidepressant use abruptly, which may lead to severe withdrawal symptoms, increasing 
emergency room visits, and even hospitalization (Grenard et al., 2011). Research showed that 
about 50 percent of patients with depression discontinue their medication during the first month 
of treatment, and nearly 68 percent of patients, discontinue their medication in the first 3 months 
of treatment (De las Cuevas et al., 2014). Results of other studies indicate that between 30 
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percent and 68 percent of patients with depression did not complete their prescribed course of 
antidepressant treatment (Aikens et al., 2005).  
2.6.1 Importance of adherence to antidepressant treatment 
Adherence to antidepressant regimes is important to achieve expected clinical outcomes. 
According to one meta-analysis, efficacy of antidepressants cannot be achieved with poor 
adherence in patients with depression (Grenard et al., 2011). That underlies the need for 
innovations to assist patients in following their prescription. Non-adherence can also increase the 
risk of relapse (Alekhya et al., 2015; NCCMH, 2010). The ratio of mental illness relapse is about 
five times greater in non-adherent patients compared to adherent patients (Masand, Roca, Turner, 
& Kane, 2009). Relapse of depression, in turn, may affect long-term prognosis, severity of 
depression recurrence, and difficulty of treatment. Moreover, non-adherence to antidepressants is 
associated with increased rate of emergency visits, longer hospital admission, low quality of life, 
and significant cost at individual, family, and health care system levels (Vives et al., 2014).  
2.6.2 Factors Affecting on non-Adherence behavior  
In response to the substantial negative impact of non-adherence behavior, identifying 
high risk factors associated with non-adherent patients is important from the view of both clinical 
practice and interventions targeting these patients (Rivero-Santana, Perestelo-Perez, Pérez-
Ramos, Serrano-Aguilar, & De las Cuevas, 2013). Several studies identified predictive factors 
associated with non-adherence behavior in pharmacological treatment. Jin, Sklar, Oh, and Li 
(2008) in a literature review categorized potential predictive factors for non-adherence in five 
categories:  
! Patient-centered factors, such as demographic factors and patient-physician 
relationship; 
! Therapy-related factors, such as treatment complexity and medication adverse 
effects; 
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! Healthcare system factors, such as lack of accessibility; 
! Social and economic factors, such as social support and treatment affordability; 
and  
! Disease factors, such as severity and duration of a disease.  
 
Research focused on antidepressant non-adherence found a broad range of factors 
associated with premature discontinuation of these drugs. Likewise, in the categorical system 
provided by Jin et al. (2008), the potential predictive factors for antidepressants non-adherence 
can also be summarized in the same five groups (Table 2-1). Examples of factors that can be 
included in the categories of patient-centered factors are patient forgetfulness (Bulloch & Patten, 
2010), patient’s specific personality type or issue such as being extroverted or having a 
personality disorder (Akerblad, Bengtsson, Holgersson, von Knorring, & Ekselius, 2008; Holma, 
Holma, Melartin, & Isometsä, 2010; Woolley, Fredman, Goethe, Lincoln, & Heeren, 2010), 
substance abuse (Holma et al., 2010), and low motivation to continue treatment  (Masand, 2003). 
The group of therapy-related factors can include antidepressants’ adverse effects (Fortney et al., 
2011) such as sexual dysfunction, (Cohen, Kühn, Sträter, Scherbaum, & Weig, 2010), concern 
about adverse effects, such as possibility of addiction (Brown et al., 2005) , impact on 
personality (Chakraborty et al., 2009), and being doubtful about drug effectiveness (Hoencamp, 
Stevens, & Haffmans, 2002). The group of socioeconomic factors contains issues such as cost of 
antidepressants and lack of coverage by insurance companies. This may lead to the erroneous 
views in patients that antidepressants are not necessary (Kennedy, Tuleu, & Mackay, 2008). The 
group of healthcare system factors includes poor instruction of intake (Woolley et al., 2010), and 
lack of follow-up care by clinicians (Masand, 2003). Finally, the group of disease factors include 
patient’s perceived severity of depression and duration of symptoms (Demyttenaere et al., 2008).  
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Table 0-1 Potential Predictive Factors Affecting Non-adherence towards Antidepressants 
Category Example of potential Factors in each category 
Patient-centered factors Patient forgetfulness, specific personality type 
Therapy-related factors Antidepressants’ adverse effects, drug ineffectiveness 
Socioeconomic factors Cost of antidepressants  
Healthcare system factors Lack of follow-up care by clinicians, instruction of intake 
Disease factors Perceived severity of depression and duration of symptoms 
 
There are several inconsistencies in the literature regarding the significant factors 
affecting drugs adherence in patients with depression. For example, from ten studies that tested 
the impact of depression severity on non-adherence, only two of them concluded that depression 
severity was a significant predictive factor (Rivero-Santana et al., 2013). Among studies that 
evaluated the relationship between basic demographic factors and non-adherence, there is no 
consistency on the findings related to gender, educational level, living situation, income, marital 
status, or employment status (Rivero-Santana et al., 2013).  
One of the major reasons for this inconsistency is the complexity of non-adherence and 
the underlying factors. For example, education level might not directly be related to non-
adherence behavior (Rivero-Santana et al., 2013). In fact, other confounding variables such as 
attitude towards medication may drive any observed association between education and non-
adherence.  
2.6.2.1 Attitude as a significant predicative factor for non-adherence to antidepressants 
Patients’ self-reports about medication effectiveness have received growing attention in 
the area of psychopharmacology. Cognitive representations, that is, the person’s thoughts about 
their medication, may be associated with therapeutic outcomes (Richardson et al., 2013). This 
perspective is supported by cognitive representation models such as the Health Belief Model 
(HBM) (Green & Murphy, 2014) and the Population and Theory of Planned Behavior (TPB) 
(Ajzen, 1985). According to these models, the intention and motivation of patients to present a 
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specific health behavior, such as taking medication, is a function of three factors: 1) individual 
attitude towards the behavior, 2) perception of social norms regarding the behavior, and 3) 
intention to perform the behavior. 
Attitude is a tendency or disposition of an individual to a particular act (Bergman, 1998), 
representing the overall evaluation of that act. In other words, attitude is a function of an 
individual’s belief, which is the base of comparing and contrasting potential harms and benefits 
of a specific behavior (Richardson et al., 2013). For example, a patient who believes that taking 
antidepressants causes more harm than good has a negative attitude towards taking 
antidepressants.  
There is well established that understanding patients views about their problems and their 
treatments can significantly improve process of treatment (Moncrieff, Cohen, & Mason, 2009). 
Aikens et al. (2005) emphasized the importance of association between patients’ perceptions 
about medication and the clinical outcome, such as adherence. Aikens et al. (2005) showed that 
outcomes of the interventions targeting non-adherence behaviors (such as intensified follow up 
plan) ultimately depend on the patients’ willingness to take the drugs. 
Research showed that across chronic medical illness in general, non-adherence is loosely 
associated with demographic information and clinical variables, such as severity of the 
symptoms or type of drug adverse effects, but more strongly it is associated with patients’ beliefs 
and attitudes, perceived necessity, and perceived medication risks (Aikens & Klinkman, 2012), 
(Acosta et al., 2013; Aikens et al., 2008; Brown et al., 2005; Chakraborty et al., 2009; De las 
Cuevas et al., 2014; López-Torres et al., 2013; Richardson et al., 2013; Verdoux et al., 2000). It 
is more likely that patients with positive attitudes show better adherence behavior than patients 
with negative or indifferent attitudes(Aikens et al., 2005; De las Cuevas et al., 2014; Richardson 
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et al., 2013). It is ultimately patient perception of beneficial aspects of the medication versus the 
harmful aspects that will determine the acceptance or rejection of a medication (Christensen, 
2004) (Acosta et al., 2013). For example, recent studies found that a majority of patients on 
antidepressants have erroneous views towards these drugs, which in turn influence adherence 
behavior (Chakraborty et al., 2009) (Jacob, Ab Fatah Ab Rahman, & Hassali, 2015). A study 
with a sample of 573 primary care patients indicated that the only identifiable baseline predictive 
factor of early discontinuation was belief about the appropriateness of taking antidepressants 
(Aikens & Klinkman, 2012). Moreover, a significant negative correlation has been found 
between patients’ attitudes and beliefs toward antidepressants and the percentage of days of 
missed dosages (Jacob et al., 2015). On the other hand, Hung, YIaCHAO, and JAUa (2014) 
found that the main reason for patients continued acceptance of depression treatment was a 
positive view toward antidepressants effectiveness.  
 “Patients’ perspective towards antidepressants treatment is complex, neglected and 
ambivalent” (Demyttenaere et al., 2004). It has been evident that identifying potential predictive 
factors for attitude may have significant implications for understanding the complexity of this 
phenomenon and therefore, designing effective interventions to improve drug therapy adherence 
(Kessing et al., 2005). Patients with depression may have some specific beliefs and perceptions 
that may lead to failure to follow antidepressant instructions. For example, concerns about 
addictive possibilities and perceived distress received from adverse effects are significant factors 
leading to negative attitude toward antidepressants and consequently non-adherence behavior 
(Fawzi et al., 2012).  
According to Horne’s theoretical model (Lin et al., 1995), beliefs about medication in 
general seem to be most relevant for adherence at the start of treatment (Vergouwen, Burger, 
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Verheij, & Koerselman, 2009). For example, believing that antidepressants are associated with 
harmful aspects increase the patients’ sensitivity and decrease the patients’ tolerability for anti-
depressants.  
Aikens and Klinkman (2012) suggested that there are different factors affecting 
medication adherence in the acute and maintenance phase of antidepressant treatment. In the 
acute phase of treatment, a change in functional health predicts change in medication beliefs. 
Patients’ perceptions become more positive as medication becomes effective. On the other hand, 
occurrence of side effects reinforces the belief that there is harmful aspect of the drug. In the 
maintenance phase, patients' beliefs about antidepressant necessity versus harmfulness were the 
only identifiable predictor of adherence. Perceived necessity for antidepressant treatment is 
directly connected to the antidepressants perceived effectiveness. The perceptions of potential 
harm is connected to adverse effects and withdrawal symptoms in the case of missing a dosage 
or dose reduction (Aikens et al., 2005).  
2.7 Potential Predicative Factors Associated With Attitude Towards Antidepressants 
Attitudes of patients and caregivers toward chronic psychiatric disorders appeared to be 
shaped by pharmacological treatment factors, healthcare system factors, social-cognitive and 
psychological factors, patient-related factors, and depression factors. 
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Table 0-2 Factors Affecting Patients Attitude Towards Antidepressants (Suggested by Literature) 
Category Factors in each category 
Pharmacological treatment factors • Perceived effectiveness 
• Perceived necessity 
• Perceived concerns 
• Adverse drug reaction 
• Perceived distress from adverse effects 
Healthcare system factors • Patient-provider relationship 
• Healthcare settings 
• Affordability 
Social-cognitive and psychological 
factors 
• Stigma and cultural related factors 
• Partner supports 
Patient-related factors • General concern and necessity 
• Knowledge about pharmacological aspects of medication  
• Socio-demographic factors 
• Educational level 
Depression factors • Depression severity, type, and duration 
• Patient insight about depression 
 
Table 2-2 shows the categories and factors in each category affecting patient attitudes 
towards antidepressants. The following sections explain the factors and their association with 
attitudes.  
2.7.1 Pharmacological treatment factors  
Identified factors in the pharmacological treatment category include medication perceived 
effectiveness, adverse effect reaction (side-effects), perceived distress from side effects, 
perceived necessity, and perceived concern of treatment. 
2.7.1.1 Perceived effectiveness 
Drug effectiveness is a strong predictive factor for shaping patients’ attitudes in both the 
acute and the maintenance phase of treatment. Patients with depression generally express the 
effectiveness of antidepressants as subjective experiences that mostly indicate the impact on their 
quality of life. The patients commonly suffer from emotional problems and cognitive 
impairments, such as “stress” and “slow information processing speed” (Culang-Reinlieb, Sneed, 
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Keilp, & Roose, 2012) that restrict their capabilities in daily functioning and social 
participations. Therefore, from patients’ viewpoints, antidepressant effectiveness is the extent to 
which they help patients reduce emotional problems (Demyttenaere et al., 2004; Ferguson, 
2001), improve cognitive functionality, such as psychomotor speed and ability to plan and 
initiate a behavior (Demyttenaere et al., 2004; Reilly JL, 2011), and enhance their coping 
mechanisms, such as dealing with stress or difficult relationships (Demyttenaere et al., 2004; 
Prins, Verhaak, Bensing, & van der Meer, 2008).  
2.7.1.2 Perceived necessity  
From the layperson’s viewpoint, the necessity of antidepressants as the main source of 
treatment is much lower than other methods of treatment, such as psychotherapy. People usually 
view counseling as the best solution for depression treatment (Demyttenaere et al., 2004). 
Therefore, it is not surprising that the perspective of patients with mental disorders regarding the 
perceived necessity of pharmacological treatment is in line with this viewpoint. From 49% to 
84% of patients with mental disorders who are looking for treatment feel that pharmacological 
treatment is not a desirable solution (Prins et al., 2008). A plausible implication of these findings 
is that patients with depression may discontinue taking medication in the acute phase of 
treatment if they find perceived effectiveness less than expectations. Surprisingly, they may also 
discontinue the treatment prematurely if they feel better, assuming they no longer need 
medication to feel better.  
2.7.1.3 Perceived concerns 
Patients’ perceived concerns about antidepressants mechanism and its long-term effects 
on patients’ quality of life are strongly associated with patients’ negative attitudes towards 
antidepressants (Aikens et al., 2005; Benton, Hill, et al., 2011; Demyttenaere et al., 2004; Horne, 
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Weinman, & Hankins, 1999; Hunot, Horne, Leese, & Churchill, 2007). The main concerns of 
patients on antidepressants are related to addictive possibilities (Chakraborty et al., 2009; Jacob 
et al., 2015; Prins et al., 2008) and immunity to antidepressants (Kessing et al., 2005). 
Demyttenaere et al. (2004) in a self-report scale, the Antidepressant Compliance Questionnaire 
(ADCQ), designed for assessing patients attitudes toward antidepressants introduced four 
dimensions to measure patients’ concerns including addictive possibility of antidepressants, 
control over feelings and thoughts, altering personality, and immunity to antidepressants. In 
another self-report scale, the Beliefs about Medicine Questionnaire (BMQ) (Horne et al. (1999), 
perceived concern is measured based on three dimensions: 1) long-term effects and its impact on 
quality of life; 2) concern about the mechanism and addictive possibilities of antidepressants; 
and 3) concern about losing autonomy because of the effects of the medication.  
2.7.1.4 Adverse drug reaction  
Adverse effects of antidepressant treatment correlate with the perceived harmfulness of 
antidepressants (Aikens et al., 2005). This provokes negative attitudes towards the drugs 
(Dougherty, Klein, Olino, Dyson, & Rose, 2009; Murata et al., 2012; Ng, Smith, King, Ong, & 
Schweitzer, 2012), and in turn leads to patients’ non-adherence (De las Cuevas et al., 2014; 
Dougherty et al., 2009). Cash and Brown (2000) reported that related adverse-effects of weight 
gain influence patient attitude toward antidepressants and therefore lowers patients’ acceptability 
of the drugs. Bradley, McGrath, Brannen, and Bagnell (2010) also found that among adolescents, 
the most adverse effects that made adherence to antidepressant treatment difficult were the 
increase of weight among girls and the sexual side effects among boys.  
Patients may express adverse effects of antidepressants as physiological symptoms that 
are directly correlated with pharmacological aspects of the medications. But there is still a large 
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number of patients who express adverse effects in terms of subjective complaints (Hogan et al., 
1983) such as “not feeling like themselves”, “ unable to sit”, or  “ alcohol craving”. These 
adverse effects are recognized as behavior toxicity of pharmacological treatment and may reflect 
extrapyramidal or autonomic side-effects, or subtle and frequently syndromes of akathisia 
(Hogan et al., 1983). Further, patients may report side effects as emotional problems (Kikuchi, 
Uchida, Suzuki, Watanabe, & Kashima, 2011; Price, Cole, & Goodwin, 2009; Sansone & 
Sansone, 2010) or cognitive dysfunction (Sayyah et al., 2016) such as “aggressiveness” or “brain 
fog”. In addition, impacts of adverse effects on daily functioning and social participation 
(Giannangelo, Bowman, Dougherty, & Fenton, 2005) and in overall impact on quality of life, 
such as job loss are determinant factors that influence patients’ attitudes towards antidepressants 
(Hofer et al., 2004). Self report scales for measuring ADRs associated with antidepressents are 
reported in Appendix A.  
2.7.1.5 Perceived distress from adverse effects 
 “There is preliminary evidence that pharmacogenetic variations may affect the efficacy 
and tolerability of antidepressant drugs” (NCCMH, 2010). It is also convincible that patients 
self-attention to internal bodily sensation can vary from patient to patient and this can lead to 
their expressing a range of intensity for identical physiological and emotional pain (Hogan et al., 
1983). The perceived pain (distress) from medication can influence patient attitude toward 
medication and in turn can determine patient drug intake behavior. For example, patient may 
frequently forget to follow a prescription. This information implies that in addition to a specific 
ADR and the level severity associated with it, perceived stress received from adverse reaction is 
another treatment factor affecting on patient attitude toward medication. For example, a young 
female patient experiencing a small weight gain may receive high perceived distress that may 
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result in antidepressant discontinuation. While for another patient who experienced the same 
amount of weight gain, the level of perceived distress from this adverse effect may be low.  
Overall, patient distress from antidepressants adverse effects is not only a function of 
patient tolerability, but also a function of perceived stress received from depression symptoms 
and also concern about the long term effect of adverse effects on mental and physical 
functioning.  
Regarding the importance of perceived distress in shaping attitudes toward 
antidepressants, educational strategies designed merely to inform patients the type of side-effects 
may be relatively ineffective in patients whose interceptive cues provide less than favorable 
information about the medication in their body system.  
2.7.2 Healthcare system factors  
Patient-provider relationship and healthcare setting are factors that are associated with 
medication attitude. Few studies discussed medications affordability as factors that may 
influence attitudes towards medications.  
2.7.2.1 Patient-provider relationship 
Several studies emphasized patient positive experience as a strong predictive factor of 
patients’ positive attitudes toward medications and adherence behavior (Chakraborty et al., 2009; 
Day et al., 2005; Demyttenaere et al., 2004; Hunot et al., 2007; Prins et al., 2008; Vives et al., 
2014). The importance of this interaction is not limited to the prescriber-patient relationship. Day 
et al. (2005) suggested that patients’ admission experiences and relationship with healthcare 
staffs also influence patients’ attitudes toward medication. Studies have found that in a patient-
centered approach where providers actively seek to understand patients’ perspectives to 
treatment and respect patients’ preferences by involving them in the process of treatment 
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decision making and providing supportive continued management, providers are most likely to 
enhance and maintain patients positive attitude toward therapy (Day et al., 2005; Hunot et al., 
2007).  
The Antidepressants Compliance Questionnaire (ADCQ) (Demyttenaere et al., 2004), 
incorporated patient-physician interaction as one of the main components for assessing patient 
attitude toward antidepressants. Patients’ perceptions of physicians’ knowledge, patients’ 
perceptions of the sufficiency of knowledge provided by physicians about disorder and treatment 
process, and patients’ perceptions of communication effectiveness such as the perception of 
clinicians interest to a patient’s problem and the level of support received from clinicians are 
three dimensions that ADCQ addressed in assessing patient physician interaction Demyttenaere 
et al. (2004).   
2.7.2.2 Healthcare settings 
Few studies evaluated the relationship between patients’ attitudes toward psychotic 
medications and healthcare settings, i.e. primary care sites vs. psychiatric sites. Aikens et al. 
(2005) suggested that patients with depression treated in primary care settings are more likely to 
discontinue antidepressants at initial stages. A plausible explanation is that patients have more 
uncertainty about diagnosis results and prescribed treatment in primary care settings compared 
with psychiatric settings. This uncertainty can lower patients’ perceived necessity for 
antidepressants, which may result in a negative attitude toward medications.  
2.7.2.3 Affordability 
Affordability is a significant factor for predicting patient adherence behavior (Jin et al., 
2008). Nevertheless, studies related to attitude did not consider this factor as a potential 
predictive factor for attitude toward antidepressants, but Weiden et al. (1994) suggested lack of 
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insurance coverage and unaffordability of a drug may reduce the necessity of medication from a 
patient’s view point.  
2.7.3 Psycho-social factors  
Psycho-social factors that are significantly associated with attitude towards medication 
are stigma and cultural related factors, and perceived support from partners ass well as family 
and friends. 
2.7.3.1 Stigma and cultural related factors 
Stigma against depression and antidepressants are significant factors for negative attitude 
and premature discontinuation in patients with depression (Acosta et al., 2013; Jacob et al., 2015; 
Malpass et al., 2009). Stigma about the use of antidepressants is similar to the stigma against 
depression, such as perceived emotional and mental weakness and inability to cope with daily 
problems. However, lack of belief in the therapeutic efficacy of antidepressants and showing 
non-adherence behavior are indicators of avoiding to being labeled as mentally ill (Acosta et al., 
2013; Castaldelli-Maia et al., 2011).  
2.7.3.2 Partner support 
Patients perceived support from partners, family, and friends is associated with patients 
positive attitude towards antidepressants (Demyttenaere et al., 2004). This factor is incorporated 
as one of the components in the Antidepressants Compliance Questionnaire (ADCQ). Items in 
this component measure patient’s perceived support from partners regarding their views about 
being diagnosed with depression and treated with antidepressants (Demyttenaere et al., 2004).  
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2.7.4 Patient related factors 
Patients related factors that may influence patients’ attitudes about antidepressants are 
general concern and necessity of medications, knowledge about antidepressants’ mechanisms 
and adverse effects, socio-demographic information, and patient’s education.  
2.7.4.1 General concern and necessity 
Horne et al. (1999) in the Concern-Necessity Framework discussed that patients’ general beliefs 
about the necessity and harmfulness of medications are significant factors affecting patients’ 
attitudes toward prescribed medications and adherence behavior. Patients who have concerns 
about pharmacological treatment and believe that natural remedies or changing their life style 
will have better healthcare outcomes than pharmacological treatment are more likely to reject a 
prescribed medication or show non-adherence behavior, particularly at initial phase of treatment.  
2.7.4.2 Knowledge about medication 
Clarifying the purpose of a medication, possible physiological adverse effects, the nature 
of regimen, and the proper time for discontinuation are a set of pharmacology knowledge that 
healthcare providers need to share with patients with depression.  
A qualitative study (Haslam, Atkinson, Brown, & Haslam, 2005) showed that many 
patients taking antidepressants suffer from side-effects that they felt they were not sufficiently 
informed about them and mechanisms of their management. Gabriel and Violato (2010) 
discussed that patients with more knowledge about their illness and their treatment are likely to 
be have positive perception about treatment and, in tern, to be more adherent. 
2.7.4.3 Socio-demographic factors  
Gender, age, ethnicity, and education level are important predisposing characteristics 
influencing attitude and perceived needs in people with depression. 
   
31 
Women are two times more likely to seek treatment for depression as they believe less in 
the addictiveness of antidepressants (Prins et al., 2008). Young, senior, and minority-group 
patients are more vulnerable having a low perceived need and a negative attitude towards 
treatment. Young people prefer to cope with depression symptoms without seeking for help, 
because they view depression as a sign of weakness and feel embarrassed to express their 
feelings. On the other hand in the elderly, diagnosis is usually missed, particularly in patients 
with a stressful life and retirement (Prins et al., 2008). Minority groups tend to have less access 
to healthcare services, and they also have a different perceived need and attitude toward 
pharmacological treatment (Scheppers, Van Dongen, Dekker, Geertzen, & Dekker, 2006). 
Contrary with Prins et al. (2008) findings pertinent to age and gender, some studies found that 
age and gender are not significant predictive factors for attitude towards antidepressant (Jacob et 
al., 2015; Murata et al., 2012; Ng et al., 2012).  
2.7.4.4 Educational level 
Education level is loosely associated with attitude toward medication and belief toward 
antidepressants(Murata et al., 2012; Ng et al., 2012). Intuitively, it may be expected that 
individuals with a higher education are more motivated to follow prescriptions. However, 
patients with a higher education may be more skeptical about the mechanism of antidepressants 
or the accuracy of diagnosis. In addition, they may have more access to alternative sources of 
treatment, thereby they will show less positive attitudes toward antidepressants compared to 
patients with low education. On the other hand, patients with a low education level may have 
more trust in a physicians’ diagnosis and treatment plan (Jin et al., 2008). 
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2.7.5 Depression disorder characteristics 
Depression disorder characteristics including type, severity, and duration and patient 
insight about depression characteristics may influence patients attitude toward antidepressants.  
2.7.5.1 Depression severity, type, and duration  
“Patients with major depressive disorder appeared to have a more negative view of 
antidepressants than those with bipolar disorder” (Acosta et al., 2013).  Murata et al. (2012) also 
found that there is no correlation between types of depression including melancholic, 
nonmelancholic, and bipolar depression and attitude toward antidepressants. In terms of duration, 
Ng et al. (2012)) did not find a significant correlation between the duration or severity of 
depression and the patients attitude was found. 
2.7.5.2 Patient insight about depression  
A majority of patients believe that depression is a psychological problem rather than a biological 
problem (Hansson, Chotai, & Bodlund, 2010; Jacob et al., 2015; Jorm, Christensen, & Griffiths, 
2005). This erroneous view causes patients to reject biological interventions, i.e., antidepressants 
in moderate- to-severe cases, as they feel they can heal themselves by simply changing their 
behavior or personality(Prins et al., 2008) 
The factors (explained in this section) identified by literature as important factors affecting 
attitude will be used for developing initial themes for data analysis. The the detail of data 
analysis procedure is explained in the methodology section.  
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2.8 Self-Report Scales Used in Antidepressants Studies for Measuring Attitude 
Identifying dimensions of patients attitude towards psychotic medications, particularly 
antidepressants is a challenging work, partly due to the lack of reliable and comprehensive 
methods to capture predictive factors affecting patients’ attitudes. Few studies have attempted to 
develop structured methods, such as self-report measures, to operationalize the concept of 
attitude towards psychiatric drugs in various scales (Demyttenaere et al., 2004; Hogan et al., 
1983; Horne et al., 1999; López-Torres et al., 2013). The well-validated self-report scales for 
assessment of attitude among patients with psychotic disorders include the Drug Attitude 
Inventory (DAI) (Hogan et al., 1983), The Rating of Medication Influence Scale (ROMI) 
(Weiden et al., 1994), the Antidepressants Compliance Questionnaire (ADCQ) (Demyttenaere et 
al., 2008), and the Beliefs about Medicines Questionnaire (BMQ) (Hogan et al., 1983). The 
detail of the self-report scales is presented in Appendix B.  
2.8.1 Methodological Limitations of self-report scales  
Self report scales, including the ADI (Drug Attitude Inventory), the ADCQ 
(Antidepressant Compliance Questionnaire), the BMQ (Beliefs about Medications 
Questionnaire), and the ROMI (Rating of Medication Influence Scale), are non-intrusive and 
efficient to capture information about patients’ attitudes and beliefs toward psychiatric 
medications (Nunkoosing, 2005). However, they are associated with some limitations.  
First, these tools are different in dimensions used for measuring attitude and the impact of 
medications on patients’ quality of life (Richardson et al., 2013) Wolters, Knegtering, van den 
Bosch, and Wiersma (2009). While ADI, ADCQ, and BMQ assigned some items for assessing 
patient’s perceived necessity and concern directly or indirectly, ROMI did not include factors for 
measuring patient concern about medications. In terms of healthcare settings, ADCQ and ROMI 
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included items expressing quality of patient-physician relationship and also psychosocial 
support, but ADI and BMQ did not. BMQ is unique in terms of assessing patient belief in 
general towards medications. This factor has a significant role in adherence behavior at initial 
stage of treatment. In addition, ROMI is unique in suggesting items assessing patient perception 
of illness.  
Second, the focus of the questionnaires is on extrapyramidal side effects and patients’ 
subjective experiences with medications, whereas physiological side effects such as muscle 
spasm may have a strong impact on forming patients’ attitudes toward medications. Studies 
interested in finding association between side effects and attitude, need to administer other 
questionnaires, such as self-report antidepressant Side-Effect Checklist (ASEC) or Liverpool 
University Neuroleptic Side Effect Rating Scale (LUNSERS) Ng et al. (2012).  
Third, the DAI, the ROMI, the BMQ, and the ANT questionnaire are primarily developed 
to assess attitudes toward antipsychotics. They have thus been mainly used among patients with 
psychosis or schizophrenia, and few studies used them in patients with depression (Grover, 
Chakrabarti, Sharma, & Tyagi, 2014). 
Fourth, studies employing the scales represented the scales’ output score in 
a continuous range, in a set of ordinal discrete values (such as a Likert scale) or in a binary 
construct (positive attitude vs. negative attitude). Although, representing data in an ordinal 
discrete values may capture meaningful variance in data to some extent, a binary construct 
discards the variance. To simplify process of data analysis, most of the studies represented output 
in a binary construct.  
Fifth, self-report questionnaires depend on individuals’ ability to understand items and 
their willingness to reveal personal information. Patients tends to report minimally with a 
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reluctance to be critical (Nunkoosing, 2005). Participant answers may be biased because of 
“social desirability despite its anonymity and confidentiality and distance from the researchers or 
those responsible for clinical care” De las Cuevas and Sanz (2007). Furthermore, reliability of 
questionnaires may be affected by patients’ memory recall, specifically for questions that need 
long term recall period or are not specified by time period. These limitations can affect response 
accuracy and consequently the validity and reliability of the questionnaire. 
Sixth, there is always this risk that patients with most the positive or most negative 
attitude may have a high tendency to participate in studies focused on measuring attitude or 
adherence, while patients with indifferent attitudes may be less willing to participate in these 
studies. This problem can lead to sample bias and thereby limit generalizability of studies’ 
findings to the population. 
The premise of this study is that patients’ self-reports experience in online healthcare 
forums may constitute a reliable source to uncover various dimensions of attitude towards the 
medications, and in turn, addresses the limitations of self-report scales (questionnaires) in 
measuring patients attitudes toward antidepressants.  
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2.9 Social Media and its Application in Healthcare 
Novel social media technologies have provided patients with a unique platform to freely 
report their experiences and express their attitudes about healthcare services and treatments. The 
number of social media applications with a focus on healthcare topics has been constantly 
growing in recent years (Metke-Jimenez & Karimi, 2015).The findings of a public opinion 
survey conducted in 2009 by Pew Research Center’s Global Attitudes Project showed that 61 
percent of Americans looked online for general health information, 41 percent read others 
experience and 30 percent were actively participating in creating new knowledge (Fox & Jones, 
2012).   
Patients with mental disorders usually prefer to share health experiences and concerns 
with each other rather than in clinical research studies or with their healthcare providers 
(Blenkinsopp, Wilkie, Wang, & Routledge, 2007; Leaman et al., 2010). This may be stigma 
associated with mental disorders and help seeking for the conditions (Griffiths et al., 2009). 
Currently, many patients’ self-reports about their experience with pharmacological 
therapy in online communities are specifically in the area of adverse drug reactions. The 
International Society of Drug Bulletins emphasized in 2005 that “patient reporting systems 
should periodically sample the scattered drug experiences that patients reported on the internet” 
(Leaman et al., 2010). 
Previous studies showed that clinical trials and post-marketing surveillance systems 
established by regulatory agencies, such as the Adverse Event Reporting System (AERS) of 
Food and Drug Administration (FDA), are not able to detect potential risks of drugs pre and post 
marketing. It is estimated that such surveillance systems capture less than 10 % of the Adverse 
Drug Reaction (ADR) occurrence, due to the voluntary nature of the systems in data collection 
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and perhaps patients’ negative perceptions of the systems (Yang, Yang, Jiang, & Zhang, 
2012). These limitations have led to major concerns in public health; thousands of incidents of 
hospitalizations and deaths have occurred due to undetected and uncontrolled risks (Karimi, 
Metke-Jimenez, Kemp, & Wang, 2015). 
According to recent studies showed, patients’-self reports of ADRs and drug efficacy to 
surveillance systems have the same quality as reports by healthcare professionals (Uher et al., 
2009). As such, patients’ self-reports are used as a reliable source for risk discovery through 
programs such as FDA’s MedWatch program or the UK MHRA’s Yellow Card Scheme. 
However, many patients do not report to these systems, perhaps due to negative attitude towards 
providers, ignorance of the availability of these systems, or their severity of illness (Yang et al., 
2012). Instead, they prefer to report and discuss their detailed experience with prescribed 
medications in various social media platforms, such as online support groups and message 
boards. Accordingly, these social media platforms have turned out to be reliable sources for 
discovering various aspects of medications benefits and risks, such as drugs’ adverse effects, 
drug effectiveness, and drug impacts on patients' quality of life.  
2.10 Challenges in Health Information Extraction from Consumer Health Posts 
Social media health-related content is typically found in the form of unstructured, natural 
language text.  Regarding the relatively large size of this type of data in social media, methods  
for automatic extraction and analysis of the data received considerable attention (Sarker et al., 
2015). However, performance of the methods is affected by the inherent complexity of the posts.  
This complexity is the result of: 
1) Colloquial phrase and sentence structure,  
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2) Deviation of lay person language from professional medical language in expressing the 
pharmaceutical effects of drugs, and  
3) Ambiguity in presentation of a specific term; a given term may be used variously as a 
side-effect, a withdrawal symptom, or a drug indication.  
Due to the first challenge, the conventional methods for named entity recognition for 
detecting boundaries of terms and phrases are subject to bias inherent in the data (Liu & Chen, 
2013).Therefore, a dictionary-based approach to named entity recognition  has been used as an 
alternative. Nevertheless, because of the second and third challenges, the systems face low recall, 
leading to high frequency of undetected desirable terms, such as side-effects and withdrawal 
symptoms.   
The lexicon-based approach for name entity recognition in the area of 
pharmacovigilance currently dominates other methods of data extraction in consumer health 
posts. The lexicons have been mostly developed by combining standard medical vocabularies 
including COSTART (that was developed by the FDA for coding post-marketing ADR reports 
and was later replaced by MedDRA), the FDA Adverse Event Reporting System (FAERS) 
(Edwards et al., 2013), MedEffect (Canadian Adverse Reaction and Medical Device Problem 
Reporting database) ("Medeffect Canada. MedEffect Canada [Internet],"), SIDER (which has 
been developed based on resources published by public sources, mainly the FDA such as 
structured product labeling (SPL)) (Kuhn, Letunic, Jensen, & Bork, 2015) , the Drug Bank 
Database (Wishart et al., 2006), and the European agency for the Evaluation of Medical Product 
(EMEA) (Gardner, 1996). The lexicons were mainly built on clinical trial findings and 
clinicians' reports, which often have low coverage of colloquial expressions available 
in consumer health posts. To address this problem, pharmacovigilance studies used few 
   
39 
approaches that mostly focused on augmenting the standard medical lexicons by embedding 
Consumer Health Vocabularies (CHV). CHV was developed mainly with the purpose of 
covering colloquial expression of health professional vocabularies (Zeng & Tse, 2006).   
2.10.1 Automatic extractions of ADRs from consumer health posts 
Leaman et al. (2010) constructed a lexicon of SIDER, MedEffect, and COSTART, 
which were augmented with CHV and a small set of colloquial expression of ADRs to identify 
adverse drug reaction in consumer drug reviews in the "Daily Strength" forum. In addition, the 
search algorithm was set on window-based search with size five to capture syntactic variation in 
ADR expressions composed of two or more parts, such as “gained huge weight” for “weight 
gain”. To address the ambiguity and distinguish ADRs from drug indications and beneficial 
aspects of drugs, they used a rule-based approach built on the closest verb to the 
ADR expressions. The study had 78.3% precision and 69.9% recall, and F-measure 73.9%. (see 
Table 1 for a summary of these studies.) 
Benton, Ungar, et al. (2011) complied a lexicon of dietary supplements, pharmaceutical 
terms mentioned in the Cerner Multum’s Drug Lexicon, list of signs and symptoms in the 
Medicinenet database, FAERS, and CHV to identify ADRs of hormonal drugs used for breast 
cancer treatment in breast cancer healthcare forums. Since the authors could not filter reviews for 
the desirable drugs, they used co-occurrence techniques to determine the association between 
mentions of the drugs and ADRs. The authors did not provide any information about employing 
specific methods to address colloquial phrases or ambiguity in the health posts. The reported 
recall was 35.1%, precision 77%, and F-measure 73.9%. 
Liu and Chen (2013) designed AZDDrugMinor, a general application for detecting ADRs 
in health post forums. MetaMap (A. R. Aronson, 2006), a tool that mainly developed for 
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identifying in unstructured texts medical concepts expressed by standard medical 
vocabularies, was configured to recognize all terms belonging to ‘Chemicals and Drugs’ and 
‘Disorder’ semantic groups. Then the identified terms were compared against the list of ADRs in 
FAERS. To identify negated side-effects, NegEX (Chapman, Bridewell, Hanbury, Cooper, & 
Buchanan, 2001) was used. To distinguish ADRs from drugs indications, they used 
the drugs indications list specified in FAERS database. The application was tested by 200 
sentences collected from a forum and showed 56.5% recall, 82% precision, and F-measure 
66.9%.  
Nikfarjam, Sarker, O’Connor, Ginn, and Gonzalez (2015) designed the ADRMine, a 
feature-based machine learning system, to identify adverse effects from health posts' sentences 
in Daily Strength and Twitter. First, to address the challenge of colloquial expression of ADRs in 
the posts, they trained a supervised sequence labeling CRF classifier on a set of corpora from 
Daily Strength (4720 reviews) and Tweeters (1340). In these two corpora, the drug 
reviews were annotated for the presence of ADRs, the span (boundary) of the ADRs, and the 
beneficial effects of drugs. To address the ambiguity (distinguishing ADRs from instances of 
other semantic types), they used a list of features, including a binary feature indicating 
presence/absence of ADRs that construed, based on the same ADRs lexicon developed by 
Leaman et al. (2010), part of speech of the token, context features, and negation. Moreover, to 
extend the semantic variability of the ADRs annotated in the corpus (Daily Strength 
and Tweets), they used the word embedding technique (word2vec) (Ganguly, Roy, Mitra, & 
Jones, 2015) trained on unseen drug review posts. The result for daily strength was 78% 
recall, 86% precision, and 82% F-measure, and for Twitter 76% recall, 68% precision, and F-
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measure 72%. The authors attributed the errors to the colloquial expressions of ADRs, 
spelling errors, and informal sentence structure. 
(Sarker & Gonzalez, 2015) designed a feature-based machine learning system to classify 
text segments from drug review posts into the ADR or non-ADR categories. First, they trained 
three supervised classification approaches, including Naïve Bayes (NB), Support Vector 
Machines (SVM) and Maximum Entropy (ME) trained on the two corpuses of daily strength and 
Twitter introduced by (Nikfarjam et al., 2015). To improve performance of the system, they 
created a binary feature using the same ADRs lexicon developed by Leaman et al. (2010). The 
binary feature indicating presence/absence of ADRs mentions. They also created a numeric 
feature, which was calculated by counting the number of ADR mentions divided by the number 
of words in the text segment. The authors also used other features for representing semantic 
properties, including n-grams, UMLS semantic types and CUIs, synonyms extracted from 
WordNet, and sentiword scores. Among the tree feature-based classifiers, SVM 
significantly outperformed NB and ME in both Daily Strength and Twitter corpora with F-
Score 67% and 54% respectively. Authors attributed the relatively low F-scores to 
misspelling, short posts, ambiguous statements, and colloquial expression of ADRs, such as 
descriptive phrases of adverse effects, non-standard terms and high variability of semantic 
representation of specific ADRs in health posts.  
Huynh, He, Willis, and Rüger (2016) trained and tested four different structures of Neural 
Network for classifying ADRs assertive text segments on a social media source (the same 
Twitter corpus introduced by (Nikfarjam et al., 2015)) and a non-social 
media source, the Adverse Drug Effects (ADEs) (Gurulingappa, Mateen-Rajput, & Toldo, 2012), 
which was constructed by sampling from MEDLINE case reports. Among Convolutional Neural 
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Network (CNN), Recurrent Convolutional Neural Network (RCNN), Convolutional Recurrent 
Neural Network (CRNN), and Convolutional Neural Network with Attention (CNNA), CNN and 
CRNN had 51% F-measure on Twitter data and 87% F-measure on the ADEs corpus. The low 
performance of Neural Network classifiers on the Twitter corpus compared with the non-social 
media corpus occurred due to high structural variability in text segments including ADRs and 
high syntactic and semantic variability of ADR expressions in social media posts. 
(Nguyen et al., 2017) attempted to calculate the frequency of the top 10 ADRs of the 
top10 psychiatric medications in LiveJournal, Reddit posts, Reddit comments, and Twitter. The 
data for top 10 ADRs was collected from the SIDER database. To improve performance of their 
system in capturing semantic and syntactic variability of the 10 ADRs (mentioned by SIDER), 
they employed the word embedding technique  (word2vec framework). For example, for 
instances of “diarrhea”, the word2vec included the alternative spelling or misspelling in the final 
tally. The authors did not provide any information about the accuracy of their system in finding 
semantic and syntactic variations of the ADR terms, but they concluded that the frequency of 
ADRs calculated in social media by extending the list of ADRs has better agreement with the 
frequency of the ADRs in the SIDER database. 
As the low recall of the ADRs extraction systems and low F-measure of ADRs assertive 
text segment classifiers show, informal sentence structure, low coverage of standard medical 
lexicons for colloquial expression of ADRs, and ambiguity in semantic types of medical terms 
are three main obstacles in enhancing performance of the systems. Even the use of advanced 
machine learning methods, such as deep learning and the word2vec framework did not upgrade 
performance of the systems significantly. Moreover, augmenting the standard lexicons with 
CHV did not improve results of the systems significantly, indicating that the CHV is not rich in 
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colloquial expression of ADRs. Therefore, there is clearly a need for an annotated corpus that not 
only clarifies the text segments of health posts for presence of specific information, such as drug 
effectiveness and ADRs and detecting desirable medical terms, but also filling the gap between 
patients’ and clinicians’ terminologies by mapping the colloquial expressions to standard 
medical terminologies.   
Table 0-3 Specifications of Studies Used Lexicon-based Approach and Machine Learning Methods for 
Automatic Extraction of Health-Related Information from Consumer Health Posts.  
Study Purpose Professional lexicon 
used 
Methods for 
extending 
standard medical 
lexicon 
Identifying 
semantic type of 
expressions  
performance  
Leaman, 
Wojtulewi
cz et al. 
(2010) 
Identifying 
ADRS from 
Daily Strength 
COSTART, SIDER,  
MedEffect,  
 
 
CHV, a small set 
of colloquial 
language mapped 
to UMLS,  
Window based 
search 
 Rule-based 
approach that 
uses cures from 
nearby terms 
78.3% 
precision, 
69.9% recall, 
73.9% F-
measure  
Benton, 
Ungar et 
al. (2011)  
ADRs of 
hormonal breast 
cancer drugs 
from breast 
cancer forums  
Dietary supplements, 
Pharmaceuticals 
terms mentioned in 
Cerner Multum’s 
Drug Lexicon, sign 
and symptoms in 
Medicine website, 
FAERS database 
CHV —- 77 precision,  
35.1 % 
recall, 73.9% 
F-measure 
 
 Liu and 
Chen 
(2013)  
A general 
application for 
detecting ADRs 
in health post 
forums 
UMLS, MetaMap the 
findings compared 
with by FAERS 
database. 
CHV NexEX (for 
negation 
detection), 
FAERS 
Database to 
distinguish drug 
indication from 
ADRs 
82% 
precision, 
56.5% recall, 
66.9% F-
measure. 
Nikfarjam
, Sarker et 
al. (2015) 
Identifying 
ADRS in Daily 
Strength and 
Twitter 
The lexicon generated 
by Leaman, 
Wojtulewicz et al. 
(2010) used for 
constructing binary 
feature indicating 
presence/absence 
of ADRs  
Training a 
supervised CRF 
classifier 
on corpuses from 
Daily Strength 
and Tweeters, 
Word2Vec to 
extend the 
semantic 
variability of of 
the ADRs 
annotated in 
the corpus 
Applying 
Features 
including art of 
speech of the 
token, context 
features, and 
Negation 
detection. 
 
86% precisio
n 
78% recall,  
82% F-
measure 
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2.10.2 Corpora Developed Using Consumer Health posts 
Currently, there are two open-source corpora based on health-related social media: (1) a 
Twitter corpus that was built on 10,822 instances of randomly selected tweets (each instance of 
tweet is a maximum of 140 characters) for 71 drugs prescribed for chronic illness, and (2) the 
CADEC corpus, constructed based on drug review posts on the online message board 
“askapatients.com". These corpora are summarized in Table 2. 
The tweets in the Twitter corpus were double coded by two annotators for presence of 
ADRs, spans of ADR indications, and beneficial effects. For this data set, the Inter Annotator 
Sarker and 
Gonzalez 
(2015) 
Binary 
classification of 
ADR assertive 
text 
 
lexicon developed by 
Leaman, Wojtulewicz 
et al. (2010) used for 
generating a binary 
and numeric features  
Training 
Classifier 
Methods on two 
corpuses: twitter 
and Daily 
Strength 
 
Generating a set 
of features, 
representing 
semantic 
properties of a 
text (e.g., n-
grams, 
sentiment, 
polarity, topic, 
synonyms 
extracted from 
WordNet) 
Twitter 
Corpus: 53% 
F-measure  
Daily 
Strength 
Corpus: 67% 
F-measure  
 
 
Huynh, 
He et al. 
(2016) 
Binary 
classification of 
ADRs assertive 
text 
 
    
No lexicon Four different 
structure of 
Neural Network 
based Classifiers 
were trained on a 
Twitter corpus 
— Convolutiona
l Recurrent 
Neural 
Network: 
51% F-
measure  
 
 
Nguyen, 
Larsen et 
al. (2017)  
Frequency 
estimation f top 
10 ADRs of the 
top10 psychiatric 
medications.  
Sources: 
LiveJournal, 
Reddit posts, 
Reddit 
comments, and 
Twitter. 
10 top side effects of 
psychiatric 
medications in the 
SIDER.  
 
 The word2vec 
framework for 
generating the 
alternative 
spelling or 
misspelling in the 
final tally 
— No computed 
recall/specifi
city/F-
measure. 
Conclusion:  
 
The 
word2vec 
increase the 
estimation 
frequency to 
the point of 
agreement 
with SIDER. 
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Agreement (IAA) calculated using Cohen’s Kappa was 71%. The authors normalize the 
identified medical terms by mapping layperson expressions to the UMLS (Ginn et al., 2014) 
The CADEC corpus  consists of 1,231 comments for two sets of drugs, Diclofenac and 
Lipitor. The drug reviews were annotated for span of ADRs (6,318), symptoms (275), and 
disease (283), and drug names (1,800). The pair-wise agreement between annotators was 
calculated using Metke-Jimenez, Karimi, and Paris (2014) method, which was 86.5% , when 
span and annotation settings were both relaxed and 60.4 % , when span and annotation settings 
were both strict. All the entities other than drug names were mapped to SNOMED CT. All the 
drugs were mapped to AMT (the Australian Medicines Terminology). In addition, all the ADRs 
also mapped to MedDRA (Karimi et al., 2015). 
2.1.3 Corpora developed using biomedical literature.  
There are also other corpora for identifying ADRs that developed based on biomedical 
literature, mainly from Medline case reports and abstracts.  These are summarized in Table 2. 
 Gurulingappa, Klinger, Hofmann-Apitius, and Fluck (2010) developed a corpus of 
ADRs and diseases using randomly selected MEDLINE abstracts. It consists of 813 mentions of 
adverse effects and 1,428 mentions of disease. Further, Gurulingappa, Mateen-Rajput, et al. 
(2012) developed a corpus using 2,972 medical case reports randomly selected from MEDLINE. 
The corpus was annotated for mentions of drugs (5,063), adverse effects (5,776), dosage (231), 
as well as the relationships between drug-adverse effect (6,821) and drug-dosage (279). In 
addition, Gurulingappa, Rajput, et al. (2012) created Adverse Drug Effects (ADEs), a corpus of 
annotated sentences, indicating the presence/absence of ADRs, which were obtained from 2,094  
MEDLINE medical case reports. The corpus contains annotations of 5,063 drugs, 5,776 
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conditions (e.g. diseases, signs, symptoms), and 6,821 relations between drugs and conditions 
representing clear adverse events. 
Table 0-4 Specifications of Existing Corpus Relevant to the Corpus Specified in this Study 
 
Although the corpora annotated for mentions of ADRs using biomedical literature and 
clinical notes in Electronic Health Records (EHRs) have important implications for automatic 
extractions of ADRs from these resources, they may not provide significant performance 
improvement for ADRs identification in consumer health posts in social media. As Sarker and 
Gonzalez (2015) showed, incorporation of ADEs corpus (Gurulingappa, Mateen-Rajput, et al., 
2012) with corpus obtained from social media data does not provide significant improvement in 
the accuracy of ADRs of an assertive sentences-classifier system, because the corpus structure is 
Study Source Type Entity and Size  Normalized 
Gurulingappa, 
Klinger et al. 
(2010) 
Medicine 
abstract 
Biomedical 
literature  
813 ADRs  
1,428 mentions of disease 
… 
Gurulingappa, 
Rajput et al. 
(2012)  
2,972 medical 
case reports 
randomly 
selected from 
MEDLINE 
Biomedical 
literature  
Drugs (5,063), Adverse 
effects  (5,776), dosage (231) 
Relationships between drug-
adverse effect (6,821) and 
drug-dosage (279) 
…. 
Gurulingappa, 
Mateen-
Rajput et al. 
(2012)  
2,094  
MEDLINE 
medical case 
reports. 
Biomedical 
literature  
5,063 drugs, 5,776 conditions 
(e.g. diseases, signs, 
symptoms), 6,821 relations 
between drugs and conditions  
… 
Ginn, 
Pimpalkhute 
et al. (2014).  
10,822 
instances of 
randomly 
selected tweets 
Social Media-
Twitter 
Presence of ADRs, spans of 
ADR indications, and 
beneficial effects 
Mapped to UMLS 
concepts 
(Karimi, 
Metke-
Jimenez et al. 
2015) 
1,231 comments 
for two sets of 
drugs  
Social Media 
(askapatient.co
m) 
ADRs (6,318), symptoms 
(275), and disease (283), and 
drug names (1,800) 
Identified entities 
mapped to 
SNOMED-CT, 
AMT, and 
MEDRA. 
Our corpus 896 comments 
for two classes 
of psychiatric 
medications: 
SSRI and SNRI 
Social Media 
(askapatient.co
m) 
Sentence classification: 
presence of Side-effects, 
Withdrawal symptoms, Drug 
indicators, Effectiveness, and 
Ineffectiveness.  
Entity identification: side-
effects, withdrawal 
symptoms, and drug 
indicators.  
Identified entities 
mapped to both 
UMLS and 
SNOMED-CT 
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not compatible with the social media corpora. In addition, corpora developed with biomedical 
literature follow grammatical rules and are not rich in colloquial expression of medical entities. 
Therefore, they do not address the challenges of ADR medical entity extractions from consumer 
health posts in social media. 
In response to these challenges, we developed a corpus in this study that addresses 
pharmacological effects of psychiatric medications including ADRs, drugs indications, and drug 
effectiveness. We followed a systematic approach to develop this corpus consisted of two main 
components:  entity identification, and entity normalization. The identified entities were mapped 
to the equivalent medical concepts in both the UMLS and SNOMED CT. ADRs and WDs were 
further classified as physiological, psychological, cognitive, and functional problems (e.g., 
limitation in daily functioning, social activities or inter-personal relationships) that did not 
receive any attention in previous studies. The methodology for developing this corpus is 
explained in the methodology section of this study.  
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                              Chapter 3: Methodology 
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This study involves a mixed-method approach for providing structured data from 
unstructured drug reviews for testing hypotheses concerning attitudes and adverse drug reactions 
associated with antidepressants. Methodology for developing the structured data and testing the 
hypotheses consisted of seven major phases: 
! Phase 1: identification of data source and drug source 
• Drug sources of this study are Sertraline (brand name: Zoloft), Escitalopram 
(brand name: Lexapro), venlafaxine (brand name: Effexor XR), duloxetine (brand 
name: Cymbalta).  
• Data source of this study is a healthcare forum called “askapatient.com”. 
! Phase 2: Data collection 
This phase includes the following steps: 
• Developing an Application Program Interface (API) for data collection 
• Calculating the sample size: 892 reviews were collected for four drugs specified 
in this study. 
! Phase 3: Developing an Analytical Framework fro generating structured data from 
unstructured text 
 This phase includes the following steps: 
• Developing the initial analytical Framework using deductive approach (reviewing 
the literature) 
• Annotating the drug reviews using the initial analytical framework 
• Generating themes using inductive approach (open coding) 
• Developing the final analytical framework by refining themes obtained from 
inductive and deductive approaches. 
! Phase 4: Applying the final analytical framework to the drug reviews 
This phase includes the following steps: 
• Data preprocessing: This step includes using regular expression codes to remove 
personal information and noisy pattern from sentences structure. 
• Splitting drug reviews to sentences. 
• Annotating sentence using analytical framework: This step includes developing 
guideline for annotators, developing annotation environment, calculating inter-
annotator agreement and resolving disagreement between annotators.  
! Phase 5: Entity identification 
 This phase includes the following steps: 
• Developing guidelines for identifying Adverse Drug Reactions (ADRs), 
Withdrawal Symptoms (WDs), and Drug Indications (DIs) 
• Annotation process  
• Calculating inter-annotator agreement 
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! Phase 6: Terminology association (entities normalization) 
• Developing guidelines for mapping the identified entities (ADRs, WDS, and DIs) 
to UMLS and SNOMED-CT. The guidelines include requirements for selective 
proper/preferred concepts, procedure of mapping, and instruction for selecting 
proper standard concept for colloquial expressions of ADRs/WDs/DIs. 
• Reviewing the mapping for consistency  
! Phase 7: Usability of the data set 
The structured dataset provided through phase 1 to phase 6 used for generating and 
testing hypotheses related to association between variables and ADRs identified in 
this study. This phase includes the following steps: 
• Summarizing the dataset 
• Using imputation methods for handling missing values 
• Testing hypotheses 
• Developing a predictive model  
 
Figure 1-3 shows the summary of the research methodology and the outcome of each phase, 
which is specified in the result section.  
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Figure 0-1 Summary of the research methodology 
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Phase 1  
3.1 Data Source Information 
3.1.1 Data sources 
We examined data from a healthcare forum "askapatient.com" that compiles uncensored 
user comments on the effects of taking different sorts of medication from people with a range of 
diagnoses. In this forum, patients can record their experience with a medication by filling out a 
form for a medication brand name. This form is composed of eight fields including rating, reason 
for prescription, side-effects, comments, gender, age, duration/dosage, and date of posting the 
review. Patients can rate their satisfaction with drugs ranging from 1 to 5, where 1 presents the 
least satisfaction and 5 presents the highest satisfaction. Patients are supposed to report drugs’ 
ADRs in the side-effects field and the detail of their experience in the comment field. However, 
patients reported various aspects of their experiences, such as drugs’ effectiveness or perceived 
distress received from ADRs, in both fields. Table 3-1 shows an example of posts for Cymbalta 
in "askapatient.com". 
Table 0-1 An Example of a Post for Cymbalta in "askapatient.com” 
 
3.1.2 Drug Source 
We used drug review posts in "askapatients.com" to collect information for four 
psychiatric medications, including Sertraline (brand name: Zoloft) and Escitalopram (brand 
name: Lexapro) from Selective Serotonin Reuptake Inhibitor (SSRI) Class and venlafaxine 
(brand name: Effexor XR) and duloxetine (brand name: Cymbalta) from Serotonin 
Ratin
g  
Reason  Side-effect Comment  Gender Age  Duration Date 
3 fibromyalgia
/depression 
Nausea, diarrhea, 
upset stomach, 
dry mouth, 
sleepiness 
I have only been on 30mg for 4 
days and have the extreme runs.  
Upset stomach and no appetite.  
Pain in minimal though and I feel 
less anxious and depressed. 
F 38 4 days 2009-10-05 
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Norepinephrine Reuptake Inhibitor (SNRI) Class. These four drugs have been primarily 
prescribed for depression and mood disorders, and according to a dataset from Symphony Health 
Solutions*, they had the highest prescription rate in 2012. Although the medications have shown 
substantial evidence of effectiveness in promoting mood elevating properties, they are associated 
with a significant number of ADRs causing debilitating impacts on patients’ daily activities and 
social participation.  
Phase 2 
3.2 Data collection  
3.2.1 Website policy 
All the data in the healthcare forum “askapatient.com” are anonymous and publicly 
available, however some respondents may disclose their email address or their phone number in 
the field of comment. We sought IRB approval through University of Wisconsin-Milwaukee 
(UWM) and we received the following response: 
“Based on the activities described in the Determination of UWM IRB Submission form, your study does 
NOT involve research with human subjects and IRB review and approval is NOT required for your 
project. By analyzing publicly available posts, you will not be obtaining data through intervention or 
interaction with the individual and you will not be obtaining private information.” 
 
 We also attempted to contact the website administrators, but we did not receive any 
replies despite repeated requests. Regarding the anonymous data recording process, website 
privacy policy, and response of UWM to our IRB request, we decided it is ethically acceptable to 
conduct a passive data collection from the healthcare forum. Thus we did not seek IRB approval 
for data collection phase. To further protect respondents’ identities, we removed all the emails 
and phone numbers from dataset.  
   
54 
3.2.2 Designing application program interface (API) 
The website does not have API (application program interface) access. We developed a 
web-crawler system to collect all the respondents comments available in this website for the four 
antidepressant drugs. Because data in this website are classified based on the type of drugs, it is 
possible to easily filter other drugs that are not purpose of this study. For each respondent’s 
comment, type of disorder, side effects, comments, dosage, duration of the drug intake, age, and 
gender were collected, if they were available. The information was collected in August 2016.  
3.2.3 Calculating the sample size  
Since the focus of this study is on patients ‘attitudes towards antidepressants, we first 
filtered review posts in which patients reported depression with or without comorbid with other 
mental/physical illness as the reason for drug prescription. Table 3.2 provides information about 
the total number of reviews available in the forum for the four drugs focused on in this study and 
the number of reviews after filtering the dataset for depression.  
In order to select a subset of data that sufficiently represents the whole dataset in the 
healthcare forum, we used the following sample size formula (Charan & Biswas, 2013): 
𝑆𝑎𝑚𝑝𝑙𝑒 𝑆𝑖𝑧𝑒 =  𝑧! × 𝑝(1 − 𝑝)𝑒!1 + (𝑧!  × 𝑝 (1 − 𝑝)𝑒!  𝑁  )  
Where z is the confidence interval, e is the margin of error, p is the standard deviation, 
and N is the population size. For this study, z is 90%, e is 5%, p is 0.5 to ensure the sample is 
large enough, and N is the number of post reviews for each drug in the healthcare forum.  The 
calculated sample for Zoloft, Lexapro, Cymbalta, and Effexor XR were 213, 219, 231, 229 
respectively. We used Python Random Module (Python, 2017) to select the calculated sample 
from the healthcare from randomly.  
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Table 0-2 Total Number of Review Posts and the Calculated Sample Size 
Drugs Number of reviews 
available in the forum 
Number of reviews include depression 
as the reason for drug prescription 
Sample Size 
Zoloft 1528 980 213 
Lexapro 1913 1145 219 
Cymbalta 2481 1573 231 
Effexor XR 2129 1447 229 
 
Phase 3 
3.3 Developing the Analytical Framework for Generating Structured Data  
Management and summarization of unstructured data in qualitative research is a critical 
aspect in data analysis. The Framework method is a flexible tool that provides researchers with 
the approaches of developing themes to generate highly structured data from qualitative data.  
The Framework method was developed at the qualitative research unit at the National 
Center for Social Research in the United Kingdom for large-scale policy research. However, it is 
becoming an increasingly popular approach in medical and health research data (Gale, Heath, 
Cameron, Rashid, & Redwood, 2013). Like other qualitative approaches, the Framework method 
helps to identify similarity and discrepancy in qualitative data before determining the 
relationship between different parts of the data. This identification involves developing a 
descriptive summary of the data clustered around themes.  
Depending on the research question, the Framework method uses an inductive, a 
deductive, or a combination of inductive and deductive approaches on the inductive-deductive 
continuum. The difference between these three approaches is the way in which the themes for 
developing structured data are generated. In the deductive approach, themes are developed based 
on literature, pervious theories, or specifics of a research question. In  the inductive approach, 
generates themes from data by open coding and refining themes. In a combined approach, a 
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study starts with  predefined themes to explore, but also it leaves space to discover the 
unexpected aspect of respondents experiences with the subject of the study.  
To provide structured data from the review posts, we adopted the Framework method by 
focusing on a combined approach (inductive-deductive). A deductive approach was used that 
involved reviewing the literature the set of important variables affecting attitudes towards 
antidepressants, which construct the initial that provided a framework for data analysis. 
Conducting the inductive approach generated the list of themes for data analysis that were not 
discussed by the literature. The following steps were followed for constructing the final set of 
codes for qualitative analysis of reviews. 
3.3.1 Developing the initial analytical framework using deductive approach 
We conducted a review of literature to identify important clinical and personal factors 
affecting patients attitude to antidepressants. Table 3.3 provides the identified factors (codes) 
from literature with their description. The factors were categorized into five categories, including 
pharmaceutical treatment factors, healthcare system factors, psycho-social factors, patient related 
factors, and disorder related factors. The identified factors were used as the initial codes for 
constructing the initial Analytical Framework. Each identified code may include sub-codes 
indicating the spectrum of the levels of patient experience for that variable.   
3.3.2 Coding (annotating) the drug reviews using the initial analytical framework 
The purpose of this step is to understand to what extent the pre-defined themes could be 
applied to the comments. In addition, it helped us to identify passages of comments that could 
not be mapped to the predefined codes. 
For the purpose of initial analysis, 310 reviews from the combined drug samples were 
randomly selected. Because, reviewers entered their experiences with antidepressants in two 
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fields, including side-effects and comments, we first combined the two fields and generated one 
segment of text for each review that was identified by drug id. 
Table 0-3 Description of Predefined Themes Developed Deductively from Literature Review 
Categories  Factors (predefined 
codes) 
Description  
 
 
 
 
 
 
Pharmacologi
cal treatment 
factors 
Perceived 
effectiveness 
Patient’s subjective assessment of antidepressant helpfulness in reduction of depression 
symptoms, enhancing emotional and cognitive functionalities, and in overall, enhancing 
life quality.  
Perceived necessity  
 
Patient subjective assessment of antidepressant necessity in improving and maintaining 
current and future health conditions. For example, patient may find an antidepressant 
vital in reducing the risk of relapse.  
Perceived concern Patient subjective assessment of antidepressant harmful aspects in long-term. Patient 
may view antidepressant as an agent, which is addictive, take control over feelings and 
thought, and altering personality in long-term. 
Side-effects  Any adverse reactions that patient report as side effects of antidepressants intake. 
Antidepressants’ adverse reaction may include physiological side-effects, emotional 
syndromes, cognitive impairment, and limitations on daily functioning, and in overall 
reducing quality of life 
Perceived distress 
from side-effects 
Patient’s perceived distress from antidepressants side effects depends on patient’s self-
attention to internal bodily sensation that may have an influence on patient tolerability 
of side effects. Patient may show the distress by using adjective showing severity of a 
side effect, negative impact on work or daily activities, or visiting emergency 
department. A severe side-effect including self-harm and suicidal ideation or attempt 
reflects distress received from antidepressants.  
Healthcare 
system 
factors  
 
Patient-provider 
relationship 
Patient expresses their satisfaction or dissatisfaction with healthcare providers from 
various aspects, such as perceived support from providers or perception of healthcare 
providers knowledge about illness and treatment. 
Healthcare settings Patients may demonstrate a higher level of trust and satisfaction towards diagnosis and 
treatment offered in a psychiatric setting compared with a primary care setting.  
Affordability Patient may complain about the high cost of antidepressants and lack of insurance 
coverage.  
 
 
Psycho-social 
factors  
 
Stigma and cultural 
related factors 
Patient may express their concern about stigma and cultural-related factors that may 
make prolonged pharmacological treatment notoriously difficult for patients. For 
example, the public may view antidepressants intake as a sign of weakness or 
incapacity to deal with daily emotional distress that may influence on patient 
acceptance of antidepressants. 
Partner support Patients may express their perceived support from partners (family and friends) about 
having depression as a proper diagnosis and having an antidepressant as a proper 
treatment.  
Patient-
related 
factors 
General concern and 
necessity 
Patient may express their general view toward medications. For example, they may 
view all the medications harmful and believe natural remedies and changing life style 
will have a better healthcare outcome than pharmacological treatment. 
Knowledge about 
medication 
Patient may complain about lack of knowledge of side effects or complexity of 
treatment, proper time of discontinuation, and withdrawal adverse effects.  
Education level  Patient may disclose their level of education in the comments or in the section of 
demographic information.  
Disorder 
related 
factors 
Patient insight about 
source of depression 
Patient may express their insight towards the source of depression, and severity of 
symptoms. For example, patient may attribute source of depression to psychological 
problem rather than biological factors.  
Severity of 
depression 
/symptoms 
Patient with major depression disorder may have a higher tolerability of adverse effects. 
In addition, patient’s perceived effectiveness of antidepressant may be higher in the 
patients.   
Type of depression Type of depression may be an important factor in shaping patient’s attitude toward 
antidepressants.  
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Selected reviews with drug ids were arranged in rows and predefined codes were arranged in 
columns, developing the initial framework of analysis. Microsoft Excel was used for developing 
the initial framework of analysis.   
Figure 3-1 provides an excerpt of the initial framework of analysis that was generated 
using pre-defined codes. As illustrated in the figure, we highlighted each meaningful passage of 
text and attached it to a cell corresponding to the appropriate code in the initial framework. For 
passages of text that did not fit into the existing themes in the framework, we determined and 
documented the theme of the passage and recorded it in a new column named “Not-Matched”.  
We also created a column named “Not-applicable” that contains passages without any 
meaningful information about respondents’ experiences with antidepressants. For example:  
• “Feel free to email me, I have been through it all with Effexor.”  
• Thank God I was pregnant or I may NEVER have forced myself through to the 
other side!!!”  
 
Patients in the review posts did not provide any information about the pre-defined themes 
of “type of healthcare setting” where they received treatment for depression, “stigma and cultural 
related factors”, or “educational level”. In addition, the initial analysis showed that there is little 
information available in the reviews for some of the predefined themes, including 
“affordability”, “general concern and necessity”, “partner support”, and “patient insight about 
depression”. Table 3.4 provides the identified codes and related sub-codes with examples from 
patients’ reviews for each code.  
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Figure 0-2 an expert of initial comment analysis generated using predefined themes  
   
60 
3.3.3 Generating codes (themes) using inductive approach (open coding) 
Table 0-4 Predefined Themes Developed Inductively with Examples from Drug Reviews 
Predefined codes Sub-codes Examples from patients’ reviews  
Perceived 
effectiveness 
Positive “Anyway, my life is on track, I have nothing to be depressed or sad about.” 
Negative But I still havnt noticed any change in my energy or anxiety. 
 
Perceived 
Necessity 
Positive  “All in all, I love it. I have not have a depressed moment since I've been on it, 
approx. 8 month. I do not think I cannot live without it.” 
Negative “There's no doubt that Effexor XR saved my life, however long-term use is not 
the best.” 
Perceived concern 
 
 
 
Concern 
about side-
effects  
“Pure poison!” 
“I was so scared to take it that I delayed it because I read all the comments on 
this site.” 
Concern 
about 
withdrawal 
symptoms 
“I am worried about trying to cut down gradually as I read so much scary stuff 
about going off it.” 
“The withdrawal is hell. You would think you were going through heroin 
withdrawals.” 
ADRs  “Typical with effexor XR- Dizzy, jaw tight, teeth grinding.” 
Perceived Distress 
from side-effects  
Tolerable 
(low) 
“I had tolerable, minimal side effects.” 
“I didn't really experience any side effects...” 
“The side effects are far less hassle than being in my dark depression.” 
Intolerable 
(high) 
“The side effects are hell.” 
“No wonder I suffered so many side effects.” 
Physician patient - 
interaction 
Positive “My pharmacist convinced me that it was safe for me to use along with my 
topamax, and encouraged me to try it. I'm really glad I did.” 
Negative “I am suffering and should of not trusted the NP who prescribed the pills without 
first checking it out.” 
Healthcare setting 
* 
 “Respondents did not explicitly mention in which healthcare setting they 
received treatment for depression.” 
Affordability * 
 
 “If the depression doesn't eventually cripple you, the costs will. 
It is too expensive if you don’t have insurance!” 
Stigma and cultural 
related Factors 
  Non of the respondents did not explicitly complain about stigma or did not 
present any information indicating cultural factors affecting on patients attitudes 
antidepressants. 
Partner support* Positive  No example 
Negative “My husband has no compassion to my withdrawal symptoms.” 
General concern 
and necessity* 
  “Do NOT believe the MDs and pharm corp. hype and lies! FLEE!” 
Demographic 
information 
 “Basic demographic information including age and gender was reported by 
respondents.” 
Knowledge about 
medication 
 “No one ever told me even as I was seeing my psych and psychologists weekly, 
and my physician, that what I was experiencing could be from the drug.” 
Education level*  Patient did not disclose their education level in their comments. The website also 
did not provided a field to request responded educational level. 
Patient insight 
about depression * 
Positive 
insight  
Mental illness (i.e. lack of serotonin) is just like any other defect the human 
body can have.  
Negative 
insight 
No example 
Severity of 
depression/sympto
m 
 Some of the respondents in the field of “reason of prescription” or their 
comments mentioned severity of depression or their symptoms, such as: 
“The depression is so terrible that I am very keen to give Lexapro a fair try.” 
Type of depression  Some of the respondents mentioned type of their depression in the field of 
“reason of prescription” or in the comments.  
Duration of 
depression 
 Most of the respondents in the filed of “duration/dosage” reported duration of 
antidepressant’s usage.  
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Our regular team meetings enable us to discuss the proposed ideas, discover patterns, and 
an impression for alternative viewpoints, thus ensuring that one researcher’s particular 
perspective did not dominate and that agreement upon codes (themes) is a team conclusion. We 
revised the initial framework by defining new themes and refining the existing codes to 
incorporate unfitted passages of comments. We revised the initial framework by defining new 
themes to incorporate unfitted passages of reviews.  
Patients in the review posts stated their experiences with withdrawal symptoms (WD) and 
perceived distress from WDs. They also included experiences with withdrawal and 
discontinuation. Moreover, patients might express their overall attitude and pre-treatment 
concern with medications. They also may have some suggestion for readers about the quality of 
the drugs. 
Table 3.5 demonstrates new themes developed through the process of the inductive approach 
(open coding).  
3.3.4 Developing the final analytical framework by refining the themes 
The process of refining, applying, and re-refining themes was repeated until no new 
themes (codes) was generated. To develop the final analytical framework, we took the following 
steps:  
1) Each theme in the predefined framework that did not fit with information provided in 
reviews was excluded from the final framework. For example, we removed “healthcare 
setting,” “stigma and cultural related factors”, “educational level”, and “dosage of 
medication”. 
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2) If a predefined or a new theme fit in less than 5% of information provided in reviews, we 
excluded them from or merged them with other themes in the final framework. Similarly, 
Table 0-5 New Themes Generated Through the Process of Inductive Approach (Open Coding) 
New Themes  Sub-Themes  Examples 
Withdrawal 
symptom 
 “I weaned slowly from 150mg to 75 to 37.5 and off. I feel nauseous 
alot and my depression and social anxiety has returned almost 
100%.” 
“Do not wean off effexor too soon as i had one very bad day and 
experienced mild halloucinations.” 
Perceived 
distress from 
Withdrawal 
Symptoms 
 
Low (tolerable) “Could miss a dose or two and no problem.”  
High 
(intolerable) 
 
“Trying to come off of the medication is very difficult.” 
Overall attitude Positive “I think that this drug is great, but only for certain people.” 
 
Negative “This drug is just a poison.” 
“This drug ruined my life.” 
Drug indication  “My depression mostly manifested in an inability to start new 
projects, rather than any feelings of sadness.” 
“I used to be so depressed and anxious, that I didn't want to leave 
the house. I have a long history of depression and anxiety.” 
Recommendation 
to others 
Positive  “I would definitely recommend Effexor XR.” 
Negative “Do not take this medication!!!!” 
Experience of 
Withdrawal 
Discontinuation  “I stopped this drug after two days.” 
Weaning off  “Cutting the dose in half,When I went down to taking none,  
experience withdrawal effects.” 
Missing dosages “Can not miss a single dose or I feel awful.” 
“I experience when missing a dose.” 
Switching 
 
“I have insisted on stopping the effexor, and now the doctor is 
pushing pristiq (the "new and improved" effexor).” 
Switched to Luvox which I am finding much more beneficial.” 
Decision about 
discontinuation 
“I think I m going to quit.” 
Dosage/duration  “I started out on Effexor XR 75 mg, and was slowly raised from 
there to Effexor XR 300 mg.  Then I was changed to the generic 
Venlafaxine XR 300 mg.” 
Experience with 
Other 
medications 
 “I was given zoloft from my pyschiatrist and started at 50mg per 
day and was steadily increased to 100mg.||| the doctors increased 
my dose to 150mg.” 
“Started taking it after Prozac and (can't remember the name) made 
my stomach hurt so bad.” 
Problem with 
financial support 
 “ I did a rapid decline on my cymbalta because I lost my 
insurance.” 
Problem with 
social support 
 “ Thankfully I have a wonderful husband who helped me past the 
side-effects.” 
Not applicable  “Hope the comments help and good luck.” 
“I honestly can't tell a difference when I am on or off of Effexor 
XR.” 
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“affordability”, “partner support” and “patient insight about depression” were excluded 
and “general concern and necessity” was merged with “overall attitude”.  
3) All codes that were conceptually related and subjectively difficult to distinguish between 
their applicability to a passage of text were combined in the final framework. 
Accordingly, “perceived necessity” and “perceived effectiveness” are conceptually related 
and subjectively difficult to distinguish in application to passages of text, therefore they 
were combined in the final framework as “perceived effectiveness”. For example, the 
following passage can be labeled as both “perceived effectiveness” and “perceived 
necessity”. 
“All in all, I love it.  I have not have a depressed moment since I've been on it, approx. 8 
month”. 
4) Although ADRs and withdrawal symptoms are conceptually related and both reflect 
adverse drug reaction, we distinguish between them as two separate codes in the final 
framework. A patient may receive minimal distress from an antidepressant’s side effects, 
but perceive severe withdrawal symptoms during the process of discontinuation, which 
may negatively affect the patient’s attitude. Distinguishing ADRs from withdrawal 
symptoms is important from the perspective of clinical trials and interventions designed 
specifically to help patients manage the process of a drug’s discontinuation.  
5) Perceived concern for the prescribed drug includes passages of text, in which reviewers 
expressed their perceived distress from ADRs, WDs, or the overall distress they 
experienced with the drug. Thus, we defined two new codes “perceived distress from 
ADRs” and  “perceived distress from WDs” to express perceived express towards ADRs 
and WDs. For the passage of text in which a patient expressed overall perceived distress 
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from a drug without distinguishing it for WDs and ADRs, we assign it to the code 
“overall attitude”.  
6) Some patients directly mentioned how the information obtained from online sources 
including online messaging boards influenced their attitude toward antidepressants and in 
turn their behavioral reaction. This information can provide important evidence about the 
impact of an online sources on shaping attitudes toward medications. However, because 
of the paucity of the information, we did not define any new theme covering this type of 
information in the final framework. The following provides examples of such sentences: 
• “I don’t want all those withdrawals I m reading about”. 
• “I was so scared to take it that I delayed it because I read all the comments on 
this site”. 
 
Table 3.6 presents codes and sub-codes in the final framework, each with a brief 
explanatory description and examples from reviews.   
 
 
 
 
 
 
 
 
Table 0-6 Themes (items) in the Fianl Analytical Framework with Description and Example from Patients 
Comments 
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Code Sub-codes Description   Example 
Adverse Drug 
Reaction 
Presence  If patient reported explicitly he experienced 
side-effects with or without listing the ADRs 
in the sentence/comments 
“I couldn't take Effexor XR. It gave me 
horrible nightmares and I kept waking 
up.” 
Absence If patient reported “they did not experience 
any ADRs” 
“I did not have any side-effect.” 
Perceived 
distress from 
ADRs  
(ADR-PD) 
 
High - Explicit mentions: If patient explicitly 
mentioned that they suffered from ADRs, 
- Functional problems: If patient reported 
functional problems associated with ADR, 
such as limitation in daily functioning, social 
activities, and work performance  
- Qualifiers indicating severity: If patient 
used any qualifiers indicating severity of the 
symptoms. Such as severe, debilitating, 
intolerable.  
- Severe ADRs: If patient reported severe 
ADRs having negative impact on patient 
quality of life, such as suicidal 
ideation/attempt, self-harm, bed-ridden. 
Patient hospitalization or emergency visit 
also shows the presences of ADRs causing 
high-perceived distress. 
“The side effects are intolerable.”  
“Have been able to work (software 
developer) if attempting this drug 
during work week.” 
“Severe nausea and dizziness.” 
“That drug caused nausea and increased 
suicidal thoughts.” 
Low	 Explicit mentions: If patient explicitly 
mentioned that the ADRs were tolerable. 
Qualifiers indicating mildness: using 
Qualifiers indicating mildness of ADRs, such 
as slightly, mild. 
Qualifiers are indicating non-persistency: 
Using qualifiers indicating non-persistency of 
ADS, given that ADRs are NOT associated 
with qualifiers indicating severity of ADRs.  
No experience of ADRs: If patient explicitly 
mentioned they did not experienced any 
ADRs. 
“Any side effects were, for me, 
tolerable compared to the benefits.” 
“Mild headache”  
“Headache for two days, but severe 
headache for two days indicates high-
perceived distress.”  
 “The withdrawal made me very dizzy.” 
Withdrawal 
symptoms 
(WDs) 
Presence If patient complained about occurring new 
symptoms occurred in the process of dosage 
reduction, discontinuation, or missing 
dosages (unintentional withdrawal) of the 
medication, with or without listing the WDs 
symptoms 
“I weaned slowly from 150mg to 75 to 
37.5 and off. I feel nauseous alot and 
my depression and social anxiety has 
returned almost 100%.” 
“Do not wean off effexor too soon as i 
had one very bad day.” 
Absence If patient reported that they did not   
WD-perceived 
distress 
(WD-PD) 
High  If patient mentioned they a) suffered from 
withdrawal symptoms, b) and/or they 
reported functional problems associated with 
the WDs, c) and/or they used qualifiers 
indicating severity, d) and/or they mentioned 
severe WDs, the WD is high.  
“The withdrawal symptoms are 
horrible.”  
“I was in bed for about one week.” 
“I missed a dose yesterday, and now I'm 
nauseous.” 
“ I can not function. Feel I am 
poisoned.” 
“The withdrawal side effects especially 
brain flashes or brain zap was VERY 
PAINFUL.” 
Low a) If patients explicitly mentioned that 
withdrawal symptoms were tolerable, b) used 
indicators showing low perceived distress, c) 
used qualifiers showing tolerability of the 
symptoms, d) using qualifiers showing non-
persistency of the symptoms, given that the 
“Withdrawal was fine.” 
“When I stopped the drug, I had mild 
dizziness.” 
“I experienced headache for few days 
after reducing the dosage.” 
“I had no experience of withdrawal 
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symptom was tolerable, e) explicit mention of 
no experience of withdrawal symptoms. 
symptoms.” 
Effectiveness 
(EF) 
 A drug is effective, if patients reported that 
his health condition has been improved or his 
symptoms were treated after drug 
consumption. 
“For the first few weeks it helped me 
feel better.” 
Ineffectivenes
s (INF) 
 A drug is ineffective; if patient reported that 
his/her health status did not improve, became 
worse, or still has the same symptoms. 
“It did not help me at all.” 
Patient –
physician 
interaction 
(PPI) 
Positive 
(P) 
If patient’s express of communication with 
providers indicated implicitly/explicitly that 
patient has high level of trust in providers and 
she/he was satisfied with communication with 
providers.  
 
“Success with these meds truly depends 
on staying in touch with your 
physician.” (Implying trust in 
physicians) 
 
“My doctor and I decided to stop taking 
it.” (implying providers involved 
patient in the process of decision 
making), which can lead to patient 
satisfaction. 
Negative 
(N) 
- If patients express of communication with 
providers indicated implicitly/explicitly that 
patient were not satisfied with healthcare 
providers.  
- Patient may complain about provider’s 
failure in providing sufficient information or 
non-effective communication, such as 
provider’s failure to involve patient in the 
process of decision-making or treatment plan.  
“Dr. s do not understand the crazy side 
effects of starting this class of drugs.” 
(Implying patient’s complaint about 
physician’s lack of knowledge) 
The doctor still claims that 30 mg is not 
even considered a therapeutic dose, but 
I know what works. (physician failure 
to include patient treatment preference 
in the process of decision making). 
Lack of 
knowledge 
(~KN) 
 Some patients may complain that they did not 
receive sufficient information about ADRs or 
WDs symptom associated with the drug and 
and the mechanism of management of the 
ADRs/WDs. 
 
Patient may indirectly complain about lack of 
knowledge by asking questions in the forum 
or mentioning that they did research on the 
web to gain more information. 
“Cannot get straight answer from 
anyone regarding how long these 
withdrawal symptoms will last.” 
“No one informed me of the withdrawal 
nightmare.” 
“TODAY I'd like to know if my recent 
muscular twitches are related to this 
medicine.” 
“I wish I had been smart enough to do 
research on Effexor BEFORE I went on 
it.” 
 
 
 
 
 
 
Experience of 
WD 
Unintentio
nal WD 
(DXD-F) 
If patient explicitly mentioned that they 
forgot to take medication (missing dosages) 
or run out of medication.  
“When I miss a day I feel very spaced 
out, thick, groggy, sad.” 
“If I don’t take the medicine at the same 
time every day or forget a day, I will 
experience withdraw and its horrible!” 
Intentional 
WD-
Stopping  
(DXD-S) 
If patient explicitly mentioned that they 
stopped the medication. 
“I had to stop taking it.” 
“I had low blood pressure for about 2 
weeks after I stopped taking it.” 
Intentional 
WD-
weaning 
off  
(DXD-W) 
 
If patients explicitly mentioned that they are 
weaning off (tapering off) the medication. 
“I have been tapering from 60 mg per 
day.” 
“I'm stopping slowly.” 
 
Intentional 
decision 
for WD 
(DXD-
Dec) 
If patient explicitly mentioned that they 
decided to stop or wean off the medication.  
“However after dealing with this acne 
I'm going to try another med.” 
General 
attitude 
Positive 
(P) 
If patient’s general attitude towards the drug 
is positive.  
“ I really like this drug, it changed my 
life.” 
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Phase 4 
3.4 Applying the Final Analytical Framework to the Drug Reviews 
The final analytical framework has been applied to all of the drug reviews in the sample. 
We only conducted data analysis on free text of each review posts that were available in both the 
side-effects field and comment field for each review (see table 3.1 for the structure of a review). 
The majority of drug review posts are composed of multiple sentences that each covers various 
aspects of patients’ experiences with drugs, which were explained in Table 3.6. Therefore, we 
used sentences as the basic unit of analysis. In addition, data analysis at the level of sentences 
ensureed that we did not miss any important passage that can be fit to the codes in the analytical 
framework.  
The reviews are written in colloquial English language, in which patients mostly did not 
follow proper grammatical and punctuation rules. Duplicate punctuation, applying wrong 
punctuation as a sign of sentence completion, phrase construction irregularities, and 
toward 
medication 
(ATT)  
Negative 
(N) 
If patient’s general attitude towards the drug 
is negative (ATT-N). 
“ I hate the drug, it completely ruined 
my life.” 
Patient 
suggestion to 
readers about 
drug 
(sug) 
Positive 
(P) 
If patient’s suggestion to a reader (other 
patients) is positive.  
“ Zoloft is the best option for 
depression.”  
“ Ask your doctor to give you this 
drug.” 
Negative 
(N) 
If patient’s suggestion to a reader (other 
patients) is negative. 
“Please be aware of the drug and its 
consequences.” 
Dosage/durati
on 
 If patients talked about dosage or duration of 
the drug, it will be labeled as positive. 
“My doctor prescribed 25 ml for me.”  
 
Lack of social 
Support  
(~SS) 
 If patient complained that he/she did not 
receieve any social support for managing 
ADRs or process of discontinuation 
“ My husband did not understand me.” 
Lack of 
Financial 
Support (FS) 
(~FS) 
 If patients reported that because of lack of 
financial support, they had to stop the 
medication permanently or temporarily.  
“ I had to stop the medication because it 
was expensive.” 
Other drugs  “If patient discussed other drugs in the 
review.” 
“I used triazolam for Insomnia.” 
Other patients  If a reviewer explained other patient’s 
experience with medication.  
“ My son was for three years on this 
drug, be he did not feel better.” 
Drug 
Indication 
(DI) 
 Any sign or symptom that patient clearly 
mention that it was the reason for drug 
indication and/or it was treated by the 
medication 
“my anxiety disappeared because of 
Zoloft.” 
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abbreviations are common in the review posts. The reviews may also include personal 
information, such as phone numbers, emails, or URLs. Therefore, before applying the framework  
to the data, we pre-processed data to remove the noisy patterns and personal information from 
the data set.  
3.4.1 Data Pre-processing 
 Processing of the data was composed of text-cleansing and sentence boundary detection. 
In the first step, we formulated regular expression rules to remove: 1) the personal information 
including emails, phone numbers, and URLs from the reviews, and 2) the noisy patterns in the 
reviews’ structure. Table 3.7 shows some nois patterns in the reviews and the regular expression 
codes for handling those issues. We did not remove emoticons from sentences, because they may 
represent perceived distress from a medication’s adverse effects or satisfaction with a 
medication. For example, in the following sentence, the emoticon represents antidepressants 
effectiveness. “I quit this drug and started on LAMICTAL which saved my life I now feel 
content and complete. :-)”. 
To split the reviews into sentences, after removing the noisy patterns, we used the open-
source Natural Language Toolkit (NLTK) (Bird, Steven 2006). We also used NLTK for sentence 
tokenization. Statistics on the review posts, the posts’ sentences, and tokens are presented in 
result section.  
3.4.2 Annotating sentences using analytical framework (sentence labeling) 
3.4.2.1 Developing guidelines. To maintain consistency and uniformity of sentence 
labeling across the whole sample of reviews, we developed guidelines using codes introduced in 
the final analytical framework, their definitions, and examples from the drug reviews (Table 
3.6). 
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Table 0-7 Examples of Regular Expression codes for Reducing Noise Patterns in Review Posts 
Noisy patterns Example Regular expression code 
Inserting space after full stop 
punctuations and start of a new 
sentence 
 
I have suffered many side effects 
from the prednisone used to treat 
the symptoms.I am just now 
starting to feel better. 
comments = re.sub (r'([a-zA-
Z])([\.?!])([a-zA-Z])',r'\1\2 \3', 
comments) 
 
Eliminating Emails 
 
com.uk@hotmail.comsevere 
 
 
Replacing dot before parenthesis 
with space  
 
But about a year later I tried 
others and could tolerate them 
much better. (Such as Lexapro 
and Prozac.). I hate it. 
Comment = 
re.sub(r'\.(\s*?\([^)]*\)\s*\.)', r'\1', 
Comment) 
 
Removing repeated punctuations 
from end of a sentence. 
 
Think menopause is a huge factor 
in this....i have only been on 
generic zoloft for about a week 
and a half 
comment = re.sub (r'([,.;:!?-])\1+', 
r'\1',comment) 
 
Replacing “.” with “,” when list of 
side effects are separated from 
each other with dot.  
Night terrors. Vivid dreams. 
Nightmares. auditory 
hallucinations everyday!!!!! 
never take this drug!!! 
comment = re.sub(r'\. 
(\s*(?!(?:i|she|he|He|She|I|we|We 
|They|they|it|It|You|you)\b) 
\w+(?:\s+\w+)?\s*)(?=[^\w\s]|$)' 
, r',\1', comment , flags=re.I) 
Replacing hyphen with dot when 
hyphen indicating full stop of a 
sentence 
 
Severe teeth clenching/TMJ 
which caused excruciating 
headaches - clenching came on 
right after taking the dose and 
would gradually wear off 
Comment = re.sub (r'(\s+)(\-)(\s+)', 
r'\1.\3 ', comment ) 
 
Replacing comma with dot, when 
comma indicating full stop of a 
sentence  
 
Effexor People are still having 
problems with this medication 
even after being off of it for 8 
months or more,  Please don't 
take this medication. 
Comment = re.sub (r'(\s+)(\,)(\s+)', 
r'\1.\3 ', comment ) 
 
Replacing dot after numbers when 
numbers indicating order of items 
in a list.  
 
After two to three hours vomit 2. 
Stiff muscles (Lack of oxygen?) 
3. Spacey, out of sync with time 
(as in Where did that tree come 
from? What am I doing?) 4. 
Weird, (as in How did that tree 
get there?). 5. Weak muscles 
comment = re.sub(r'(\d)\.(\s?[a-zA-
Z])',r'\1) \2'  ,comment) 
 
Inserting space between 
parenthesis and the followed 
words. 
 
"""Was deadly sick for 2 wks and 
he kept me on it regardless, 
upped the dosage three times 
over a year because it wasn't 
working(duh, it was my 
thyroid!)That dr. is history, btw!  
This time, I was very leary of 
taking anything.""" 
comment = re.sub(r'(\))(\w+)',r'\1 \2'  
,comment) 
 
Replacing ( - , )  before overall 
with dot 
 
 
and I was only on 2,5 months - 
overall - DOES do what it is 
supposed to do - you need to 
weight whether it is worth the 
side effects. 
comment= re.sub(r'[,-
](\s*[oO]verall?\s+)',r'. \1'  
,comment ) 
 
Respondents did not use any 
punctuation to indicate sentence 
stop.  
 
 
 
I was hoping it would eventually 
go away so I continued to take it 
and after the 6th day of the same 
intense side effects I finally had 
to just chunk them in the trash. 
No solution 
Incomplete sentences  i recommend the cookies.. PS.. i 
have not gained any weight.. and 
if 
No solution 
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3.4.2.2 Annotation environment. We used Microsoft Excel for developing the framework 
of annotation. The framework consists of sentences of post reviews arranged in rows and the 
defined items for sentence labeling arranged in columns. Each sentence was identified by the 
associated drug name followed by the review post id and sentence index indicating the position 
of the sentence in the review post. Annotators read the sentences and if a sentence fit into items, 
they entered 1 in the corresponding cell. The defined items in the framework were not mutually 
exclusive. In other words, a sentence may be coded as more than one individual item. For 
example, the following sentence was coded as both “effectiveness” and “perceived distress from 
ADR- low tolerability”: 
“ It really helped me, however I suffered from side effects.” 
Therefore, we coded it for both codes. Table 3-7 and Figure 3-2 presents 
a snapshot of the coding environment. 
 
Table 0-8 A Snapshot of the Coding (Annotation) Environment 
Drug_ID Sentence 
_index 
Sentences  ADR WD EF INF Other
s 
effexorXR
.217 
4 “I started on on a low dose and gradually 
increased to 150 mg.” 
0 0 0 0 1 
effexorXR
.217 
5 “I feel so much better taking this drug.” 0 0 1 0 0 
lexapro.40 1 “Lack of care for anything important in my 
life.” 
1 0 0 0 0 
lexapro.40 2 “Lack of feeling for anything, just lived day 
by day.” 
1 0 0 0 0 
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3.4.2.2 Coding (annotation) Process. Four coders (annotators) participated in the 
annotation process. All the coders possessed a minimum qualification of M.Sc. degree in health-
related studies. Two coders were pharmacy students and  two had backgrounds in public health 
and health sciences.   
We performed an interactive training for “sentence labeling” guidelines that involved 
mutual discussion between annotators to address the vague definition of items and conflicts in  
understanding each rule. We followed this step by refining the guidelines’ definitions, rules and 
examples. 
 
 
Figure 0-3 an expert of final analytical framework and comment analysis based on the framework 
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The review sample contains 887 posts for the four drugs, Zoloft  (210), Lexapro (218), Cymbalta 
(230), and Effexor XR (229). According to the method by which the sample was created, for 
each drug, the reviews were divided into five subsets according to the rating value provided by 
the patients, which ranged from 1-5. Overall, we had 20 documents (spreadsheets) 
that were divided into three non-overlapping subsets, subset 1 (7 documents), subset 2 (7 
documents), subset 3 (6 documents). Three of the coders proceeded with each of these sets. The 
fourth coders coded subset 4, which contained all documents. The review post sentences in each 
document were annotated by two annotators. The sentences in each document were coded by 
strictly applying the guideline's rules.  
3.4.2.3 Calculating inter-annotator agreement. To test reliability of themes defined in 
the final framework, we calculated inter-coder agreement between pairs of annotators annotating 
each file. Assessment of inter-annotator Agreement (IAA) demonstrates consistency among 
observational ratings provided by multiple coders. In addition, the inter-coder agreement 
indicates to what extend codes are defined firmly and precisely to exclude all unrelated passages.   
To calculate IAA, Kappa statistics are used to measure the observed level of agreement 
between coders for a set of nominal ratings and corrects for agreement that would be expected by 
chance, providing a standardized index of IRR that can be generalized across studies. The degree 
of observed agreement is determined by cross-tabulating ratings for two coders, and the 
agreement expected by chance is determined by the marginal frequencies of each coder’s ratings. 
Kappa is computed based on the equation where P(a) denotes the observed percentage of 
agreement, and P(e) denotes the probability of expected agreement due to chance” (Hallgren, 
2012): 
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𝑘 =  𝑃 𝑎 − 𝑃(𝑒)1− 𝑃(𝑒)  
Possible values for the Kappa coefficient ranges from -1 to 1, where 1 indicates complete 
agreement, 0 indicates completely random agreement, and -1 indicates complete disagreement. 
Moreover, according to the instruction for interpreting Kappa data provided by Landis and Koch 
(1977), 0.0 to 0.2 indicates “slight agreement”, 0.21 to 0.40 indicates “fair agreement”, 0.41 to 
0.60 indicates “moderate agreement”, 0.61 to 0.80 indicates “substantial agreement”, and 0.81 to 
1.0 indicates “almost perfect” or “perfect agreement”. 
 Hayes and Krippendorff (2007) introduced more conservative instruction for 
interpretation of Kappa values. They specified that Kappa less than 0.67 agreement should be 
discounted from analysis, variables with Kappa between 0.67 and 0.80 should be tentatively used 
in analysis, and variables with Kappa above 0.80 can be used for definite conclusion. Despite 
this instruction, in practice, variables with Kappa less than 0.67 are often retained in studies. 
Accepting or discounting a variable with Kappa less than 0.67 for testing hypothesis in 
qualitatively analysis strongly depends on a study’s research question and methodology.  
To report IAA agreement calculated using Kappa, the following items should be 
considered:  
1) The metric in which a variable was coded (e.g., nominal vs. ordinal, interval, or ratio); 
2) design of the study (e.g., whether all subjects vs. a subset of subjects are rated by 
coders);  
3) Intended purpose of the IAA estimate (e.g., to estimate the reliability of individual 
coders’ ratings vs. the reliability of the mean ratings from multiple coders);  
4) Reporting both the statistic and its computational variant (Hallgren, 2012).  
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For the purpose of our study, we calculated Kappa statistics based on the following 
criteria: 
1) The metrics in which all variables (codes) were coded were nominal variables. 
2) Each file was double coded. 
3) The intended purpose of the IAA estimate is to calculate reliability of individual coders. 
4) To calculate the IAA agreement, we used cohen_kappa_score from module of 
sklearn.metrics in python. This function uses the statistical method introduced by Artstein 
and Poesio (2008).  
Because the defined codes are not mutually exclusive (a passage may be coded into more 
than one individual theme), we coded them such that each individual code represented a separate 
binary variable (we dichotomized each variable (themes) into a binary variable, i.e., coded as ‘1’ 
for present and ‘0’ for absent). Using this procedure, we reduced the comparison into a 2*2 table 
based on whether each of the two coders reported the code as present or absent for each variable.  
Table 3-9 shows the IAA for each code in the final framework, and examples 
of disagreement. For ADRs and withdrawal symptoms (WD), we decided to 
exclude all sentences with general mentions of these two items, such as "side-effects" in the 
sentence: “I really suffered from side-effects." For both drug effectiveness and ineffectiveness, 
we decided to include only sentences that explicitly referred to a drug's success or failure in 
improving or deteriorating a patient's symptoms and general health. For example, the sentences: 
“I feel much worse after using the drug” should be labeled as “Ineffectiveness”, and the sentence  
“I had a really bad headache and dizziness, after my doc increased the dosage”, should be labeled 
only as “ADRs”, not both ADRs and Ineffectiveness. However, some annotators labeled 
sentences with mentions of ADRs as ineffectiveness, leading to a lower IAA for this item 
compared to other items.  
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Table 0-9 Computed IAA for each Themes in the Sentence Classification Component with Examples of 
Disagreement 
Items IAA Example of disagreement Annotator 1  Annotator 2  
ADR 0.81 “I stopped taking the lexapro, the anxiety has lightened a 
little bit, but the crying hasn’t.”  
ADR WD 
WD 0.69 “However, I have tried to taper and quit several times and 
CAN’T.” 
 
WD Others 
EF 0.82 “Helped a great deal then put on the generic and had a 
totally negative reaction.” 
EF EF & INF 
INF 0.65 “At the end of 6 weeks I still felt no difference but my best 
friend said they noticed a difference.” 
EF INF 
DI  0.91 “I really didn’t think that I was depressed, but I think since 
taking the lexapro, my mod has lifted.” 
EF EF  & DI 
ADR-PD-
high 
0.84 “I'd rather be normal sized and anxious than overweight.” ADR, SS, 
ADR-PD-
high 
ADR, SS 
ADR-PD-
low 
0.89 “Night sweats, trouble sleeping, but all of these gone away 
after a few weeks.” 
ADR,  
ADR-PD-
low 
ADR 
WD-PD-
high 
0.85 “When i miss a day i feel very spaced out, thick, groggy, 
sad.” 
WD 
WD-PD-
high 
WD 
WD-PD-
low 
0.83 “I only experience a little nausea/dizziness if I miss a dose.” WD 
WD-PD-low 
WD 
PPI-P 0.50 “My doctor switched my dosage time to morning and I noticed 
a world of change.” 
“I called my dr. office they told me to drop it down to 2.5 until 
they could see me.” 
PPI-P 
PPI-P 
Others 
Others  
PPI-N 0.59 “Every time I mentioned this to the doctors their only advice 
was to up the dose.” 
PPI-N PPI-A 
~KN 0.64 “This drug should not be given to anyone without the doctor 
notifying family/friends.” 
KN Others 
DXD-Dec 0.61 “I am going to stop the medication, because of  severe side-
effects” 
DXD-Dec DXD-S 
DXD-S 0.75 “The withdrawal was horrible, I had to stop working for two 
weeks.” 
DXD-S Others 
DXD-W 0.65 “I am in the process of discontinuation, be careful about 
withdrawal.” 
DXD-W DXD-S 
DXD-F 0.88 “ I run out of medication for few days, I felt horrible.” DXD-S DXD-F 
ATT-P  Not double coded– Removed from the final analytical 
framework 
  
ATT-N  Not double coded – Removed from the final analytical 
framework 
  
SUG-P  Not double coded– Removed from the final analytical 
framework 
  
SUG-N  Not double coded– Removed from the final analytical 
framework 
  
Dosage/d
uration 
 Not double coded– Removed from the final analytical 
framework 
  
~SS  Not double coded– Removed from the final analytical 
framework 
  
~FS  Not double coded– Removed from the final analytical 
framework 
  
Other 
drugs 
 Not double coded– Removed from the final analytical 
framework 
  
Other 
patients 
 Not double coded– Removed from the final analytical 
framework 
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Most of drug review posts do not include any explicit indicators that could be used to 
measure patients’ satisfaction with providers. For example, this sentence: “I talked to my doctor 
and he immediately suggested I come off of it”, does not clearly imply the patient’s attitude 
towards his or her provider. A patient may conclude that his or her provider did not have 
sufficient knowledge about treatment or may conclude that the provider considered his or her 
concern. This vagueness leaded to high rate of observational error and and low rate of IAA.  
For the variable, “complaining of lack of knowledge”, we decided to include patients 
reports for searching on the WEB for ADRs or WDs or advise to readers to gain information 
about ADRs or WDs as the sign of lack of knowledge. However, some of the coders did not take 
into account this indicator as sign of patients’ lack of knowledge, causing a lower IAA for this 
variable. 
3.4.2.4 Resolving disagreement. Annotators' observational errors occurred due to 
differences in annotators' interpretations of the guidelines and the differences in their 
interpretations of the review posts. A program was written to scan for instances of disagreement. 
Instances of disagreement were then reviewed and discussed by the same annotators who 
annotated the respective document earlier. For a specific item, annotation was added or removed 
if it was marked by any of the annotators, given that they both agreed on the decision. 
Otherwise, the sentences were labeled as others. The harmonization was performed over the 
complete corpus in the presence of annotators. 
Phase 5  
3.5 Entity Identification 
The focus of the first phase of the data analysis was on examining the qualitative aspects 
of knowledge (e.g., features, properties) using analytical frameworks. While the focus of this 
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phase, entity identification, is to extract medical entities including adverse drug reactions 
(ADRs), withdrawal symptoms (WDs), and drug indicators (DIs), and qualifiers representing the 
severity (QS) and persistency (QP) of ADRs, WDs, and DIs. 
Identification of ADRs and WDs from consumer health posts can directly provide a list 
of various types and frequency of ADRs and WDs associated with psychiatric medications. The 
ADRs and WDs may not be detected by clinical trials or post-marketing surveillance systems 
established by regulatory agencies, such as the Adverse Event Reporting System (AERS) of 
Food and Drug Administration (FDA). In addition, it also enables the generation and testing of  
hypotheses related to the association between different type of ADRs and WDs and 
discontinuation, adherence, and attitude.  
In the sentence-labeling phase, we labeled sentences for presence of ADRs, WD, and 
DIs. In this phase, we were able to select sentences with mentions of these entities and then 
proceed with the process of identification. 
3.5.1 Guidelines for entity identification  
Guidelines of entity identification includes the entities' definitions and rules for 
proper identification of the entities. Table 3-10 includes definitions of entities and rules for 
entities identification. The rules are related to patients' certainty in linking ADRs or WDs with 
drugs, identifying patients’ subjective complaints and functional problems, as well as excluding 
unnecessary context such as simile and metaphors from the span of ADRs, WDs, and DIs.   
Identifying patients’ subjective complaints is important because they may reflect subtle 
physiological, psychological, or cognitive ADRs associated with drugs. For example, “feel 
like I could not stop moving” reflects patient restlessness, which is a sign of akathisia (ADR of 
psychiatry medications). As another example, “body move in coordination with other people's 
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bodies” (Echopraxia) indicates an extrapyramidal symptom. Any of these symptoms have 
pharmacologically related affective components that may lead to a patient’s negative perception 
of drugs and eventually drug non-adherence.  
Identifying functional problems in drug review posts is also significant, not only for 
understanding how ADRs influence patients' normal daily activities and interpersonal 
relationships, but also for estimating the indirect cost associated with the ADRs. Overlooking 
functional ADRs when patients suffered from them has significant negative affects on expected 
clinical outcomes from medications. Moreover, collecting this information also 
enhances clinicians' abilities to predict the impact of ADRs on patients’ functionality, such as 
limitations on daily activities and social participation and restriction on work performance. 
Hence, they will be able to design more effective interventions targeting patients' attitude and 
adherence towards medications. The significance of representing signs or symptoms as 
functional problems is explained in detail in the International Classification of Functioning, 
Disability and Health (ICF) documents (World Health Organization 2010) (Giannangelo et al., 
2005) . The identified ADRs, WDs, and DIs were categorized as physiological (Phys), 
Psychological (Psycho), Cognitive (Cogn), and functional problem (FP).  
3.5.2 Entity identification process  
Four annotators participated in the process of identification and extraction of the three 
entities explained in table 3-10. We first selected the sentences with labels of ADRs, WD, and 
DIs and exported them to new excel spreadsheet documents. In the second step, the documents 
were divided into three sets and each set was reviewed by an annotator for entity identification.  
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Table 0-10 Entities' Definitions and Identification Rules with Examples 
 
For the purpose of calculating inter-annotator agreement for entity identification, the 
entire dataset was reviewed by the fourth annotator. Entity identification and extraction was 
Entit
y 
Definitions Example Rules for identification Example 
ADR Any sign or 
symptom that 
the patient 
explicitly 
associated it 
with drug 
consumption, 
except the 
phase of 
dosage 
reduction and 
discontinuation
.  
 
 
 
My doctor 
increased my 
dose and I felt 
severe dizziness 
(ADR).  
 
1. Certainty: If a patient is not 
confident about the association 
between ADR/WD and drug, the 
ADR/WD is not extracted. 
2. Subjective complaints: If 
ADR or WD was expressed as 
subjective complaints, it should 
be extracted with the entire 
necessary context.  
3. Functional problems: if 
patient mentioned his complaint 
as a functional problem, such as 
problem with daily functioning 
and social activities, it should be 
extracted and labeled as 
ADR/WD. 
4. Excluding simile and 
metaphor: If a patient used a 
simile or metaphor to provide 
information about his/her 
feelings towards ADR/WD/DI 
that simile or metaphor should 
not be extracted. 
5. Duplicates: Duplicate 
ADR/WD/DI in a sentence 
should be independently 
extracted, that is, all the 
occurrences of the entities are 
identified. 
6. Qualifiers: If ADR/WD/DI is 
associated with qualifiers 
presenting severity or 
persistency of that entity, the 
qualifier needs to be identified.  
1. It caused hair loss 
and stomach bloating 
(ADR), however I am 
not sure that hair loss 
(not ADR). 
2. It certainly erased 
the anxiety, but I 
hardly feel human 
anymore. (ADR) 
3. I would just stay 
around and do nothing 
all day (ADR) 
4. “Very hard to take 
a deep breath (ADR) 
like someone is 
squeezing my lungs. 
(Simile –non 
necessary) 
5. The anxiety (ADR)  
was debilitating. I also 
had severe headache 
(ADR), but the anxiety 
(ADR) was worse. 
6. Anxiety is now 
though the roof 
(qualifier-severity) 
6.2. Constant 
(qualifier-persistency) 
bad (qualifier-severity) 
headaches 
 
 
WD Any sign or 
symptom that 
patient 
explicitly 
associated it 
with the phase 
of dosage 
reduction and 
discontinuation 
of a drug. 
 
“Trying to come 
of has gotta be 
worse than 
heroin, 
Uncontrollable 
rage,(WD) and 
lots of 
emotional 
attachment with 
partner(WD).” 
DI Any sign or 
symptom that 
patient 
mentioned as 
the reasons for 
drug 
consumption/p
rescription.  
“My depression 
(DI) disappeared 
after drug 
usage.”  
1. Treated symptoms: a patient 
may also mention a 
sign/symptom that was relieved 
by drug consumption. That sign 
or symptom is also a drug 
indicator.  
If a patient’s sign/symptom 
became worse because of drug 
consumption, the sign/symptom 
should be labeled as both DI and 
ADR of the drug.  
This drug reduced my 
sense of guilt (DI).  
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conducted based on the rules specified in the guidelines. We did not extract general mentions of 
entities, such as “side-effects” and “withdrawal” in the sentences. For example, in these 
sentences, “I really suffered from side-effects," and "withdrawal seems impossible", side effects 
and withdrawal were not extracted. 
  Prepositions and possessive adjectives were excluded to improve consistency in spans 
of identified entities. For example, in “my anxiety became worse,” my was not extracted as part 
of anxiety. In the last step, the disagreement between annotators for the identified entities were 
resolved by Dr. Fontelo (a PhD committee member). 
3.5.2.1 Calculating Inter-Annotator agreement. To calculate inter-annotator agreement, 
we used pair-wise agreement between the annotators using the following formula (Metke-
Jimenez & Karimi, 2015):  
𝐴𝑔𝑟𝑒𝑒𝑚𝑒𝑛𝑡 𝐴! ,𝐴! =  𝑚𝑎𝑐𝑡ℎ (𝐴!, 𝐴! ,𝛼,𝛽)𝑚𝑎𝑥 (𝑛!!  , 𝑛!! )  
Where Ai represents the set of data annotated by annotator i; Aj  represents the set of data  
annotated  by annotator j; nAi is the size of identified entities in Ai and nAj is the size of identified 
entities in Aj; Max (nAi, nAj) is the maximum number of identified entities; 𝛼 parameter presents 
span strictness of identified entities and 𝛽 parameter represents tag strictness of identified 
entities. Since entities were identified from the sentences with predefined labels (tags), by 
default, they have the label of the sentences. Therefore, we excluded parameter 𝛽 from the 
calculation.  For parameter 𝛼, we set the span on strictness. Therefore, the identified entities 
must match exactly. For example, for identifying ADRs from this sentence: “the headache was 
terrible”, if annotator A identified “headache” as a side-effect, and annotator B identified 
“headache was terrible” as a side-effect, then the matching between annotators A and B is “0”. 
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The computed pairwise agreement for strict match are 0.86 for SFX , 0.81 for WD and 0.91 for 
SS, with the average 0.86 for the entire corpus. The reason for applying pairwise agreement (PA) 
for computing IAA rather than conventional measures, such Kappa, is that PA is calculated at the 
level of entities. Since the identification task requires identifying the entities and determining 
their correct boundaries, the chance agreement is effectively zero.  
Phase 6 
3.6 Terminology Association (Entities Normalization) 
While sentence classification and entity identification in drug review posts have 
significant implications for text mining and machine learning systems focusing on information 
retrieval, mapping patient expressions of these entities to the language of health professionals 
fills the gap between a layperson expressions and professional expressions of medical entities. 
This translation may benefit the generation and testing of medical hypotheses by providing 
unambiguous and standard information for statistical data collection and analysis.  
Terminology mapping typically involves identifying terms used by healthcare consumers 
and mapping them to their equivalent concepts available in medical standard vocabularies. This 
process is also referred to as normalization in other research (Karimi et al., 2015). An example of 
such normalization is CADEC corpus, in which the identified entities from drug review posts 
were mapped to SNOMED-CT, MEDRA, and ATM (Karimi et al., 2015). 
To normalize the entities in our corpus, we mapped the identified entities including 
ADRs, WDs, and DIs to their corresponding concepts in both the Unified Medical Language 
System Metathesaurus (UMLS Meta) and the Systematized Nomenclature of Medicine–Clinical 
Terms (SNOMED-CT). 
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UMLS Meta is a compendium of many standard medical vocabularies that provides a 
mapping structure among vocabularies, allowing one to translate among various terminology 
systems. UMLS Meta is organized by concepts. Each concept is assigned one or more semantic 
types (categories) and a Concept Unique Identifier (CUI). Semantic type covers a broad category 
of medical concepts, such as sign/symptoms, mental or behavioral dysfunction, and intellectual 
products. Different lexical representations of the same concept can be identified by CUIs. UMLS 
Meta has been used for identification and retrieval of medical entities from clinical and 
biomedical literature and clinical notes in Electronic Health Record (EHR) Systems . Automatic 
extraction systems built on UMLS Meta, such as MetaMap, have demonstrated high recall and 
precision for identifying medical entities in biomedical literature and clinical notes (Fung, Jao, & 
Demner-Fushman, 2013). However, as Nikfarjam et al. (2015) showed, MetaMap performance 
in entities identification (ADRs and drug indications) from consumer health posts showed 47% 
precision and 39% recall on corpuses from the “Daily Strength” forum and Twitter. Mapping 
ADRs and drug indications to UMLS Meta, in addition to the normalization benefit, reveals 
consumer health vocabulary that have not been covered by medical terminologies.   
SNOMED CT is considered to be the most comprehensive, multilingual clinical 
terminology in the world. The primary purpose of SNOMED CT is to encode the terms available 
in health information to support effective clinical recording for improving patient care. 
Accordingly, it is intended to provide a core general terminology for EHR systems. Mapping 
layperson expressions of medical entities to SNOMED-CT supports seamless information 
sharing between Personal Health Record (PHR) systems and EHR systems. In addition, Mapping 
to SNOMED-CT as the most comprehensive standard terminology supports providing an 
unambiguous data collection for statistical analysis. Moreover, mapping data to both UMLS 
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Meta and SNOMED-CT reveals the deficiency of SNOMED-CT in covering patients’ 
expressions of medical terms compared with other terminologies in UMLS Meta.  
3.6.1 Guidelines for Terminology Association 
The process of mapping laypersons’ expressions of medical entities to professional 
expressions is based on an assumption that consumers’ and professionals’ terms express the 
same underlying concepts. For example, the consumer term “feeling sick to my stomach” 
expresses the same concept as the professional term as “nausea”. By considering this 
assumption, most research on normalizing consumer health vocabularies has focused on the 
terms rather than the underlying concepts that the terms carry (Keselman et al., 2008). However, 
proper mapping involves both syntactic and semantic mapping between terms. For semantic 
mapping, we need to understand the conceptual models in both professional and consumer terms, 
which can be mostly identified in a term’s definition and a term’s context. Accordingly, for this 
study, we applied the process of entity expression mapping to both UMLS Meta and SNOMED-
CT by creating a guideline taking into account their potentially different conceptual models. 
The guidelines have been constructed based on the reviews of clinical trial studies 
targeting ADRs of psychiatric mediations and qualitative studies investigating the themes of 
patients’ experiences with the drugs. We reviewed literature concerning three types of ADRs 
associated with psychiatric medications, including physiological, psychological, and cognitive. 
Each set of these studies contains descriptions and clinical features associated with a specific 
ADR or a group of ADRs that were mostly developed based on clinical trial reports. Studies that 
focus directly on patients’ experience reports mostly attempted to classify the experiences 
by broad themes. The identified themes are usually equivalent to medical concepts used in 
professional settings. Here, we provide examples for each set of studies associated with a type of 
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ADR and how they can be used for translating patients’ reported experiences to professional 
terms.  
1) Example of Physiological ADRs: Psychiatric medication can cause Akathisia (Salem, 
Nagpal, Pigott, & Lucio Teixeira, 2017), which is described with the following clinical 
features: feeling of inner restlessness, compelling need to be in constant motion, as well as 
motor restlessness, such as “inability to sit” or “feeling the need to pace”. These underlying 
concepts of Akathisia, patients’ expressions of ADRs indicating inner restlessness, such as 
“feel like I was inside screaming” and motor restless, such as “ I am not able to sit” could be 
translated to Akathisia. Another example of ADRs is “brain shivers”. Brain shivers are a 
sensation of “sudden shake, vibration, tremor, jolt” in addition to electric shock that 
patients feel in the brain and that mostly occur due to missing dosages or discontinuing the 
drugs abruptly. Other terms that have been used to describe this symptom are “electric brain 
thingies,” “brain zaps,” and “brain flips” (Aronson, Jeff 2005). Hence, any mentions of 
these terms with the same underlying concept, such as “feeling electrical shock in the brain” 
in the review posts can be translated to “brain shivers”. 
2) Example of Psychological ADRs: Psychiatric medications are associated with a general 
syndrome of indifference as a behavioral syndrome and as an emotional syndrome (Sansone 
& Sansone, 2010). Behavioral indifference, a clinical feature of “apathy”, is manifested by 
patients’ lack of desire to engage in activities, lack of desire to make any 
changes, not caring about anything, or similar symptoms. Therefore, any terms reflecting 
behavioral indifference can be translated to “apathy”. For example, “ just don't care”, and 
“just lived day by day” are equivalent to apathy. The emotional aspect of indifference is 
characterized by a restricted range in expressing emotions and feelings, a sense of blunting 
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the emotions, or of feeling numb. Accordingly, clinical features of emotional indifference 
could be described by two main concepts, “blunted affect” and “lack of capacity to feel 
emotions”. Therefore, any patients’ expression reflecting the restricting range of emotion 
could have the same underlying concepts. For example, “very slow to excite”, “ dull mood”, 
“want to express myself and cry but cannot” can be translated to blunted affect.  
3) Example of Cognitive ADRs: Executive dysfunction as a cognitive ADR of psychiatric 
medication is associated with the inability to initiate and follow processes of completing a 
task, such as problems with initiating a task, problems with organizing a task, or problems 
with switching between tasks. So, any patient’s complaints reflecting the underlying 
concepts of executive dysfunction, such as “cannot follow through on simple tasks” can be 
translated to “executive dysfunction”.  
3.6.2 Creating a dictionary 
To reduce the time to accomplish the mapping the identified ADRs (SFX and WD) and 
drug indications to UMLS Meta and SNOMED-CT, we first developed a dictionary using 2,100 
mentions of ADRs extracted from 240 review posts. First, we looked for syntax mapping of the 
identified entities with UMLS Meta concepts using the UMLS API. If a syntax match was not 
available, we translated the colloquial expressions of ADRs to proper professional medical terms 
using the guidelines, and then we selected a proper UMLS Meta concept for the term. To ensure 
the selected UMLS Meta concept reflects the original term, we checked the parent terms of each 
concept to ensure that the UMLS Meta concept and the SNOMED-CT concept associated with 
it do not carry additional meaning. The additional meaning would be inherited from the parent 
terms that are not related to the patients' experience with the medication. This dictionary was 
reviewed for accuracy and was set as the reference code for mapping the identified entities to 
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both UMLS Meta and SNOMED-CT. We updated the guidelines and the dictionary periodically 
to include new expressions of ADRs and indicators.  
3.6.3 Procedure of mapping 
The mapping procedure and selecting the proper UMLS Meta and SNOMED-CT 
concepts was conducted based on the following procedure. Annotators used the UMLS 
Terminology Services, UTS browser (2017) for the finding proper UMLS and SNOMD-
CT concepts.   
1) Search for syntax matching by setting “search type” on “normalized word” and sources on 
“all sources”.  
a) In the case of a unique concept result, evaluate the concept using the requirements for 
a proper concept (Table 3-11). 
b) In the case of multiple concepts results, select the proper concept using the 
requirements for a proper concept (table 3-11). 
c) In the case of no concept returned, go to step 2 if the original term is associated with a 
qualifier. Otherwise, go to step 3.  
 
2) Search for a partial match by removing qualifiers associated with the original term.  
a) Follow sub-steps “a” to “c” specified in step 1. 
3) Search for a synonym using the guideline of the terminology mapping 
a) Follow sub-steps “a” to “c” specified in step 1. 
Figure 3-3 shows the detail of the procedure for identifying proper UMLS Meta and 
SNOMED concepts for the identified entities. Table 3-11 presents the requirement for selecting 
proper UMLS Meta and SNOMED-CT concepts. In the case of availability of multiple UMLS 
Meta concepts for the original term, the proper concept needs to include the expressions of the 
most recent versions of SNOMED-CT. If multiple UMLS Meta candidates met the mentioned 
requirements, the proper UMLS Meta concept has a SNOMED-CT expression that is closest to 
the original term. Using the flowchart (Appendix A) and requirements for finding proper 
concepts, we mapped identified entities to both UMLS and SNOMED-CT concepts.  
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Table 0-11 Requirements for Selecting Proper UMLS and SNOMED CT Concepts 
There were some cases in which a UMLS Meta concept that is the best match for an 
original term lacks SNOMED-CT concept. In this case, we searched for another UMLS Meta 
synonym concept that is expressed in SNOMED-CT. For example, for the original term “Zombie 
like”, the closest UMLS Meta concept is “Felt like a zombie [C0857486]”, which has no 
SNOMED-CT expression. In that case, we used UMLS concept “Emotionally detached 
[C0233754]” that include SNOMED expression. 
Requirement
s 
Description   Example 
(1) 
Definition 
- Definition of a proper concept should cover 
patient’s specific physiological, behavioral, 
emotional, cognitive, or functional problem.  
 
- If the patient did not specify the severity or 
type of a reported adverse effect, we used the 
most general concept (code) that represents the 
patient ‘s reported problem. 
For patient complaint “takes a long time to 
get to sleep”, UMLS concept: “initial 
Insomnia”.  “Sleeplessness” is not correct, 
because it includes all phases of insomnia.  
(2) Semantic 
type  
The semantic type of proper concept includes 
“finding”, “sign or symptom” or “mental or 
behavioral dysfunction”. However, in some 
cases, other semantic types, such as 
“individual behavior” for concept “aggressive 
behavior is a proper map. 
 
(3) 
Hierarchical 
structure 
(ancestors 
and children) 
The SNOMED-CT concept should not convey 
additional meaning inherited from ancestors 
(parents) that are not related to patient’s 
complaint.  
For the patient complaint “inability to 
eat”, Aphagia [C0221470] is not a proper 
map, because the concept is linked to 
ancestors of swallowing finding in 
SNOMED-CT. While the patient with 
depression does not have any problem 
swallowing, they have a problem with loss 
of appetite. So [C1971624] “Loss of 
appetite” is a proper map. 
(4) Including 
SNOMED-
CT concept 
In a case of existing multiple UMLS 
candidates, the preferred concept is a concept 
that includes the most recent SNOMED-CT 
concept.   
For the patient complaint  “memory loss”, 
“Amnesia [C0002622]” compared with 
“Memory loss [C0751295]” is the proper 
concept, because memory loss includes the 
obsolete version of SNOMED-CT concept.  
(5) Syntax 
match with 
SNOMED-
CT concept 
In the case of existing multiple UMLS 
candidates meeting requirement (1), (2), and 
(3), the preferred match has SNOMED-
Concept that syntactically match with the 
original term.  
 
For example, for the patient complaint  
"restlessness", the UMLS concept 
candidates are  “Agitation [C0085631]”, 
Restlessness [C3887611],  Psychomotor 
Agitation [C3887612], and Akathisia 
[C0392156]. The proper match would be 
“Restlessness [C3887611]” due to 
including the SNOMED-Concept preferred 
term (PT) with the same syntactic match.  
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 Figure 0-4 Flowchart of Finding Proper Concept for Layperson's Expression of Medical Entities 
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Table 3-12 provides example of mapping layperson expressions to both UMLS and 
SNOMED-CT. 
Table 0-12 Examples of Mapping Entities to both UMLS and SNOMED-CT Concepts 
 
Phase 7 
3.7 Usability of the Dataset (Corpus) 
Development of structured data from drug reviews in consumer health posts has several 
implications in the area of natural language processing, such as improving performance of text 
mining algorithms, and generating and testing medical hypotheses. In the next phase we show 
drug_id Sen
_Id 
original Term UMLS (1) SNOMED-CT (1) UMLS (2) SNOMED-CT 
(2) 
Qualifier 
cymbalta.
124 
1 Felt sick C0857027 / Feeling 
Sick /Sign or 
Symptom 
No code C0231218/ M
alaise / Sign 
or Symptom 
Undifferentiate
d illness: 
Vague ill 
health 
(finding) 
[A3771172/SN
OMEDCT_US/
FN/248282002
] 
 
lexapro.1
2 
3 "zombie" 
like 
C0857486/ Felt like 
a zombie/ Finding 
no code C0233484 / 
Emotionally 
detached / 
Finding 
Emotionally 
detached 
(finding) 
[A3413164/SN
OMEDCT_US/
FN/24936000] 
 
cymbalta.
12 
2 loose my 
friends 
C0524322 / Personal 
relationship 
breakdown / Human-
caused Phenomenon 
or Process 
Personal relationship 
breakdown (finding) 
[A3626907/SNOME
DCT_US/FN/105414
008] 
   
cymbalta.
131 
1 Excessive 
sleepiness 
C0013144/ 
Drowsiness/ Finding 
Drowsy (finding) 
[A3406202/ 
SNOMEDCT_US/ 
FN/271782001] 
  Excessive 
(QS) 
Effexor.7
8 
1 minor muscle 
spasms 
C0037763 / Spasm/ 
Sign or Symptom 
Spasm (finding) 
[A3712892/ 
SNOMEDCT_US/ 
FN/45352006] 
  Minor (QS) 
effexor.9
7 
2 Sweating like 
crazy all the 
time 
C0700590 / 
Increased sweating / 
Sign or Symptom 
Excessive sweating 
(finding) 
[A3440966/ 
SNOMEDCT_US/ 
FN/52613005] 
  All the time 
(QP) 
effexor.1
1 
7 Brain zap no concept  no concept    
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how the dataset can be used for testing hypotheses concerning patients attitudes toward 
antidepressants. 
3.7.1 Identifying the underlying factors affecting patient attitude towards drugs 
The following hypotheses were formulated based on the availability of information in the 
dataset generated through phase 3 (developing the analytical framework) and phase 4 (applying 
the analytical framework) and literature review focused on measuring association between 
pharmacological treatment factors, healthcare system factors, social-cognitive and psychological 
factors, patient-related factors, and depression factors with patients attitudes towards 
antidepressants. The list of hypotheses is as follows: 
- Testing association between personal variables and attitude  
1. Age:  
a) H0: There is no association between age and attitude. 
2. Gender:  
b) H0: There is not association between gender and attitude 
 Testing association between clinical variables and attitude: 
1. Duration:  
c) H0: There is no association between duration and attitude  
2. Drug Effectiveness:  
a) H0: There is no association between drug effective-ness and attitude. 
3. Drug ADR:  
a) H0: There is no association between drug adverse reaction and attitude. 
4. ADRs-PD:  
a) H0: There is no association between perceived distress received from 
ADRs (ADRs-PD) and attitude. 
5. LK:  
a) H0: There is no association between Lack of knowledge and attitude. 
If this null hypothesis was rejected, the following null hypothesis will be tested: 
6. WD-EXP:  
a) H0: There is no association between experience of withdrawal (WD-EXP) and 
attitude. Experience of WD includes any experiences of intentional (Weaning 
off or stopping) or unintentional (missing dosage) withdrawal of a drug.   
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7. PPI: 
a) H0: There is no association between patient physician interaction (PPI) and 
attitude.   
 
In addition to the hypotheses, the relationship between variables modeled to specify the 
significance of each variable in forming a patient’s attitude towards antidepressants. We also 
hypothesized that: 
1. ADR-PD and drug effectiveness are the most significant factors affecting patients 
attitudes toward antidepressants.  
3.7.1.1 Preparing the dataset for testing hypotheses 
To increase the accuracy of data analysis and enhance the level of inter-annotator 
agreement (IAA) between coders, the unit of analysis was set at the sentence level rather than the 
whole review. Therefore, for an individual review, there may be multiple occurrence of the same 
variable (code). For testing hypotheses, we reduced the multiple occurrences to a single one 
indicating presence or absence of a variable in the drug review. 
A single drug review may be coded for contradictory codes, such as both “Effectiveness” 
and “Ineffectiveness”. That is, a patient may find medications effective for a certain point of 
time, such as acute phase of treatment, but in the maintenance phase, they may not be satisfied 
with the drug. Therefore, for reviews coded as both “effectiveness” and “ineffectiveness”, we 
recoded both effectiveness and ineffectiveness.  
In addition, a review may be coded for both ADR-PD as high and ADR-PD as low. That 
is, in one part of his or her review, a patient may report an ADR was severe and has debilitating 
effects on quality of life, while another ADR may be mild and does not have such an effect. For 
such reviews, I only include ADR-PD-high, because overall, ADR-PD for patient is high.  
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Table 0-13 Lists of the Variables, Possible Values, and Limitations Associated with each of them for 
Measuring Patient Attitude toward Antidepressants 
Variables Possible values Limitations for measuring attitude 
ADR - Presence 
- Absence  
- Unknown: no explicit report on presence or 
absence of ADR. 
1) The patient might fail to distinguish between ADRs and 
WDs and report all sign/symptoms associated with 
drugs as ADRs  
2) For some reviews, there is no explicit report on 
presence or absence of ADR. 
ADR-PD - High 
- Low 
- Moderate: when patient did not use any 
indicators showing the perceived distress 
was high or low, then it is moderate. 
 
1) AD-PD involves only three level of distress. These 
categories do not include nuance difference for ADR-
PD for patients.  
2) The definition for ADR-PD may be incomplete and do 
not include all the cases for ADR-PD-high. For 
example, persistency of ADRs indicates ADR-PD for 
some patients, while in definition we did not include it 
as sign of ADR-PD. 
WD - Presence  
- Absence  
- Unknown, if patient reported they 
experience intentional or unintentional 
WDs, but no explicit report on presence 
or absence of ADR.  
1) Patient may fail to distinguish withdrawal from ADRs 
and therefore did not report all WDs. 
2) Patients who experienced the WD, there is no explicit 
report on the presence or absence of WD. 
 
WD-PD - High 
- Low 
- Moderate: patient did not use any indicators 
showing the perceived distress was high or 
low, then it is moderate.  
WD-PD is subject to the same limitations explained for 
ADR-PD  
EF - EF: drug was effective, 
- INF: drug was ineffective 
- EF-INF:  patient reported both effectives 
and ineffectiveness of the drug during the 
process of treatment. 
- Unknown: no explicit report on EF or INF 
of the drug.  
1) Patients may fail to realized drug effectiveness because 
of the high perceived distress received from ADRs.  
2) A patient may fail to report drug effectiveness, because 
there is no request for reporting it in the healthcare 
forum.  
3) The definition for drug effectiveness may not be 
complete. For example, a patient might attempt to show 
drug ineffectiveness through reporting ADR or ADR-
PD.  
LK - Presence 
- Absence  
 
1) A Patient might fail to report their lack of knowledge or  
conducted search to gaining information about 
ADRs/WDs. 
2) Definition for complaining about lack of knowledge 
may be incomplete.  
WD-EXP DXD-Dec: existence of any indicators 
showing the patient’s decision for 
discontinuation, such as “I am going to stop” 
Patient might fail to report intentional or unintentional 
withdrawal from drug.  
DXD-WD: existence of any indicators 
showing patient experienced process of 
discontinuation, such as “weaning off” or 
“tapering off”.  
DXD-S: existence of any indicators showing 
patient already stopped the medication, such 
as “stopped”. 
DXD-F:  existence of any indicators showing 
patient experienced withdrawal 
unintentionally, such as “missing a dose” 
PPI - Patient perceived communication-positive  
- Patient perceived communication-negative  
- Unknown: no explicit report on patients’ 
satisfaction with healthcare providers.  
 
1) Most of the patient did not declare any information 
about their perspective with providers.  
2) Patient mentions of communication did not clearly 
convey their attitude toward providing, causing high 
disagreement between annotators (coders) for this 
variable.  
3) This variable was defined as binary variable, which may 
not reflect the slight differences between patient attitude 
toward medication. 
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Table 3-13 lists the variables, possible values, and limitations associated with each 
variable for measuring patient’s attitude toward antidepressants.  
3.7.1.2 Strategy for handling missing values  
To handle the missing values, we adopted different imputation methods regarding the 
nature of the missing values for each variable.  There are three assumptions for handling missing 
data:  
a) Missing completely at random (MCAR): “When observations of a variable are missing 
completely at random, the missing observations are a random subset of all observations; the 
missing and observed values will have similar distributions”(Bhaskaran & Smeeth, 2014). In 
other words, the absence of data is unrelated to other variables in the model.  
b) Missing at random (MAR): “Missing at random means there might be systematic 
differences between the missing and observed values, but these can be entirely explained by 
other observed variables” (Bhaskaran & Smeeth, 2014) . In other words, MAR means that the 
variable having missing data can be fully accounted for variables on which we have full 
information. 
c) Missing not at random (MNAR): MNAR is data that absence is neither MAR nor 
MCAR. For example, if a patient fails to report their review for drug because of difficulty of 
filling the form or fear of breaching confidentiality, the missing values are MNAR.  
The following strategies have been used for handling the missing values from the dataset. 
• Elimination of drug reviews  
1) Eliminating reviews with no text; accordingly five reviews were eliminated 
2) Eliminating reviews that did not include any information for the variables for 
testing the hypotheses; accordingly seven variables were removed from the 
sample. 
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3) We removed the variable “PPI” from the analysis, because of the low IAA 
calculated using Kappa method and high number of missing values. The IAA 
for PPI-Positive (0.5) and PPI-Negative (0.59), with overall 0.55 for PPI.  
 
• Imputation of missing values 
1) Age: The assumption for missing values for imputing missing values for this 
variable is MCAR. It was assumed that the missing value has the same 
distribution of the observed values. Therefore, we used mean of data to fill in 
the missing values.  
2) Gender: The assumption for imputing missing values for this variable is 
MCAR. Because this data is categorical, we used the mode of the variable to 
impute the missing values.  
3) Duration of usage: The assumption for imputing missing values for this 
variable is MACAR. Because the data is very skewed, the median of data for 
this variable was used for data imputation, rather than the mean of the data. 
4) ADR: The assumption for imputing missing values for this variable is MNAR. 
If patient did not explicitly reported any ADRs, I assumed that ADR is 
presence for the patient.  
5) ADR-PD: The assumption for imputing missing values for this variable is 
MNAR. According to the definition, a perceived distress from ADR is high, if 
ADR is associated with qualifiers indicating severity or debilitating effect on 
patient’s daily life. On the other hand, the perceived distress is low, if ADR is 
associated with qualifiers indicating mildness of the ADR. The detail definition 
of these two variables is presented in Table 3-6. Accordingly, if the indicators 
are not available, the ADR-PD was coded as “NA” (missing value), which may 
imply that patients found the ADR neither severe, nor mild. Therefore, we 
imputed the missing values as “moderate”.  
6) EF: The assumption for imputing missing values for this variable is MAR. For 
imputing missing values for this variable, the following procedure was 
conducted:  
1. Drug reviews with missing values were eliminated from the dataset.  
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2. The association between EF and ADR-PD, WD-experience, LK, age, 
gender, and duration were computed using the Chi-square test.  
3. Regarding the variables associated with variable EF, K-nearest 
neighborhood (KNN) was used for the whole dataset to impute the 
missing values.  
7) WD-Experience: WD-experience includes the patient’s intentional and/or 
unintentional withdrawal of WD, including variables “DXD-S”, “DXD-W”, 
and “DXD-F”.  The assumptions for coding these variables were, if the patient 
explicitly reported experience of intentional or unintentional discontinuation, 
then WD-Experience is “presence”, otherwise the WD-Experience is 
“absence”. Accordingly, there was no missing value for this variable.  
8) LK: For variable lack of knowledge (LK), if a drug review includes any 
indicators showing lack of knowledge (table 3-6), the review was coded for 
LK-presence, otherwise the LK-absence. Accordingly, there was no missing 
value for this variable.  
3.7.2 Testing Association between ADRs and Attitude 
Identifying ADRs that are significantly associated with negative attitude towards 
antidepressants is important from the clinical perspective. It is important that healthcare 
providers understand whether exposure to different type of ADRs can increase the risk of 
developing negative attitudes and consequently non-adherence behavior in patients.  
To measure the association between antidepressants’ ADRs and attitude or adherence, the 
Antidepressant Side-Effect Checklist (ASEC) (Uher et al., 2009) has been used. The ASEC was 
constructed as a self-report scale to measure twenty-one physiological antidepressants’ ADRs. 
For each item, the patient can specify whether a symptom (if present) is likely to be linked to 
antidepressants adverse effects (yes or no).  
Patients’ expression for ADRs in a healthcare forum are associated with wide semantic 
variation, leading to limitations in statistical analysis for testing hypothesis related to different 
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ADRs and attitude. This study normalized the semantic variability of ADRs by mapping them to 
UMLS Meta concepts. The details of the normalization was provided in “3.6 Terminology 
association”. Expressions of ADRs were mapped to the closet syntax match in both UMLS and 
SNOMED-CT. Therefore, some ADRs maybe syntactically different, but semantically related 
UMLS Meta concepts. For example, “headache” (mapped to the UMLS Meta concept “[ 
C0018681] Headache”) and “severe headache” (mapped to UMLS Meta concept  “[C2957106] 
severe headache”) are semantically related. For each ADR mentioned in the ASEC, we grouped 
semantically related UMLS Meta concepts. In the next step, we calculated the total frequency of 
items in each group, and then tested associations between each group of ADRs and patients’ 
attitudes toward antidepressants.  
3.7.3 Statistical Methods 
For testing hypothesis for this study, we used Chi-square, ANOVA, and ordinal logistic 
regression.  
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4.1 Dataset Statistics 
The original sample size was calculate using formula for calculating sample size, which 
was 892 reviews, with 432 in the SSRI class (Zoloft  (213) and Lexapro (219)) and 460 in the 
SNRI class (Cymbalta (231) and Effexor XR (229)). Five posts were excluded from the sample, 
because they lacked any content. Table 4.1 shows statistic for sample of this study.   
The final sample is almost equally divided between SSRI and SNRI classes. Table 4 shows 
demographic information of the whole sample, as well as each class of drugs separately. Almost 
50% of the reviews was recorded by patients who were satisfied with drugs, while 33% of 
patients were dissatisfied with the drugs, indicating that patients with negative experience are not 
dominant in this healthcare forum. 68% of the posts were posted by patients with age less that 
40. This is possibly due to higher access to Internet in young patients and their willingness to 
report their experience with medications. The gender proportion in the sample for female is 
significantly higher than for male for both classes of drugs. Duration of usage is highly skewed 
due to the effect of outliers. Posting reviews after 1 day of treatment may indicate high concern 
of patients about the treatment.  
4.2 Statistics on Developing and Applying the Analytical Framework  
For the first phase of this study, the framework method was used to provide structured 
data from text-based consumer reviews of the antidepressant drugs specified in this study. In the 
framework method, a hybrid approach of inductive and deductive analysis was applied for 
coding and theme development. In the deductive approach, a comprehensive set of articles and 
self-report scales (questionnaires) that has been used in studies with focus on measuring patients’ 
attitudes towards antidepressants and psychiatric medications have been reviewed to identify the 
important factors affecting patients attitudes towards antidepressant medications. The identified 
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factors were categorized into five major categories, including pharmacological treatment, 
healthcare systems, psycho-social factors, patients-related factors, and disorder related factors. 
The factors were used for building the initial Framework of analysis. 
 
Table 0-1 Dataset Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dataset statistics Dataset SSRI SNRI 
Sample Size 892 432 460 
No. of reviews with text  887 428 459 
Time span Feb 2001  
Sep 2016 
Feb 2001 
Aug 2016 
July 2004 
Sep 2016 
Attitude  3.16 3.33 3 
Attitude rated as 1 195 (23%)   
Attitude rated as 2 104 (12%)   
Attitude rated as 3 152 (17%)   
Attitude rated as 4 209 (24%)   
Attitude rated as 5 219 (25%)   
Gender F 669 (76%) 
M 212 (24%) 
Missing value (11) 
F 310  (72%) 
M 118 (28%) 
Missing value (4) 
F 359 (79%) 
M 94  (21%) 
Missing value 
(7) 
Age Avg. 37 
Med. 35 
Sd = 12.03 
Missing values 
(10) 
Avg. 35 
Med. 34 
Avg. 38 
Med. 37 
Age range 14-83 14- 73 14- 83 
Age categories 
<20   
>= 20 <30  
>=30 <40    
>=40  <50   
>=50 <60 
<=60 
 
49    (6%) 
242  (27%) 
249  (28%) 
200  (23%) 
106 (12%) 
33  (4%) 
  
Duration of usage Avg. 18 months 
Med. 5 month 
SD. 31.7 (month) 
Avg. 19 months 
Med. 5 months 
Avg. 17 months 
Med. 5 month 
Duration of usage (range) 1 day - 20 years 1 day- 16 years 1 day - 20 years 
Duration of usage categories 
< 1 month    
>= 1 month  < 3 months 
>= 3 months < 6 months   
>= 6 months < 1 year     
>=1 year <2 year 
>=2 years <5 years 
>=5 years <10 years     
>= 10 years  
 
215 (24%) 
116 (13%) 
120 (14%) 
125 (14%) 
82 (9%) 
128  (15%) 
66 (7%) 
27 (3%) 
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300 drug reviews were coded using the codes (themes) at initial analytical Framework. 
Using inductive approach (open coding), passages of text that did not match into the codes in 
initial framework were discussed for more analysis in weekly meeting. Overall, eleven new 
themes were identified, including withdrawal symptoms, perceived distress from withdrawal 
symptoms, experience of withdrawal (intentional and unintentional discontinuation), decision for 
discontinuation, recommendation to others for the drug usage, experience with other 
medications, drug indications, problem with financial support, problem with social support, 
overall attitude toward medications, and recommendation to others.  
The codes (themes) generated using deductive and inductive approach were refined by 
availability of patient expression for each theme, difficulty in differentiating between themes, 
and also relevance of the theme to measuring attitudes towards antidepressants. The final 
analytical framework includes 29 themes. Table 4-3 lists the themes in the final analytical 
framework. To improve consistency of annotating (coding) using the analytical framework, the 
reviews were split to sentences. The detail of splitting drug reviews to sentences was explained 
in the methodology section.  
Table 4-2 presents statistics on posts, sentences, and tokens. In average, patients on 
SNRI drugs had longer posts, 7.1 vs. 6.4 for number of sentence, and 117.5 vs. 103.3 for number 
of tokens. In average, patients on SNRI drugs had longer posts, 7.1 vs. 6.4 for sentence length, 
and 117.5 vs. 103.3 for tokens. However, the range of sentence number in SSRI drug is higher 
than SNRI drugs.  
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Table 0-2 Statistics on Frequency of Posts, Sentences, and Tokens 
 
 
 
 
 
 
Table 0-3 Frequency of Themes after Resolving Disagreements for the Whole Dataset 
 
Table 4-3 shows the counts of annotated variables (themes) for the complete corpus and 
for both psychiatric categories of drugs separately. 33% of sentences included information about 
adverse drug reactions in the sample. 17% of the sentences provided information about drug 
 Corpus SSRI  SNRI 
No. Posts 887 428 459 
No. Sentences  6004 2749 3255 
Avg. posts length (sentence) 6.77 6.42 7.1 
No. Sentences (range) 1-35 1-35 1-25 
No. Tokens  98186 44237 53949 
Avg. Posts length (word) 110.7 103.36 117.53 
Themes (variables) Corpus SSRI SNRI 
ADRs 2004 985 1019 
WD 279 64 215 
EF 1078 575 503 
INF 308 143 165 
DI 806 422 384 
PPI 280 121 159 
PPI-P 55 26 29 
PPI-N 87 34 53 
KN 70 18 52 
ADR-PD-low 404 193 211 
ADR-PD-high 976 455 521 
WD-PD-low 61 27 34 
WD-PD-high 355 66 289 
Decision for Discontinuation (DXD-dec) 49 17 32 
Intentional Discontinuation (DXD-S) 212 103 109 
Intentional Discontinuation-(DXD-W) 93 38 55 
Unintentional discontinuation (DXD-F) 58 15 43 
ATT-P (overall attitude towards drug-
Positive) 
58 34 24 
ATT-N (overall attitude towards drug-
Negative) 
223 72 151 
Suggestion to others (positive) 39 24 15 
Suggestion to others (negative) 84 33 51 
Dosage 277 151 126 
Other patient  10 6 4 
Lack of social support (SOS)  2 0 2 
Lack of financial support (FS) 18 4 14 
Other drugs 374 181 193 
others 778 309 469 
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effectiveness, and only 5% of the sentence included information for patients’ perceptions about 
healthcare providers. This information indicates that this data source is a rich source to evaluate 
pharmacological aspects of psychiatric medications, but not a rich source for patients-physician 
interaction. Comparing the frequency of sentences including negative recommendation about 
drug usage (84) to readers with frequency of sentences providing negative suggestion (39) 
indicates that patients with negative experiences with drugs are more likely to suggest others not 
to use the drugs. 12% of the sentences did not provide any informative information for the items 
(codes) defined in the final analytical framework.  
To reduce the complexity of final analytical framework, themes that were directly related 
to patients’ attitudes were eliminated from the Final analytical framework. Therefore, ATT-P, 
ATT-N, Suggestion to others (positive) and Suggestion to others (negative) were removed from 
the framework. In addition, themes “dosage” and “other patients” were removed from the final 
analytical framework because they do not provide any information for the patients’ attitudes 
towards medications. Lack of social support (SOS) and Lack of financial support (FS) were also 
removed from the analytical framework because of high missing values for the themes.  
Using the analytical framework, all the sentences were double coded by participation of 
four annotators with health-related background. The inter-annotator agreement (IAA) was 
calculated using Kappa. The Average IAA for the whole dataset was 0.75 with the lowest IAA 
for patient-physician interaction-positive attitude (0.5) and highest IAA for Drug indication 
(0.91).  
4.3 Statistics on Summarized Dataset 
Because annotation of comments were conducted at sentence level, an individual drug review 
maybe annotated several time for availability of a theme (code). To summarize annotation at 
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comment level, multiple expressions of a theme were reduced to a single one for a review posts.  
For example, several sentences in a drug review maybe annotated for the presence of ADRs, but 
at the level of a review (comment), we reduced it to the single presence of the theme (ADR). We 
summarized the whole dataset at the level of drug review using this strategy. All themes were 
considered as variables. Table 4-4 shows the variables and their frequency. Limitations of each 
variable for measuring patients’ attitude toward drugs and the strategy for filling missing values 
were discussed in the methodology section.  
Table 0-4 Statistics on Variables Used for Testing Hypotheses 
Variables Frequency  
ADR 
Presence  
Absence                                                               
 
823 
56 
ADR-Perceived distress 
High  
Low 
Medium 
 
483 
166 
230 
Drug Effectiveness 
EF 
EF-INF 
INF 
 
524  
120  
235  
Patient-Physician Interaction 
Negative   
Positive  
Negative-positive  
Missing value: 
 
47  
62 
4  
766  
Complain of lack of knowledge 
Presence  
Absence 
 
60 
819 
Experience of Withdrawal (Intentional and/or Unintentional) 
No Experience  
Experience 
 
508 
371 
Unintentional withdrawal 
No report  
Reported 
 
831 
48 
Intentional Withdrawal 
No report 
Existence of report on intentional withdrawal 
 
639 
240 
Report on Intentional withdrawal and decision for withdrawal 
Existence of report 
No-report 
 
275 
604 
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4.4 Testing Hypotheses  
4.4.1 Measuring association between variables and levels of attitude 
To measure association between variables and levels of attitude, Chi-Square has been 
used for categorical variables and Anova was used for continuous variables. Table 4-5 lists the 
variables, related hypothesis, the type statistical test used for testing hypothesis, and P-value. For 
this study, P-value was set on 0.05. All the analysis was conducted using RStudio, version 
1.0.153. 
We reject the null hypotheses for variables ADR experience, ADR-Perceived distress, 
Drug Effectiveness, Complaint of lack of knowledge (LK), Duration of usage, Experience of 
Withdrawal (Intentional and/or Unintentional), and Intentional Withdrawal (weaning off and 
stopping the medications). In fact, these variables are significantly associated with patients 
attitude towards antidepressants.  
For two variables age and gender, there is not enough evidence to reject the null 
hypothesis. So we conclude that these two variables are not significantly associated with 
attitudes towards antidepressants specified in this study.   
Table 0-5  List of Variables, Hypothesis, Statistics Test, and computed P-values   
Variables Hypothesis Statistic 
method 
Values P-value 
ADR Experience  
 
ADR and attitude are 
independent variables. 
Chi-square   X-squared 
= 31.11 
2.907e-06* 
ADR-Perceived distress  
 
ADR-Perceived distress 
and attitude are 
independent variables. 
Chi-square X-squared 
= 231.6 
< 2.2e-16* 
Drug Effectiveness 
 
Drug Effectiveness and 
attitude are independent 
variables 
Chi-square X-squared 
= 548.52 
< 2.2e-16* 
Complaint of lack of 
knowledge (LK) 
 
LK and attitude are  
independent variables. 
Chi-square X-squared 
= 59.358 
3.957e-12* 
Experience of 
Withdrawal (Intentional 
and/or Unintentional)  
WD-Experience and 
attitude are independent 
variable. 
Chi-square X-squared 
= 55.624 
2.404e-11* 
Intentional Withdrawal Intentional Withdrawal 
and variable are 
Chi-square X-squared 
= 64.009 
4.161e-13* 
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Figure 4-1, Figure 4-3, Figure 4-4, Figure 4-5, Figure 4-7, Figure 4-9, Figure 4-11, Figure 
4-13 shows distribution of “gender”, “age”, “duration”, “experience of ADRs”, “perceived 
distress from ADRs”, “drug effectiveness”, “withdrawal experience”, “complaint of lack of 
knowledge” for each level of patients attitude respectively.  
Figure 4-2, Figure 4-6, Figure 4-8, Figure 4-10, Figure 4-12, Figure 4-14 shows 
frequency of “gender”, “experience of ADR”, “perceived distress form ADRs”, “drug 
effectiveness”, “withdrawal experience”, and “complaints for lack of knowledge” for each level 
of attitude. 
 
 
 
 
 
 
 
 
 
independent variable. 
Gender Gender and attitude are 
independent variables. 
Chi-square X-squared 
= 2.6812 
0.6125 
 
Age 
Age and attitude are 
independent variables. 
 
ANOVA F-value= 
0.7183 
0.3969 
Duration of usage Duration of usage and 
attitude are independent 
variables. 
ANOVA F-value= 
43.665 
6.756e-11* 
   
106 
 
Figure 0-1 Distribution of gender for each level of patients attitude 
 
 
Figure 0-2 Frequency of gender for each level of attitude 
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Figure 0-3  Distribution of age for each level of attitude  
 
 
Figure 0-4 Distribution of duration of usage for each level of attitude 
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Figure 0-5 Distribution of presence and absence of ADRs for attitude levels 
 
 
Figure 0-6 Frequency of ADR for each level of attitude 
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Figure 0-7. Distribution of perceived distress from ADRs (high, low, medium) 
 
figure 0-8 Frequency of perceived distress from ADRs 
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Figure 0-9 Distribution of drug effectiveness 
 
 
Figure 0-10 Frequency of drug effectiveness 
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Figure 0-11 Distribution of withdrawal experience for levels of attitude 
 
 
Figure 0-12 Frequency of withdrawal experience for each level of attitude 
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Figure 0-13 Distribution of complaints for lack of knowledge 
 
 
Figure 0-14 Frequency of complaints for lack of knowledge for each level of attitude 
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4.4.2 Developing a predictive model 
To find the best fitting model to describe the relationship between the independent variables 
(outcome variables ) and attitude (dependent variable), we used ordinal logistic regression. We 
used polr command from the MASS package in R to estimate an ordered logistic regression 
model. The command name comes from proportional odds logistic regression, highlighting the 
proportional odds assumption in the model. “Polr” uses the standard formula interface in R for 
specifying a regression model with outcome followed by predictors. 
For developing the model we did not include age and gender, because they are not 
significantly associated with patients attitude toward antidepressants.  The following equation 
shows the relationship between independent and dependent variables: 
 
 
 
Table 4-6 shows the coefficient, standard error, and p-value for the outcome variables for this 
model.   
 
 
 
 
Table 0-6 Values of statistical model 
Variable Co-efficient Std. Error P-value 
ADR_Experienced (1) -0.511989943 1.170552e-01 1.220362e-05 
ADRPD (low) 1.938705530 1.876554e-01 5.091863e-25 
ADRPD (medium) 0.804059699 1.584470e-01 3.882502e-07 
EFINF (EF-INF) -0.870736633 1.945260e-01 7.598449e-06 
EFINF (INF) -3.979180295 2.123201e-01 2.274740e-78 
ExperienceWD (1) -0.700315050 1.382074e-01 4.038538e-07 
Lack of knowledge 1 -0.433608481 3.215736e-01 1.775311e-01 
Duration 0.000259638 8.441442e-05 2.099712e-03 
Attitude ~ Experience of ADR + ADR_ Perceived distress  + Effectiveness + 
Experience of WD + duration of usage+ lack of knowledge  
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Table  4-7 shows  the confidence interval for the outcome variables in the model. 
Table 0-7 Confidence Interval for the Outcome Variables in the Model 
Outcome variables  Minimum Maximum 
ADR Experienced (1) NA NA 
ADRPD (low) 1.5397784239 2.34744346 
ADRPD (medium) 0.4932958996 1.1160166506 
EFIN (FEF-INF) -1.2550505954 -0.4878371728 
EFINF (INF) -4.4199855660 -3.5554091696 
Experience WD (1) -0.9723098874 -0.4297849025 
Lack of knowledge 1 -1.0830989795 0.1830980650 
Duration 0.0001209877 0.0004024088 
 
 Analysis of coefficients (Table 4-7) showed that “drug effectiveness” and “perceived 
distress from ADRs” are the most significant factors affecting patients’ attitudes toward 
antidepressants.  
Comparing our findings with findings of literature showed that in line with literature, 
“drug ineffectiveness”,  “experience of ADR”, and “lack of knowledge” and “duration of 
treatment (usage)” are associated with negative attitude towards antidepressants. Demyttenaere 
et al. (2004) and (Reilly JL, 2011) showed drug effectiveness is strongly associated with patient 
attitude towards antidepressants. For “experience of ADR” several studies found that experience 
of ADR is associated with negative attitude towards medications (Dougherty et al., 2009; Murata 
et al., 2012; Ng et al., 2012). (Haslam et al., 2005) and (Gabriel & Violato, 2010) found that 
patients with more knowledge about their illness and their treatment are likely to be have 
positive perception about treatment and, in turn, to be more adherent. Association between 
variable “patient-physician interaction” and attitude were not tested, because of low IAA for this 
variable and high rate of missing values. 
As the results in table 4-5 shows, age and gender are not associated with levels of 
attitude. Therefore, we did not include them in the predictive model. The findings are in 
agreement with findings of studies conducted by Jacob et al. (2015), (Murata et al., 2012), and 
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(Ng et al., 2012). However, our findings for age and gender are contrary to the findings of study 
conducted by Prins et al. (2008).  
We found “Experience of withdrawal” associated with negative attitude towards 
antidepressants. However, this variable was not discussed by literature.  
4.5 Statistics on Entities Identification 
In the second phase of the study, ADRs, WDs, and DIs were identified and extracted 
from sentences that in the first phase of this study were annotated as ADRs, WDs, and DIs. All 
the entities were identified by strictly following guidelines covering the rules of identification, 
such as patients’ certainty in linking ADRs and WDs to the drugs. In addition to identifying the 
physiological, psychological, and cognitive patient complaints about the drugs, the impact of the 
ADRs on patients’ daily functioning and social participation were also extracted. Identifying 
functional problems is significant for understanding the impact of ADRs on patients’ quality of 
life. It is also important for estimating the indirect cost associated with the ADRs (Giannangelo 
et al., 2005). Collecting this information enhances clinicians' abilities to predict impact of ADRs 
on patients’ functionality and work performance. Hence, they will be able to design more 
effective interventions targeting patients' attitude and adherence towards medications. 
Four annotators (coders) identified the boundary (span) of the ADRs/WDs/DIs in the 
sentences. All the entities were double coded by strictly following the guidelines of entities 
identification. The computed pairwise agreement for strict match was 0.86 for ADRs, 0.81 for 
WDs and 0.91 for SSs, with the average 0.86 for the whole corpus. The reason for applying 
pairwise agreement (PA) for computing IAA rather than conventional measures, such as Kappa, 
is that PA is calculated at the level of entities. Since the identification task requires identifying 
the entities and determining their correct boundaries, the chance agreement is effectively zero. 
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Table 4-8 lists frequencies of identified entities for the total corpus, for each class of 
drugs, and for each type of entity separately. From 6,534 identified entities, 73% are ADRs, 12% 
are WDs, and 18% are drug indicators. In total, 41% of the entireties were duplicates, with the 
highest frequency of duplicates for drug indicators (89%), and lowest frequency for withdrawal 
symptoms (20%), indicating that patients mostly use the same medical terms to describe the 
reasons for drugs prescription. This result may be due to similar information given by providers 
to patients. Physiological entities constitute 59% of the total entities, followed by psychological 
entities (35%), Cognitive entities (5%) and Functional problems (2%), showing that the review 
posts are not a rich of the impact of ADRs or WDs on patients’ quality of life. For the purpose of 
designing more effective medication adherence interventions, it would be useful if healthcare 
forums also ask patients to report the impact of drugs on their daily functioning and social 
activities.  For ADRs and WDs, psychological and cognitive expressions have higher variability 
than physiological expressions. That is due to level of subjectivity of these types of entities 
leading to creating various phrases by patients to express their subjective complaints. For two 
classes of psychiatric medications, SSRI and SNRI, the distribution of ADRs and drug indicators 
is almost similar.  
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Table 0-8 Statistics on Entity Identification Component for Each Class of Drugs and Type of Entities 
Separately 
 
Table 4-9 provides examples of the top 5 identified entities for each type of entities and 
class of drugs separately. Overall, ADRs and WDs can lead to debilitating functional problems, 
such as restricted work performance, loss of job, poor educational performance, emergency visit, 
and hospitalization. 
 
 
 
 Total Physiological  Psychological Cognitive Functional  
 Entiti
es 
Unique All  Unique All Unique All Unique All Unique 
Corpus-
entities 
6,534 59%  
(All) 
(3856) 
3,83
4 
63% 
(All) 
2422 
2266 51% 
(All) 
1165 
29
7 
79% 
(All) 
(236) 
13
6 
131 (All) 
96% 
ADR 
Corpus 
4774 
 
66% (All) 
3176 
338
0 
62% 
(All) 
2098 
1061 76% 
(All) 
(804) 
24
7 
77% 
(All) 
(191) 
85 96% 
(All) 
(82) 
ADR-
SSRI 
2236 1374 155
3 
880 521 372 11
9 
81 42 40 
ADR-
SNRI 
2537 1802 182
6 
1218 540 432 12
8 
110 43 42 
WD-
Corpus 
592 79% 
(All), 
470 
355 74% 
(All) 
263 
180 83% 
(All) 
(151) 
26 100% 
(All) 
(26) 
31 97%(All) 
30 
WD-
SSRI 
129 91 72 45 51 40 5 5 1 1 
WD-
SNRI 
463 379 283 218 129 111 21 21 30 29 
SS-
Corpus 
1168 17% (All) 
210 
99 61% 
(All) 
61 
1025 20% 
(All) 
210 
24 79% 
(All) 
19 
20 95%(All) 
19 
SS-SSRI 621 153 30 20 568 114 14 10 9 8 
SS-SNRI 547 157 69 41 457 96 10 9 11 11 
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Table 0-9 The Top Five Identified Entities for Each Class of Drug s and Type of Entities Separately 
 Physiological –top 
(5) 
Psychological- top (5) Cognitive- top (5) Functional - top (5) 
SSRI -
ADRs 
Weight gain (55), 
nausea (38), dry 
mouth (30), 
insomnia (30), 
fatigue (25) 
vivid dreams(19), 
nightmares (9), 
increased anxiety (9),  
suicidal thoughts(9), 
anxiety (9) 
Memory loss(6), 
brain fog (4), 
inability to 
concentrate (3), hard 
to focus (4), 
forgetfulness  (2) 
Called in sick(2), 
impossible to do my 
job (1), struggling to 
learn new things 
(1),unable to 
function(1),struggle 
just to comb my 
hair(1) 
SNRI- 
ADRs 
Insomnia(47), 
constipation(37), 
weight gain(34), 
nausea(32), dry 
mouth(28) 
vivid dreams(19), 
anxiety (14),  
nightmares (13), no 
sex drive (12), loss of 
sex drive(8) 
Memory loss (6), 
confusion(4), 
spacey(3), inability 
to concentrate(3), 
couldn't focus on 
anything (2) 
Hospitalized (2), 
unable to function (1),                                                                         
loss of friends(1)                                                                        
unable to work(1), 
cannot drive (1)                                                                               
SSRI- 
Withdraw
al 
symptoms  
Dizziness (7), 
upset stomach (3) 
,brain zap (2), 
nausea (2) , crying 
spell (1)                                                                     
Irritability (4), 
suicidal thoughts (2), 
aggression (1), crying 
spells (1), very 
anxious (1)
Slight confusion (1)            
Severe mental 
confusion (1), 
Couldn’t concentrate 
(1),
Memory sucks (1) 
Ended up in the er (1),   
1/2 weeks in phych 
word (1) 
SNRI 
Withdraw
al 
symptoms  
Dizziness(16), 
nausea (11), brain 
zaps (8), headaches  
(6), dizzy (6) 
Mood swings (5), 
nightmares (3), moody 
(2), feel like a walking 
zombie  (2), 
aggressive (2) 
Dissociative episodes 
(1), foggy (1), lack of 
concentration (1), 
confused (1), cannot 
think  (1), feel spaced 
out(1) 
can't function (1), 
could not drive (1), 
Difficulty tidying 
house (1), Difficulty 
performing shopping 
activities (1), 
Difficulty performing 
educational 
activities(1) 
SSRI-
Drug 
Indicators 
Insomnia (4), upset 
(2), impatient (1),  
fibromyalgia (1),  
physical pain (1) 
Depression (163), 
anxiety (127), anxiety 
(32), depressed (15), 
panic attacks (14) 
intrusive thoughts  
(3), obsessive 
thoughts  (2),  
confused (1),  racing 
thoughts  (1),   inner 
critic (1) 
lost my job (2),  
isolating  (1),  barely 
functional (1),  
dysfunctional (1) 
SNRI-
Drug 
Indicators 
Pain (12), fatigue 
(6), insomnia (2), 
fibromyalgia (4),  
migraines(2) 
Depression (185), 
anxiety (103), anxious 
(9) suicidal thoughts 
(6),social anxiety (6)  
obsessive thinking 
(4) Mental clutter(2), 
memory loss (1), 
rumination (2), 
memory loss (1) 
Loss everyone in my 
life (1), could not 
function at work (1),  
lost everyone in my 
life (1), harsh edge to 
my inter-action with 
others 
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4.6 Statistics on Terminology Association 
In the third phase of this study, the identified entities were normalized by mapping to 
both the UMLS Metathesaurus and SNOMED-CT. This mapping benefits the generation and 
testing of medical hypotheses related to associations between ADRs, WDs and patients attitudes 
and discontinuation behavior of patients by providing unambiguous and standard information for 
statistical data collection and analysis.   
To improve accuracy and consistency of mapping, guidelines was developed using 
clinical trials addressing the ADRs of the drugs specified in this study and qualitative studies 
investigating the themes of patient complaints about the drugs. Each ADR concept is associated 
with a set of attributes reflecting patients’ problems. For example, “executive dysfunction” is a 
term taken from the clinical trials literature and mapped to the Metathesaurus and SNOMED-CT.  
The concept of executive dysfunction as a cognitive ADR is associated with inability to initiate and 
follow processes of completing a task, so a patient complaint of “cannot follow through on simple 
tasks, can be mapped to “executive dysfunction” as a general concept.  The guidelines also includes 
the requirements for selecting proper/preferred UMLS and SNOMEDCT concept, and flowchart for 
mapping to both UMLS and SNOMED-CT.  
Table 4-10 shows statistics for normalization component. The final set contains 698 
UMLS concepts for ADRs, showing that out of 3176 unique identified ADRs and WDs, only 
14% of them are unique standard medical concepts. On average, for each standard ADR concept, 
there is 4.5 layperson expression of ADR/WD, reflecting the challenge of automatic 
identification of ADR/WD using standard medical lexicons. From 210 unique identified drug 
indicators, 81% are unique standard concepts, showing that patients mostly use the diagnosis 
results provided by healthcare professionals to report the reason for drug prescription. 
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Overall, all three types of entities (ADRs, WDs, and Drug Indicators) were mapped to 
811 UMLS concepts, from Which 154 concepts did not include SNOMED expressions. 
Therefore, we attempted to use equivalent medical concept that semantically match the primary 
concepts and include expressions of SNOMED-CT concepts. Table 4-11 lists the most frequent 
UMLS concepts in the corpus that did not include SNOMED-CT concepts. 
This study also identified qualifiers representing severity (QS) and persistency (QP) of 
the entities. Identifying the qualifiers can help healthcare providers to estimate the debilitating 
effects of ADRs/WDS on patient quality of life and whether they need to use any specific 
interventions to improve patient adherence to medication.  
Table 0-10 Statistics on Entities Normalized with UMLS and SNOMED-CT Concepts 
 
 
Entities  Physiological Psychological Cognitive Functional 
ADRs 698 462 197 42 31 
The five most 
frequent ADRs 
after 
normalization 
 Sleeplessness 
(171), nausea 
(169), weight 
gain (148), 
lack of libido 
(138), 
headache (106) 
Anxiety (92), 
detailed recall of 
dream (62), 
depressed mood 
(41), apathy(38), 
feeling 
suicidal(38) 
Foggy feeling in 
head (44), unable 
to concentrate 
(30), amnesia 
(19), memory 
impairment (15), 
forgetful (14) 
Difficulty in daily 
functioning (10), 
emergency room 
admission (9), 
social withdrawal 
(8), hospitalization 
(6), bed-ridden (5) 
WD 218 109 72 18 19 
The five most 
frequent WDs 
after 
normalization  
 Dizziness (43), 
nausea (32), 
headache (27), 
malaise (10), 
Irritable mood 
(16), depressed 
mood (11), mood 
swings (10), 
nightmares (8), 
severe anxiety 
(6) 
Confusion (4), 
unable to 
concentrate (3), 
mental suffering 
(3), Foggy 
feeling in head 
(2), actual low 
self control (1) 
Difficulty in daily 
functioning (4), 
bed-ridden (3), 
restricted work 
performance (3), 
difficulty driving a 
car (2), emergency 
room admission 
(2). 
Drug 
indicators 
171 46 103 9 13 
The five most 
frequent WDs 
after 
normalization  
 Pain (13), 
fibromyalgia 
(9), 
sleeplessness 
(14), fatigue 
(6), tired (4) 
Depressed mood 
(444), anxiety 
(258), panic 
attacks (27), 
feeling suicidal 
(22), social fear 
(17)  
Obsessive 
thoughts (13), 
unable to think 
clearly (2) 
Difficulty in daily 
functioning (4), 
difficulty 
maintaining 
relationships (2),  
Loss of job (3) 
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Table 0-11 The Most Frequent UMLS Concepts in the Corpus without SNOMED Expressions 
 
 
 
 
 
 
 
 
 
 
 
T 
Table 4-12 shows statistics on the qualifiers indicating intensity and persistency of the ADRs and 
WDs. Identifying the qualifiers can help healthcare providers to estimate the debilitating effects of 
ADRs/WDS on patient quality of life and whether they need to use any specific interventions to improve 
patient adherence to medication.  
Table 0-12 Frequency of Identified Qualifiers Associated with ADRs and WDs  
 
 
 
 
 
4.7 Testing association between specific type of ADRs and levels of Attitude  
After normalizing the ADRs, we tested the association between 21 physiological ADRs with 
levels of attitude. The 21 physiological ADRs that were specified in the Antidepressant Side-
Effect Checklist (ASEC) are dry mouth, drowsiness, insomnia (difficulty sleeping), blurred 
vision, headache, constipation, diarrhea, increased appetite, decreased appetite, nausea, problems 
UMLS-Primary Concept SNOMED
-CT 
Primary 
Concept 
Frequency UMLS-Equivalent 
Concept 
SNOMED-CT 
Concept 
C0859330 / Foggy feeling in 
head / Finding 
 
No Code 46 C0683369 / Clouded 
consciousness / Sign or 
Symptom 
Clouded 
consciousness 
(finding)  
C0857507 / Spaced out / 
Finding 
No Code 34 C0349446 / 
Dissociative trance / 
Mental or Behavioral 
Dysfunction 
Dissociative trance 
(disorder) 
C0392703/ Shakes/ 
Finding 
No Code 33 C0040822 / Tremor / 
Sign or Symptom 
Tremor (finding) 
C0549209 / Feeling jittery 
/ Sign or Symptom 
No Code 29 C0849963 / Feeling 
nervous / Sign or 
Symptom 
Feeling nervous 
(finding) 
C0857486 / Felt like a 
zombie / Finding 
No Code 24 C0233484 / 
Emotionally detached 
/ Finding 
Emotionally 
detached (finding) 
Category Frequency Example 
Mild 112 Slight (27), mild (22), a little (14), slightly (10), 
minor(5)  
Moderate  67 Moderate (6), Somewhat (3), semi (2), possibly 
some (1) 
Severe 432 Extreme (52), severe (40), extremely (17), 
horrible (17), terrible (16) 
Persistent  243 Constant (16), always (13), constantly (11), 
chronic (7), chronic (6) 
Not-persistent 317 at first(22), occasional(12), in the beginning (12), 
sometimes(11), initial(7) 
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with urination, problems with sexual function, palpitations, feeling light-headed on standing, 
feeling like the room is spinning, sweating, increased body temperature, tremor, disorientation, 
yawning, weight gain (Table 4-12). For each ADR mentioned in the ASEC, the semantically 
related UMLS Metathesaurus concepts were grouped and the association between that group of 
ADRs with attitude were tested. In total, 128 unique UMLS concepts for ADRs (out of 698 
concepts), which were identified in the phase of entity normalization, were grouped with ADRs 
specified in the ASEC questioner. Association between these ADRs and attitude was evaluated 
using X-square. For ADRs that the frequency for a level of attitude in the contingency table was 
less than 5, Fisher-exact test has been used. The result of the study showed that weight gain, 
yawning, disorientation, palpitation, increased appetite, and dry mouth are associated with 
patients’ attitude towards antidepressants. While other ADRs in the ASEC are not associated 
with patients’ attitudes toward antidepressants.  
Table 0-13 Testing Association between ADRs and Attitude 
 Variables  Statistic test P-value for X-
Square 
P-Value for Fisher 
Exact Test 
Physiological 
ADRs specified in 
the ASEC 
Questionnaire 
Headache 8.4545 0.07628  
Insomnia 4.007 0.4051  
Drowsiness 2.7613 0.5985  
Blurred. Vision 6.6146  0.1577  
Dry mouth 11.801 0.01889*  
Constipation 1.9675 0.7417  
Diarrhea 7.1359 0.1289  
Decreased  
Appetite 
3.6637 0.4534  
Increased. Appetite 19.862 0.0005318 * 
 
 
Palpitation 9.2751 0.05458 
 
0.06515 
Sweating 5.4177 0.2471  
Disorientation 10.995 0.02662 
 
0.02323 
Yawning 19.116 0.0007457 0.002313 
Increased body 
temperature 
4.4946 0.3432 0.4051 
Weight gain 10.488 0.03296  
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The result of studies conducted by De las Cuevas et al. (2014) using ASEC questionnaire 
also showed that “weight gain” and “dry mouth” associated with patient adherence toward 
medications. 
In addition to the ADRs specified in the ASEC questionnaire, we also tested the 
association between psychological ADRs including “emotional indifference”, “apathy”, 
emotionally detached”, “mood swing”, “anxiety”, and “motivation” and cognitive ADRs 
including “Difficulty in concentrating” and  “memory problem”. Overall 36 unique UMLS 
concepts for ADRs that semantically related to the psychological and cognitive ADRs were 
grouped and tested for the association with attitude. All the psychological and cognitive ADRs 
were strongly associated with patients’ negative attitude toward antidepressants (Table 4-13).  
The frequency of ADRs (specified in table 3) for levels of attitude (1-5) depicted in from Figure 
4-15 to Figure 4-39. 
Tremor 4.8804, 0.2998  
Problems with 
urination 
3.2561 0.5159 0.3724 
Problem with 
sexual functioning 
23.689 9.218e-05  
Nausea or vomiting 0.2873 0.9906  
Vertigo 3.3951 0.494 0.5618 
Light headed 6.5986, 0.1587  
Psychosocial ADRs 
specified in the 
literature  
Emotional 
indifference 
21.131 0.0002983  
Apathy 20.332 0.0004293 2.224e-05 
Emotionally 
detached 
24.477 6.407e-05  
Mood Swing X-squared = 
11.913 
0.01801  
Anxiety 23.346 0.000108  
Problem with 
Motivation 
32.532 1.489e-06  
Cognitive ADRs 
specified in the 
literature  
Difficulty in 
concentrating 
18.661 0.0009162 
 
0.0004507 
Memory problem 25.283, 4.413e-05 4.413e-05 
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Figure 0-15 Frequency of headache for each level of attitude 
 
 
Figure 0-16 Frequency of insomnia for each level of attitude 
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Figure 0-17 Frequency of drowsiness for each level of attitude 
 
Figure 0-18 Frequency of blurred vision for each level of attitude 
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Figure 0-19 Frequency of constipation for each level of attitude 
 
Figure 0-20  Frequency of diarrhea for each level of attitude 
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Figure 0-21 Frequency of decreased appetite for each level of attitude 
 
Figure 0-22 Frequency of increased appetite for each level of attitude 
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Figure 0-23 Frequency of sweating for each level of attitude 
 
Figure 0-24 Frequency of disorientation for each level of attitude 
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Figure 0-25 Frequency of yawning for each level of attitude 
 
 
 
Figure 0-26 Frequency of weight gain for each level of attitude 
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Figure 0-27 Frequency of problem with urination for each level of attitude 
 
 
Figure 0-28 Frequency of sexual dysfunction for each level of attitude 
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Figure 0-29 Frequency of nausea or vomiting for each level of attitude 
 
Figure 0-30 Frequency of nausea or vertigo for each level of attitude 
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Figure 0-31 Frequency of emotional indifference for each level of attitude 
 
Figure 0-32 Frequency of apathy for each level of attitude 
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Figure 0-33 Frequency of emotionally detached for each level of attitude 
 
Figure 0-34 Frequency of mood swings for each level of attitude 
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Figure 0-35  Frequency of restricted emotion (emotional indifference + apathy + emotionally detached + 
restricted motivation)  for each level of attitude.  
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Figure 0-36 Frequency of anxiety for each level of attitude 
 
 
Figure 0-37 Frequency of motivation for each level of attitude 
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Figure 0-38 Frequency of difficulty in concentration for each level of attitude 
 
Figure 0-39  Frequency of memory problem for each level of attitude 
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This study involves both qualitative and quantitative approaches for the purpose of 
pharmacovigilance for psychiatric medications and generating and testing hypotheses concerning 
patients’ attitudes toward antidepressants. The source of data is a healthcare forum called 
“askapatient.com” and the drug source are four psychiatric antidepressant medications including 
Sertraline (brand name: Zoloft) and Escitalopram (brand name: Lexapro) from the Selective 
Serotonin Reuptake Inhibitor (SSRI) Class and venlafaxine (brand name: Effexor XR) and 
duloxetine (brand name: Cymbalta) from the Serotonin Norepinephrine Reuptake Inhibitor 
(SNRI) Class.  
5.1 Significance of Social Medial for Providing Insight about Attitude and Adherence 
Behavior 
 
The data analysis using the framework method showed that drug review posts in social 
media provide significant insight for patients’ perception and attitude towards antidepressants 
and pharmacological aspects of dugs. However, it does not provide any insight for patients’ 
adherence to medications, because the key factor in definition of adherence is a patient's 
agreement with the healthcare providers’ treatment plan and drug reviews do not contain explicit 
information indicating whether a patient’s withdrawal from medication was according to 
healthcare providers’ recommendations or not.  
5.2 Significance of Social Media in Identifying Underlying Factors Associated with Attitude  
1) The analysis of data using analytical framework showed that drug reviews posts can be a 
significant source for underlying pharmacological factors affecting patients’ attitudes. 
However, it does not provide reliable information to evaluate healthcare system factors, 
such as patients’ perceived perceptions from communication with healthcare providers.  
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2) In this study, we measured association between patients perceived distresses from ADRs 
using patients drug review comments. This variable was measured using explicit 
indications including qualifiers representing severity, negative impacts of ADRs on daily 
activities and social life, and reporting severe life-threating ADRs (suicidal ideation, 
suicidal attempt, and self-harm). The result of the data analysis showed that perceived 
distress from ADRs is significantly associated with patients’ attitudes toward 
antidepressants. However, currently there is no self-report scale that was specifically 
designed to measure patient perceived distress received from ADRs associated with 
antidepressants. Although the Antidepressant Compliance Questionnaire (ADCQ) and the 
Beliefs about Medications Questionnaire (BMQ), the Drug Attitude Inventory (DAI) 
includes items that measure patients concern for antidepressants, such as long term 
affects and its impact on patient quality of life, losing autonomy, possibility of addiction, 
and control over feelings, they do not measure perceived distress that patients directly 
received from ADRs. For example, a patient may experience severe dry mouth, but does 
not have concern about long-term effects of antidepressants on life quality or control over 
feeling.  
In addition, the total ADR score obtained from the Antidepressant Side-Effect Checklist 
(ASEC) does not represent perceived distress that a patient received from a set of ADRs. 
For example, a patient may obtain total score “four” from four reported mild ADRs, 
while another patient may obtain total score “three” from one severe ADR. Apparently, 
the second patient received higher perceived distress from the first one, however the 
calculated total number does not represent it.  
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3) Drug reviews also provide information about patients withdrawal experience as 
significant predictive factors for patients attitude toward antidepressants. However, self-
report scale for measuring patients’ attitude for antidepressants do not include any items 
related to patients’ withdrawal experience.  
5.3 Limitations of Social Media in Identifying Underlying Factors Associated with Attitude 
Drug reviews in healthcare forums compared with self-report scales has some limitations: 
1) First, they are not a rich source of patients’ perceptions towards healthcare providers. 
The ADCQ, a self-report scale that specifically designed for measuring patients attitude 
towards antidepressants, includes a component that measure three dimensions of patient-
physicians interaction: 1) patient’s perception of physician’s knowledge; 2) patient’s 
perception of sufficiency of knowledge provided by physicians; and 3) patient’s 
perception of communication effectiveness with providers. We attempted to measure 
patients’ satisfaction with healthcare providers using the three dimensions in the drug 
reviews. However, majority of the patients did not provide explicit indications showing 
their perceptions towards clinicians, which caused low IAA among annotators.  
2) Drug reviews posts also do not provide explicit information about patients general 
concern and necessity towards medications. However, the BMQ self-report scale includes 
components for measuring general concern and necessity towards medications. In 
addition, the BMQ includes a component for measuring the perceived necessity of a 
prescribed medication, while in the data analysis of this study, patients’ expressions of 
perceived necessity for antidepressants was labeled as “drug effectiveness”, because of 
difficulty in differentiation of perceived effectiveness and perceived necessity in sentence 
classificantion.  
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3) Furthermore, while the ADCQ self-report scale can capture patients perceived social 
support, few patients expressed their perceived social support in drug reviews.  
By comparing items in the final analytical framework and the self-report scales (the 
ADCQ, the BMQ, and the DAI), we conclude that drug reviews cannot be used as an alternative 
source for measuring patients’ attitudes towards antidepressants compared to self-report scales. 
However, they can be used as a supplementary source, due to providing insights for some 
underlying factors that are not available in the self-report scales.  
5.4 Significance of Social Media in Identifying ADRs and WDs Associated with 
Antidepressants 
 
Identifying ADRs and WDs from drug review posts showed that this data source is a 
valuable source for identifying ADRs and WDs associated with antidepressants. Although Uher 
et al. (2009) demonstrated that adverse effects of antidepressants can be reliably assessed 
through self-report scales, the inherent limitations associated with the scales, such as low 
coverage of potential adverse effects, particularly the rare ones, may reduce the reliability and 
validity of the scales. For example, the ASEC scale does not cover psychological, cognitive and 
functional problems associated with antidepressants, which is the major limitation of studies 
employing this scale for measuring ADRs associated with antidepressants (Bet, Hugtenburg, 
Penninx, & Hoogendijk, 2013; Uher et al., 2009).  
The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) and the 
WHO Quality of Life Assessment-Brief version (WHOQOL-BREF) are other self-report scales 
used for measuring the ADRs associated with antidepressants. The LUNSERS is also associated 
with some limitations. First, it is not specifically designed for measuring antidepressants’ adverse 
effects. Second, the ADRs indicating emotional problems and cognitive dysfunctions are very 
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limited and do not reflect a wide range of emotional and cognitive adverse effects of 
antidepressants.  
Items in the WHOQOL-BREF assess individual quality of life from a general perspective 
that may not be directly related to the impact of antidepressants on quality of life. For example, 
items such as “level of satisfaction with living place” or “having enough money to support your 
needs” do not measure the impacts of ADRs associated with antidepressants.  
These scales may also suffer from patients’ recall bias, because they do not define a 
specific time-period during which the adverse effects have been occurred. Hence, patients may 
just report severe adverse effects they experienced and disregard the mild ones (Bet et al., 2013).  
Patients’ self-reports in healthcare forums are not associated with these limitations. First, 
patients can access the forums at their own convenience. Hence, their reports may not suffer 
from memory bias. Second, in contrast with structured questionnaires that limit the patients’ 
reports to a specific set of ADRs, patients in healthcare forums can report any psychological, 
physiological, and cognitive ADRs using their own language. So, there is no concern regarding 
the patients’ wrong interpretation of ADRs specified in the questionnaires (self-report scales). In 
addition, patients voluntarily report their experiences with medications. So, the concern for 
hiding information or breaching confidentiality would be minimized.  
Regarding this information, we can conclude that drug review posts in social media can 
address limitations associated with to self-report scales (questionnaires) and they can be used as 
an alternative source for measuring ADRs associated with antidepressants.  
5.5 Implications of this Study 
5.5.1 Developing tools in the area of text mining algorithms and machine learning 
for extraction of health related information from consumer health posts    
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The three phases of this study: 1) applying the analytical framework at level of sentences; 
2) identifying ADRs, WDs, and DIs; and 3) mapping the identified entities to both UMLS and 
SNOMED-CT concepts, provides a corpus that has several implications for developing tools in 
the area of text mining and machine learning for extracting health related information form 
consumer health posts. First, the generated dataset can be used to improve the recall of 
dictionary-based systems designed for automatic identification of pharmacological 
aspects of drugs. Second, the dataset has a significant implication in developing and evaluating 
text mining and machine learning systems aimed to identify ADRs, WDs, and drug indications 
from consumer health posts in social media. Third, the dataset can be used for training machine 
learning-based classifiers aiming to distinguish ADRs from other semantic types, such as drugs 
indications. Forth, the dataset has important implications for developing and testing automatic 
system aimed to measure effectiveness and ineffectiveness associated with psychiatric 
medications. Fifth, it can be used for developing systems targeting automatic mapping between 
layperson expression of health information to UMLS and SNOMED. 
Currently, there is one open source corpus that has been developed using consumer health 
posts, which is called CADEC ("Health Information Technology for Economic and Clinical 
Health Act," ; Karimi et al., 2015). This corpus consists of 1,231 comments for two categories of 
drugs, Diclofenac and Lipitor. The identified entities include ADRs, symptoms, disease, and 
mentions of drugs, which were mapped to SNOMED-CT, MEDRA, and AMT.  
Our corpus is different from the CDADE from several important aspects, including type 
of drugs studied, methodology of development, identified entities, and normalization process. 
Because of the nature of the psychiatric medications and the patient population of this study, the 
ADRs events, specifically functional problems are not expected to be well-covered by the 
   
144 
CADEC corpus. Moreover, the corpus created in this study includes the drug 
effectiveness/ineffectiveness and qualifiers representing severity and persistency of ADRs and 
WDs that are not covered by CADEC. Finally, all the identified entities were mapped to UMLS, 
which was not reported by CADEC.   
5.5.2 Testing the association between physiological, psychological, cognitive, and 
functional problems with attitude 
 
In this study, 698 ADRs and 218 WDs were identified from which the association 
between 164 ADRs and attitude were tested. 128 ADRs were grouped using ADRs specified in 
the ASEC questionnaire, and 36 ADRs grouped into psychological and physiological ADRs 
specified in the literature. Accordingly, we did not measure the association between 534 ADRs 
(specified in the dataset) with attitude. The ADRs, such as “detailed recall of dream” and 
“suicidal feeling”, “malaise” may have severe negative effect on patients’ attitudes toward 
antidepressants and consequently adherence behavior. Future studies can investigate the 
association between the ADRs and patients’ attitudes.  
5.5.3 Developing self-report scales  
The dataset that was produced using the analytical framework and the ADRs/WDs 
identification phase can be used for designing patient-driven self-report scale for measuring 
patients’ attitudes towards antidepressants.   
4.5.4 Implications of the analytical framework 
The analytical framework developed in this study has significant implications for data 
analysis from other healthcare forums collecting patients’ experiences with pharmacological 
treatments and also personal health records that include patients’ experiences with medications.  
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5.5.5 Implication of the findings related to the factors associated with attitude 
Findings of this study have significant implications for developing clinical interventions 
aiming to improve patients’ attitudes and adherence towards medications. In this study, we 
showed that lack of knowledge about ADRs and WDs is significantly associated with patients’ 
negative attitudes towards antidepressants. Therefore, clinicians should design and implement 
effective communication mechanisms to inform patients the potential ADRs and WDs that they 
may experience during the process of treatment and discontinuation.  
In addition, we found that patients’ withdrawal experience is associated with patients’ 
negative attitudes towards antidepressants. The finding implies that clinicians should consider 
interventions to reduce the perceived distress that patients may receive during the discontinuation 
process of antidepressants.  
We also found that drug effectiveness is the most significant factor associated with 
attitude, implying that patients at initial phase of treatment may discontinue antidepressants 
abruptly if they do not find it effective in resolving depression symptoms. Regarding the fact that 
antidepressants full effects are not seen for typically four to six weeks, clinician should consider 
interventions to track antidepressants’ effectiveness and inform patients for treatment mechanism 
of the drugs.  
5.6 Limitations of this Study 
1) Lack of information on drug-drug interactions, drug-herb interaction, and drug overdose: 
Identifying ADRs for consumer health posts and evaluating their associations with patients’ 
attitude toward drugs and antidepressants has some limitations. The focus of patients in the 
review posts was mostly on a specific drug. Hence, it is not clear whether the reported adverse 
effects are merely caused by the drug or it is the result of interaction of the drug with other 
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potential drugs or herbal treatments. Moreover, some of the ADRs for psychiatric medications, 
such as suicidal ideation or emergency visits, can happen due to patient’s overdose, which were 
not available in these review posts.  
2) Uncertainty of data in social media: Although patients’ self-report experience is a reliable 
source for evaluating pharmacological effects of medications, the risk of inaccurate and false 
information still exists. 
3) Concern about dominating dissatisfied patients in drug reviews forum: There is a concern 
that patients with negative perception for medication have more willingness to report their 
experiences with medications. However, the statistical analysis of the sample size in this study 
showed that almost 50% of patients were satisfied with psychiatric medications as they rated 
them as 4 and 5. While only 35% of patients rated the drugs as 1 and 2. In addition, the data set 
showed that almost half of the reviewers used the antidepressants more than a year, suggesting 
that they were not the most dissatisfied patients with antidepressants. 
4) Concern about misinterpretation of ADRs and WDs:  one problem with data analysis for 
consumer health posts for psychiatric medications is the possibility that users misinterpret the 
symptoms of their mental disorder with ADRs. Although this study recorded only ADRs that 
patients certainly linked them to the psychiatric medications, we cannot exclude patients’ 
misinterpretation of depression symptoms with ADRs. 
5) Concern about representativeness of the sample: As healthcare forum data are self-selected, 
there is the risk that the dataset is not representative of patient population. However, the 
distribution of sample size in this study for both gender, female and male, is consistent with 
those identified in conventional prevalence studies.  
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The review posts in an online healthcare forum may also not be a representative source 
for all demographic groups. Some minorities may not have the same access level and skills for 
adoption and usage of technology for reporting their experiences in online healthcare forums.  
6) Insufficiency of information to estimate prevalence of ADRs/WDs: This study could not 
estimate the prevalence of ADRs and WDs, as the healthcare forum contained no prompt for 
patients to disclose the particular effects. While some patients seemed to list all ADRs and WDs 
they experienced, others mentioned few ADRs. In addition, some patients reported difficulty in 
medication discontinuation, while they did not report any specific withdrawal symptoms. 
However, the significance of this study compared to the conventional methods for collecting 
patients’ experiences with medications is that the drug reviews in healthcare forums are 
spontaneous, open-ended, and uncensored format, and they were not collecteded for a specific 
project.  
7) Sample size: The sample size of this study is limited to 892 posts for four psychiatric 
medications. While this sample size is a good representative of posts available in 
“askapatient.com” for the four psychiatric medications, it may not be a balanced representative 
of other consumer posts in this forum or other healthcare forums. Additionally, it is possible that 
a specific group of patients report an unbalanced sample of experiences with drugs in the forum.  
8) Limitation for coverage of medications: Our corpus covers sentence classification and 
entities identifications for two classes of psychiatric medications, SSRI and SNRI. While 
limiting dataset to specific set of drugs enabled us to have a better understanding of the 
conceptual models associated with layperson and professional expressions of medical entities, it 
may not include the rare ADRs related to other classes of psychiatric medications, such as TCA.  
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9) Terminology Mapping challenges  
We managed to improve accuracy of inferring the intended meaning of colloquial expression of 
ADRs by use of a preliminary mapping table based on clinical trials and qualitative studies, 
contextual cues in patients reviews, and discussion meetings. However, we had some challenges 
for selecting proper UMLS/SNOMED-CT concepts for ADR expressions. Throughout the 
corpus, we could not map 130 expressions (out of 6534) to either UMLS or SNOMED concept. 
For example, the ADR of “hardly feel human anymore”, could not be mapped to any concepts 
due to uncertainty of the underlying concepts associated with it. Indeed, it is unclear what the 
patient meant with this expression: is it about the patient feelings emotionally detached, having 
a problem in performing daily activities, or is it about feeling detached from his/her mind or 
body (de-realization)? 
Another challenge is that layperson expressions of ADRs are fuzzier than the 
corresponding UMLS/SNOMED concepts. For synonym concepts, the layperson ADRs 
expressions are more likely to be “narrower-than” or “broader-than” their closest UMLS 
concept. For example, “not being able to express sadness” or “could not cry in funeral 
ceremony” were all mapped to “blunted affects”. This happens particularly for psychological 
systems and functional problems.   
There were also some cases that, while expression of an ADR is clear and can be 
translated to equivalent medical concept, no UMLS concept is available for that expression. For 
example, brain shivers (brain zap) (J. Aronson, 2005) is a medical concept that has been reported 
in a few medical research as an ADR/WD of psychiatric medication, however, no medical 
concept is available for it in UMLS. Eighty-seven (out of 130) expressions without any UMLS 
concepts were related to this medical concept.  
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Limiting drug reviews to a set of drugs prescribed for a specific disease or mental 
disorders, helps to have a better understanding of patients’ colloquial expressions of ADRs by 
comparing the expressions with clinical trial studies and qualitative studies addressed the ADRs 
for the drugs.  
10) Possibility of human errors in data analysis: Although the entire data set is double coded, 
there is still the possibility that annotators did not interpret a sentence correctly and therefore 
assign it to a wrong label. In addition, the span of the identified entities may include less or more 
information than necessary. These issues may affect the performance of machine learning 
systems trained based on this corpus to identify drug effectiveness, ADRs, and drug indications 
in consumer health posts.  
11) Possibility of bias in findings: as the statistics of data source in this study showed, 76% of 
the participants in the healthcare forum are female. So, findings of this study may be associated 
with gender bias.  
Conclusion 
In this study, using a mixed method data analysis, we showed that consumer health posts 
in social media provide a unique insight into issues such as patients perspective, withdrawal 
experience, tolerability for adverse drug reactions, and overall attitudes towards medications. 
However, drug review posts is not a rich source for patients’ perceptions of communication with 
healthcare providers, affordability of the drugs, or social support for the patients. The most 
important use of the drug reviews is providing safety detection signals for ADRs and WDs 
associated with medications. The drug reviews in healthcare forums are specifically important 
for psychiatric medications because of the limitations of clinical trials in detecting ADRs 
associated with this drugs, such as emotional indifference and suicidal ideation. 
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Using methods of framework analysis and terminology mapping, we provided structured 
data for testing hypotheses concerning patients’ attitude toward antidepressants. The result 
showed that drug effectiveness and perceived distress received from ADRs are the most 
significant factors affecting patients’ attitude toward antidepressants. In addition, among three 
sets of psychological and physiological, and cognitive ADRs associated with antidepressants, we 
found that physiological and cognitive ADRs are significantly related to patients’ negative 
attitude, while psychological ADRs are partially associated with attitude towards antidepressants.  
This work has important implications for generating and testing medical hypotheses 
concerning patients experiences with psychiatric medications specified in this study, such as 
withdrawal experience and also measuring association between ADRs and attitude. In addition, it 
can be used for improving performance of text-mining algorithms aiming to automatically detect 
healthcare information from consumer health posts and personal health records.  
Future Work 
In this study, we developed an analytical framework that can be used for identifying underlying 
factors associated with patient attitudes towards antidepressants. The analytical framework was 
created and tested using drug reviews in a healthcare forum called “askapatients.com”.  Future 
work may use the framework in other healthcare forums or personal health records to identify 
factors associated with patients’ withdrawal and perceptions towards medications. In addition, in 
this study, the phase of sentence classification, entities identification, and entities normalization 
created a corpus that can be used for developing automatic systems aimed to identify health-
related information from healthcare forums and map them to standard medical vocabularies. We 
are in the process of developing classifier algorithms to differentiate drug reviews contains 
withdrawal experience (both intentional and intentional) form drug reviews without report of 
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withdrawal. Finally, we are going to compare the identified ADRs and WDs in this study with 
SIDER Side Effect Resource, in order to identify new ADRs/WDs that were not reported by 
clinical trials.    
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Appendix A:  
Self-report questionnaire designed/used for measuring ADRs associated with 
antidepressants 
 
The Antidepressant Side-Effect Checklist (ASEC) was constructed as a self-report scale 
to measure twenty-one physiological and subjective Antidepressants’ adverse reactions. For each 
item, a patient can rate the severity of the specified adverse effect on a four-point scale (0 absent; 
1 mild; 2 moderate; 3 severe). The patients can also specify whether a symptom (if present) is 
likely to be linked to antidepressants adverse effects (yes or no). The total score can vary 
between “0”, if patients marked all symptoms as absent and “63”, if patient marked all symptoms 
as severe and specified that they are highly related to antidepressants.   
The Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) is a fifty-one 
items that was primarily constructed to measure adverse effects of antipsychotic drugs. Although 
this scale was not specifically designed for antidepressants’ adverse effects, it covers some of the 
psychological, emotional, and cognitive adverse reactions of the medications. The adverse 
effects in LUNSERS scale are classified in eight classes including extra-pyramidal, psychic, 
anticholinergic, autonomic, allergic reactions, hormonal, Miscellaneous (such as weight gain), 
and red hearings. The aim of incorporating read hearing category is to detect over-reporting 
cases. For each item, a participant can rate the severity of the specified adverse reaction on a 
four-point scale (0: not at all; 1: Very Little; 2: A Little; 3: Quite a Lot ; 4: Very Much”).  The 
total score of LUNSERS can very between “0” if patients market all specified ADR as “0” and 
“204” if marked all specified “ADRs” as “4”. 
Studies that were also interested in measuring the impact of the antidepressants’ adverse 
effects on quality of life employed the WHOQOL-BREF. The WHOQOL-BREF assesses the 
physical, psychological, social, and environmental aspects of quality of life. In this 
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questionnaire, patients can rate level of satisfaction, frequency, or magnitude of each item on a 
five- point scale. 
Ng et al. (2012) used the LUNSERS, WHOQOL-BREF, and also BAS and SAS scales to 
assess association between attitude toward antidepressants and ADRs among patients with 
psychotic and affective disorders such as schizophrenia and depression. Their findings indicated 
that there is a negative correlation between LUNSERS and DAI/BEMID scores (scales for 
measuring attitude) and attitude toward antidepressants, implying that the increased reported side 
effects are associated with poorer attitudes towards antidepressants. But they did not answer the 
question of whether there is an association between scores of WHOQOL-BREF, SAS, and BAS 
and patients’ attitudes toward antidepressants.  
To my knowledge, there have been no studies that applied ASEC to assess the association 
between patients’ attitudes and adverse effects of antidepressant. However, De las Cuevas et al. 
(2014) used this scale to find out the association between adherence to antidepressants and side-
effects. Their findings indicated that non-adherent patients reported more frequent and more 
intense adverse effects than adherent patients. In addition, adherence and non-adherence groups 
were significantly different in four reported adverse effects including “dry mouth”, “diarrhea”, 
“feeling like the room is spinning”, and “weight gain”. 
In contrast to the studies using self-report scales to identify antidepressants adverse 
effects, Murata et al. (2012) directly asked patients to report their feelings and their 
uncomfortable experiences (subjective experiences) with antidepressants at the point of care. In 
addition, the study used tracking of patients’ vital and physical signs to find out potential adverse 
effects. Their findings indicated that sleepiness, malaise, dry mouth, constipation, dysuria, 
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dizziness, cephalalgia, hidrosis, and anorexia were significant adverse effects that may lead to 
negative attitude toward antidepressants.  
Although Uher et al. (2009) demonstrated that adverse effects to antidepressants can be 
reliably assessed through self-report scales, the inherent limitations associated with the  scales 
such as not including all potential adverse effects, particularly the rare ones, may reduce the 
reliability and validity of the scales. For example, the ASEC scale does not cover adverse effects 
indicating emotional problems, cognitive dysfunctions, or quality of life. This is a major 
limitation for studies employing this scale as a self-report measure for antidepressants adverse 
reactions (Bet et al., 2013; Uher et al., 2009). The LUNSERS is also associated with some 
limitations. First, it is not specifically designed for measuring the antidepressants’ adverse 
effects. Second, items indicating emotional problems and cognitive dysfunctions are very limited 
and do not reflect the wide range of emotional and cognitive reactions linked to all agents and 
classes.  
Moreover, items in the WHOQOL-BREF assess individual quality of life from a general 
perspective that may not be directly related to the impact of antidepressants on quality of life. 
For examples, items such as “level of satisfaction with living place or having enough money to 
support your needs” do not measure the impacts of antidepressants. Also, other items such as 
“satisfaction with interpersonal relationships” or “level of performance in daily activities” do not 
provide specific information about patients’ incapacities resulted from antidepressants usage. For 
example, patients may report difficulty with driving or exercising because of “brain shivers” that 
was not specified in the WHOQOL-BREF. The limitations with WHOQOL-BREF can lead to an 
insufficient understanding of the dimensions of antidepressants’ adverse effects on a patient’s 
quality of life. These scales may also suffer from patient recall bias, because they do not define a 
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specific time period during which the adverse effects have been occurred. Hence, patients may 
just report severe adverse effects they experienced and disregard the mild ones(Bet et al., 2013).   
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Appendix B:  
Self-Report Scales Used in Antidepressants Studies for Measuring Attitude 
 
a) Drug Attitude Inventory (DAI) 
 
The DAI consists of seven components that mainly measure attitude and adherence 
behavior towards prescribed psychotic medications mainly in the maintenance phase of 
treatment. The DAI assesses patient attitudes based on two major dimensions: Patients’ 
subjective experience and the perceived necessity of medication and their concern towards 
psychotic medications. Hogan et al. (1983) concluded that patients’ attitudes towards psychotic 
medications are highly dependent on patient’s subjective experiences during a course of 
treatment.  
Table Appendix B.1. Drug Attitude Inventory (DAI): summary of components’ items 
Subjective 
Experience 
Components 1 and 2 include items measuring a patient’s subjective experiences of 
medications. These components reflect the balance of a patient’s perceived benefits of 
medication and perceived distress from adverse effects. Items in these components are 
formulated to assess impact of medication on cognitive functionalities, Interpersonal 
relationship, and emotional status.  
Necessity and 
concern 
Components 6 and 7 measure a patient’s perceived necessity of medications in 
forestalling relapse and the concern about the potential toxic effects.  
Locus of 
control 
Items in Component 4 and 5 express a patient’s perception of locus of control in taking 
medication, whether the locus of control is the physician’s authority or a lack of free 
choice for pharmacological treatment. Items in this component are generally important to 
determine adherence behavior. 
Adherence 
behavior 
Items in component 5 indicate a patient’s understanding of adherence behavior. Patients 
with an erroneous view towards adherence behavior may discontinue medication when 
they feel better or take more medication when they feel worse.   
 
The ADI has two versions: 30-item and 10-item attitudinal scales that were generally 
employed by studies focused on attitudes towards antipsychotic medications. However, it was 
also used occasionally for assessing attitudes toward antidepressant medications.  
Ng et al. (2012) used the DAI scale to compare outpatient’s attitudes on the maintenance 
phase of treatment among patients with psychotic and affective disorders such as schizophrenia 
and depression. Their findings indicated that patients with psychotic disorders do not have more 
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negative attitudes and beliefs compared to those with affective disorder, implying that the type of 
mental illness is not a significant predictive factor for attitude. They also concluded that the 
patients reported side effects have significant correlation with medication attitude and belief but 
not with education, duration or severity of illness. 
Murata et al. (2012) used the DAI tool to investigate different attitudes among both 
antidepressant-naïve (patients were not treated by antidepressants) and antidepressant-treated 
patients. They found that the mean DAI -10 total score is significantly lower in antidepressant-
treated patients compared to antidepressant-naïve patients Their findings also suggested that 
patients’ demographic variables, such as age, gender, or education are not significantly 
associated with attitude score. However, reported medication side effects and type of depression 
(melancholic, nonmelancholic, bipolar) were significantly correlated with negative attitude.  
Townsend, Floersch, and Findling (2009) employed DAI to measure adolescents’ 
attitudes towards psychiatric medications. The adolescents diagnosed with a wide range of 
psychiatric disorders including major depression. The findings of this study suggested that 
impact of psychotic medications on emotional status, cognitive functioning, and interpersonal 
relationship is strongly correlated with adolescents’ attitudes toward these medications.   
(De las Cuevas & Sanz, 2007) used DAI and to compare stable psychiatric outpatients 
attitude toward psychiatric medications with public opinion on this subject. The result of this 
study showed that receiving beneficial aspects of this medications leads to forming positive 
attitude in psychiatric patients compared with the attitude of general population without 
experience of this medication. This study also implies the stigma in society against psychiatric 
medications.  
b) Antidepressants Compliance Questionnaire (ADCQ)  
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The ADCQ (Demyttenaere et al., 2004) is self-repot scale that is primary designed to 
assess attitudes of psychiatric patients towards antidepressant medications. The ADCQ assesses 
patients’ attitudes towards antidepressants based on four dimensions: perceived patient-clinician 
relationship, concern about the mechanism of antidepressants on personality, subjective 
experience of antidepressant usage, and perceived family support. ADCQ has 33 items that were 
divided into four components. Table 2 presents a summary of the four components.  
Table Appendix B.2. Antidepressant Compliance Questionnaire (ADCQ): Summary of components' items 
Perceived patient-
clinician 
relationship 
Perceived Patient-Clinician Relationship assesses the patient’s perception of 
communication with clinicians. Items in this component mainly indicate three 
dimensions of patient-physicians interaction including: 1) patient’s perception of 
physician’s knowledge; 2) patient’s perception of sufficiency of knowledge provided 
by physicians about the disorder and treatment process; 3) patient’s perception of 
communication effectiveness, such as his perception of clinician’s interest in the 
patient’s problem and the level of support received from clinicians.   
Perceived Concern 
(Preserved 
autonomy) 
Preserved autonomy includes items indicating a patient’s concern with the 
antidepressant mechanism in the pre-treatment phase. Items in this component are 
the addictive possibility of antidepressants, control over feelings and thought, 
altering personality, and immunity to antidepressants. 
Subjective 
Experience 
(Perceived  
Benefits from 
Medications) 
And Perception of  
Adherence  
Positive Belief about Antidepressants component assesses the patient’s perception 
of antidepressants’ helpfulness in improving his coping mechanism, improving 
emotional status and removing causes (symptoms) of depression. Some of items in 
this component also indicate patient’s understanding of adherence behavior. Patients 
with erroneous views about antidepressant behavior may think they can take 
additional dosages or they can skip a dose if they feel better.  
Patients’ Partner 
Support 
Items in this component express the perceived support that a patient received from 
his/her partner or family. Whether family members agree with the diagnosis or the 
pharmacological treatment of depression influences a patient’s perception of 
antidepressants.  
 
Several studies administered the ADCQ to patients with depression to analyze patients’ 
attitude toward antidepressants based on the four dimensions proposed in this scale. The finding 
of studies (Chakraborty et al., 2009; Hung et al., 2014; Jacob et al., 2015) applied ADCQ showed 
that the majority of patients with depression reported a positive experience in the patient-
physician relationship. Hung et al. (2014) found that women had a more negative experience 
than men regarding their patient-physician relationship. Regarding the age factor, Chakraborty et 
al. (2009) and (Hung et al., 2014) did not agree on the correlation between age and the patient-
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physician relationship. While Chakraborty et al. (2009) reported older patients had a more 
negative view of patient-physician relationship, Hung et al. (2014) reported younger patients had 
lower perception of the patient-physician relationship. 
Most of the research administering the ADCQ to patients with depression, they found that 
a majority of patients believe antidepressants do not preserve their autonomy. Patients believe 
that by being on antidepressants have less control over their thoughts and feelings (Kessing et al., 
2005). They also feel that antidepressants can reduce their alertness (Demyttenaere et al., 2004; 
Kessing et al., 2005). Patients also have concern about the impact of antidepressants on their 
personality (Chakraborty et al., 2009; Jacob et al., 2015; Kessing et al., 2005). In addition, They 
have concern about addictive possibilities (Chakraborty et al., 2009; Jacob et al., 2015; Prins et 
al., 2008) and immunity to antidepressants (Kessing et al., 2005). Using the ADCQ, Jacob et al. 
(2015) found that patients have misperception about the cause of depression. Patients may 
attribute the cause of depression to non-biological factors, such as family issues or a stressful 
life.  Moreover, Chakraborty et al. (2009) found majority of patients on antidepressants reported 
that their partners or families have a positive attitude towards diagnosis and treatment. 
c) Beliefs about Medications Questionnaire (BMQ)  
 
The Beliefs about Medications Questionnaire (BMQ) (Horne et al., 1999) is a Necessity-
Concern Framework that assess patient attitude towards pharmacological treatment in general 
and also for a specific prescribed medication. Items representing patients’ necessity and concern 
are organized in four components: general necessity, general concern, specific necessity, and 
specific concern.  
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Table Appendix B.3. Beliefs about Medications Questionnaire (BMQ): a summary of components' items 
General necessity Items in the general necessity components are formulated to assess patient beliefs 
about the necessity of pharmacological treatment in curing illness. Patients with 
negative belief may feel that natural remedies are better than medications or that 
they should not take medications continuously. 
General Concern Items in this component indicate patients’ general concerns about pharmacological 
treatment based on beliefs about harmful aspects such as addiction, harm, and 
poison caused by medications and concern about overuse of medication by 
physicians.  
Specific necessity Items in this component express a medication’s effectiveness and the patient’s 
attitude about dependency to the prescribed medication as well as their concern 
about their future healthcare status and their quality of life if they continue using 
the prescribed medication.  
Specific Concern  Items in this category mainly indicate three dimensions of specific concern of 
patients including: 1) Long-term effects and its impact on quality of life; 2) The 
mechanism and addictive possibilities of antidepressants; and 3) losing autonomy 
because of the control of the medication. 
Aikens et al. (2005) used this BMQ scale to develop a categorical perspective that is 
more practical to clinicians. The categories are: skeptical (low necessity, high concerns), 
ambivalent (high necessity, high concerns), indifferent (low necessity, low concerns), accepting 
(high necessity, low concerns). Based on this framework adherence is lowest in the accepting 
group, and lowest in the skeptical group (Aikens et al., 2005; Russell & Kazantzis, 2008).  
 Brown et al. (2005) used the BMQ to find the relationship between beliefs and adherence 
to antidepressant medication. The findings of this study suggested that a great number of patients 
have concern about the long-term effects and addictive possibilities of antidepressants in 
specific, and about the overuse and harmfulness aspects of medications in general (Brown et al., 
2005).   
Aikens et al. (2008) employed BMQ to identify factors affecting beliefs about necessity 
and concern of antidepressants.  This study findings shows that perceived necessity is correlated 
with age, severity of symptoms, anticipated duration of symptoms, and source of depression 
(attribution of symptoms to chemical imbalance vs. random factors). Perceived concern was 
higher in patients using antidepressants for the fist time (who are new to antidepressants), had a 
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sufficient knowledge about antidepressants and attribute the source of depression to random 
factors rather than biological factors. Patient gender, education, age, and type of depression were 
not significantly associated with necessity and concern of antidepressants ” (Aikens et al., 2008).  
d) Rating of Medication Influence Scale (ROMI) 
 
ROMI (Weiden et al., 1994)  is a self-report scale that was primarily developed for assessment of 
attitudinal and behavioral factors affecting outpatient adherence with neuroleptic disorder . This 
scale assess patients attitude and adherence in seven major domains that we reorganize them in 
six main components: 1) subjective experience, 2) perceived necessity, 3) perceived 
psychosocial support, 4) perception about illness, 5) perceived support from healthcare provider, 
and 6) features of healthcare services. 
Table Appendix B.4. Rating of Medication Influence Scale (ROMI): Summary of Components’ items 
Subjective experience 
and adverse effects 
Two items in the domain of therapeutic regimen features including treatment 
effectiveness and perceived distress of psychotic medications indicate subjective 
experience of patients with antidepressants.  
Perceived necessity 
(prevention) 
Three items in the domain of patients characteristics represents patients belief 
about the necessity of the medications, whether patient believes his/her current 
and future healthcare status depends on medication. Fear of relapse, fear of 
hospitalization, and perceived recovery from illness are the items.  
Perception about 
illness 
Items in the domain of disease feature and psychological factors indicate patient 
perception about illness. The items assess patient perception about existence and 
severity of diseases, and whether patient feels stigma/embarrassment against 
illness. Item of substance abuse in the category patient characteristic might 
reflect patients attitude about illness and medication. 
Perceived psychosocial 
support  (Influence of 
others) 
Items in the domain of psychosocial factors domain evaluate patients’ perceived 
support received from family and also family attitude toward medication.  
Perceived physician-
patient relationship  
Items in the category of patient-physician interaction and also treatment system 
features assess patients perceived relationship with physicians and whether they 
felt any pressure/force from healthcare providers.  
Features of healthcare 
services ( adherence 
behavior) 
 
Items in domain of treatment system feature and therapeutic regimens features 
evaluate indicate feature of healthcare services, whether healthcare services is 
accessible, affordable, it is structured, and physicians believe to medications.  
In studies pertain to adherence and attitudes towards antidepressants, ROMI scale 
primarily has been applied in research related to adherence (Sajatovic, Velligan, Weiden, 
Valenstein, & Ogedegbe, 2010; Sansone & Sansone, 2012).   
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There are other scales, such as Brief Evaluation of Medication Influences and Beliefs 
(BEMIB), Medication Adherence Rating Scale (MARS) that includes items for assessing patient 
attitude, but they are mainly developed for measuring and identifying predictive factors 
influencing adherence.  
Studies used these scales has yielded two De las Cuevas and Sanz (2007) De las Cuevas 
and Sanz (2007)  or multi-factor structure Alekhya et al. (2015) as  outcome attitude. Two-factor 
structure simply classifies individuals’ attitudes as either positive or negative, while multi-factor 
structure, such as multi-point Likert scale provides more information about the effect of different 
factors on forming patients’ attitudes by classifying patients in more than 2 categories. Some 
studies may treat the sclaes outcome as a continuous variables to calculate correlation of other 
continues variable, such as correlation of adverse effects with attitude in a study conducted by 
Day et al. (2005).  
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APPENDIX A 
 
1. Lister Hill National Center for Biomedical Communications/ National Institute of 
Health (May 2016- December 2016), Research Fellow  
 
1.1. Project:  Social Media text mining and statistical analysis to identify underlying factors 
for attitude to antidepressant treatment (in progress).  
1.1.1. Designing research methodology including literature review, data collection 
method, data analysis framework, annotation guideline, and statistical analysis plan. 
1.1.2. Developing a consumer health vocabulary of medical concepts, such as side-
effects and withdrawal symptoms by systematically mapping these concepts to both 
SNOMED-CT and UMLS concepts 
1.1.3. Designing a classifier to differentiate symptoms, side-effects, and beneficial 
effects of antidepressants  
8) 
2. Biomedical Data and Language Processing Center of the Department of Health 
Sciences at the University of Wisconsin-Milwaukee, Research Fellow (January 2015, May-
2016) 
 
2.1. Project (1): Representing Depression Drug Side Effect beyond clinical Conditions 
2.1.1. Mapped drug adverse effects to limitations in daily activities and social 
participations based on data extracted from drug clinical trials and International 
Classification of Functioning Disability and Health (ICF) terminology 
2.1.2. Analyzed the result and prepared the manuscript for American public health 
association (APHA) conference. 
 
2.2. Project (2): Evaluating Acceptability and Efficacy of Antidepressant Medications based 
on Patients drug reviews  
2.2.1. Compared acceptability (satisfaction) and efficacy (effectiveness) of 13 
antidepressant drugs using patients drug reviews in Webmd.com 
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2.2.2. Analyzed the results and prepared the manuscript for American Medical 
Informatics Association (AMIA) 
 
2.3. Other projects:  
2.3.1. Analyzed the Patients Comments in Depression Groups in Facebook 
2.3.2. Health data in Social Media and Exploring Text-Mining Methods for Data 
Extraction 
 
3. Indiana University, Research Assistant (August 2012- December 2015) 
 
3.1. Project (1): The Extent to which U.S. Hospitals Promote Their Patient Engagement 
Activities and Outcomes: Preliminary Results of Quantitative Content Analysis Research 
3.1.1. Collaborated with investigators to design research methodology 
3.1.2. Conducted literature review to develop framework for content analysis  
3.1.3. Worked with PhD students to analyze contents and medical tools provided in 
hospitals’ websites 
3.1.4. Conducted statistical analysis to test the hypotheses  
3.1.5. Prepared manuscript for American Medical Informatics Association (AMIA) 
 
3.2. Project (2): Building a Portal to Health Resources for Cancer Survivors 
3.2.1. Collaborated with investigators to develop a framework for the portal 
3.2.2. Conducted a research to select proper content for the website 
3.2.3. Project (3):  Improving Healthcare Systems for Access to Care by Underserved 
Patients, 
3.2.4. Worked with investigators and team members for conducting patients interviews 
and analyzing the collected information  
9) 
4. Immunology & Asthma & Allergy Research Center (IAARI), Tehran, Iran, Informatics 
Specialist, (January 2011- August 2012) 
 
4.1. Project (1): A Clinical Decision Support System (CDSS) for diagnosing pediatric asthma  
4.1.1. Prepared a grant proposal for IAARI to finance designing and implementing a 
clinical decision support system.  
4.1.2. Worked with asthma specialists to generate diagnostic rules  
4.1.3. Worked with medical students to provide medical content of the CDSS 
4.1.4. Designed the algorithm of diagnosis  
4.1.5. Implemented a prototype of the system using Matlab 
4.1.6. Worked with programmers and user-interface designers to implement the system 
using C# 
4.1.7. Tested the system using 138 asthmatic and 138 non-asthmatic patients 
 
4.2. Project (2):  Clinical Decision Support System (CDSS) prototype for measuring level of 
asthma severity, asthma control, and asthma exacerbation  
4.2.1. Worked with asthma specialists to generate rules related to level of severity, 
control, and exacerbation 
4.2.2. Implemented system prototype using Matlab 
4.2.3. Tested the prototype using 85 asthmatic patients 
 
5. Academic Center for Education, Culture, and Research (ACECR) Tehran, Iran, 
Research Specialist, (2009-2012) 
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5.1. List of projects:  
5.1.1. Studied ICT-based SMEs in Iran and providing the government with appropriate 
solutions in order to support the enterprises.   
5.1.2. Strategic planning: a framework for Internal analysis in high tech SMEs 
5.1.3. Designed an efficient engineering and administrative system for exporting 
technical services 
 
6. Negah Nou company and Jahan Rayane Company,Tehran, Iran, IT Consultant (2009-
2010) 
6.1. Determining information systems requirements  
6.2. Designing business plan based on company's clients’ needs 
6.3. Designing system analysis framework for system analysis team 
  
7. E-Sabz Company, Tehran, Iran, Director of Analytics Department, (2007-2009) 
7.1. For the following projects, I managed a team of system analysts and programmers. I 
was also responsible for preparing marketing business plan.  
7.1.1. Content Management System 
7.1.2. Customer Relationship Management (CRM) system 
7.1.3. Archive Management System  
7.1.4. Learning Management System  
 
 
